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Epidermal growth factor receptor (EGFR) signaling leads to cellular proliferation and 
migration, and thus EGFR dysregulation can significantly contribute to the survival of tumor 
cells. Aberrant EGFR signaling due to receptor overexpression, mutation, or autocrine ligand has 
been observed in a wide variety of malignancies, and antibody drugs which inhibit EGFR 
signaling have been developed. However, the epitopes of most EGFR antibodies have not been 
characterized, and the marginal efficacies of current antibodies underscore the need for improved 
therapeutics. 
In this thesis work, we have created a novel method of epitope mapping, which is the 
determination of antigen residues responsible for mediating an antibody-antigen interaction. In 
our technique, a library of random mutants of the EGFR antigen is displayed on the surface of 
yeast, and the library is combinatorially selected for loss of binding to the antibody being 
mapped. If a mutant shows loss of binding to an antibody, then that residue is a potential contact 
residue. In addition, we found that many mutants caused a global misfolding of the antigen, 
requiring the use of high-throughput sorting to remove the misfolded mutants. The development 
of our epitope mapping method using random mutagenesis and yeast surface display enabled the 
successful mapping of four different antibodies and three designed ankyrin repeat proteins 
binding to EGFR. 
In addition, we continued work on engineering novel antibodies against EGFR domains 
II and IV. Antibodies against these domains are hypothesized to directly inhibit receptor 
dimerization and subsequent activation, as opposed to traditional anti-EGFR antibodies which 
block ligand binding. To accomplish this, peptide mimics of EGFR loops were used as antigens; 
however, antibodies generated using both yeast surface display and rabbit monoclonal 
technology were peptide-specific, but did not bind to EGFR protein. Finally, we developed a 
mathematical model to describe equilibrium EGFR ligand binding and dimerization. Based on 
observations that polyclonal antibodies against EGFR domain II or IV eliminate high affinity 
EGF binding normally observed on the surface of cells, we hypothesized that preformed inactive 
dimers were the high affinity component. Our model incorporating this hypothesis successfully 
reproduced experimental data, resulting in characteristic concave-up Scatchard plots. 
 
Thesis Supervisor: K. Dane Wittrup 
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Chapter 1: Introduction and background 
 
1.1 EGFR signaling and trafficking 
 The epidermal growth factor receptor (EGFR/Her1/ErbB1) is a type I transmembrane 
receptor tyrosine kinase and a member of the ErbB receptor family. This family includes three 
other members: Her2 (ErbB2/Neu), Her3 (ErbB3), and Her4 (ErbB4). The receptors are 
activated by a number of different ligands, such as epidermal growth factor (EGF) and 
transforming growth factor alpha (TGF-α) which bind to EGFR, and epiregulin and betacellulin 
which bind to both EGFR and Her4 (1). The exception to this is Her2, for which no natural 
ligand has been discovered. The binding of ligand drives receptor dimerization, and the various 
receptors in the EGFR family are capable of both homo- and heterodimerization with each other. 
However, it does not appear that Her2 homodimerizes at physiological expression levels, and 
homodimerization of Her3 receptors would not lead to receptor phosphorylation since Her3 is 
kinase dead and thus must be trans-activated by heterodimerization with other ErbB receptors. 
The receptor dimerization event allows for kinase activation and trans-phosphorylation of 
residues in the intracellular domain. A number of different EGFR tyrosine residues can become 
phosphorylated, depending on the stimulating ligand and dimerization partner. Following 
stimulation of EGFR by EGF, the major sites of phosphorylation include tyrosines 1086, 1148, 
and 1173 (2). Phosphotyrosine-binding proteins then associate with these residues in the ErbB 
receptor tail and become activated, initiating various signaling cascades. Many of these 
interactions have been characterized in detail, such as Grb2 binding to EGFR tyrosine 1068 and 
SHC binding to EGFR tyrosines 1148 and 1173 (3,4). EGFR has been shown to activate a 
number of signaling pathways, including the mitogen-activated protein kinase (MAPK), 
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phosphatidylinositol 3-kinase (PI3K), and protein kinase C (PKC) pathways. In addition, EGFR 
can be trans-activated by other proteins, such as G-protein-coupled receptors (GPCRs) (5). The 
various signaling cascades associated with EGFR activation are summarized in Figure 1-1. It has 
also been observed that activated EGFR may undergo nuclear translocalization and subsequently 
regulate gene expression, although the contribution of this pathway compared to more traditional 
signal transduction is unclear (6,7). The activation of EGFR thus leads to multiple cell responses, 
including cellular growth, differentiation, and migration. 
 
Figure 1-1: EGFR signaling network. (a) EGFR family ligands are shown with their binding specificities. For 
simplicity, arrows are only drawn for EGF and neuregulin 4 (NRG4), although other ligand specificities are shown 
in parentheses. (b) Signaling to the adaptor protein/kinase layer is only shown for two receptor dimers. (c) Possible 
cellular outcomes based on EGFR signaling. Figure has been reproduced from (5) with permission from Elsevier. 
 
In the absence of ligand, EGFR is constitutively internalized with a half life of ~30 
minutes and quickly recycled back to the cell surface, leading to a total receptor distribution of 
~80-90% on the cell surface at any given time (Figure 1-2) (8). The metabolic half-life of EGFR 
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in a tumor cell line is 20 hours (9); thus, a single receptor will cycle through the endocytic 
pathway many times during its lifetime. Ligand activation increases the rate of EGFR 
endocytosis 5-10 fold, but does not increase the internalization rates of other ErbB receptors 
(10). In addition, activated EGFR dimers bound to EGF are preferentially retained in the 
endosomes and not recycled (11), and these endosomes mature into multivesicular bodies and are 
targeted to lysosomes (12). This leads to the specific degradation of activated receptors and 
overall receptor downregulation. Earlier reports indicated that ligand-accelerated internalization 
required EGFR kinase activity (13,14), but a recent study found that receptor dimerization was 
sufficient to induce rapid internalization and that kinase activity was unnecessary (15). Although 
receptor ubiquitination does not affect EGFR internalization rates (16,17), ubiquitination by 
c-Cbl targets receptors to the lysosome and is dependent on kinase activity and an intact 
C-terminal region (18).  
While receptor internalization has often been viewed as a means of signaling attenuation, 
it has been shown that activated EGFR continues to signal while in the endosome through certain 
signaling pathways (19,20). Although Her2 has often been described as the preferred 
heterodimerization partner for ErbB receptors (21), mathematical modeling and experiments 
have shown that EGFR homodimerization and EGFR/Her2 heterodimerization occur with 
comparable affinities (22), and EGFR/Her2 heterodimers appear to predominate because they 
have a reduced rate of internalization and increased fraction of recycling (23). EGFR trafficking 
has been the subject of much mathematical modeling, and the system serves as a paradigm for 
other ligand-binding receptors (24). The constitutive trafficking patterns of EGFR can even 
affect the global pharmacokinetics of antibody drugs which bind to the receptor due to antibody 
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internalization and subsequent degradation (25). Additional experiments on EGFR trafficking are 
reviewed in (8) and (26). 
 
Figure 1-2: Trafficking of EGFR. Activated EGFR homo- and heterodimers are internalized through clathrin-coated 
pits and preferentially degraded. Times represent approximate mean time of the processes indicated. Figure has been 
reproduced from (8) with permission from Elsevier. 
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1.2 Biochemical and structural characterization of EGFR 
 EGFR is a 170 kDa protein that is heavily N-glycosylated but not O-glycosylated (27), 
with carbohydrate accounting for ~20% of the molecular mass. Mass spectrometry 
characterization has determined that eight of the eleven canonical N-linked sites are glycosylated 
in the A431 cell line, with two sites unglycosylated and one site glycosylated in a fraction of the 
receptors (28). The EGFR extracellular region is divided into four domains, numbered I-IV 
(Figure 1-3). Domains I and III (DI and DIII), also designated L1 and L2, are members of the 
leucine rich repeat family and are similar to domains found in the insulin receptor family (29). 
Prior to receptor crystallization, it was known that both DI and DIII contribute to ligand binding 
(30). However, domain III appears to contribute most of the binding energy, since the affinity of 
DIII alone for EGF is ~400 nM as measured solubly by isothermal titration calorimetry (31), 
while soluble EGFR ectodomain binds immobilized EGF with an affinity of ~200 nM (32). 
Domains II and IV (DII and IV), or the cysteine-rich (CR) domains, contain multiple small 
disulfide-bonded modules similar to those in laminin (33). 
 
Figure 1-3: Domains of EGFR. The extracellular region consists of domains I-IV, followed by a transmembrane 
region (TM) and the intracellular portion. The regions inside the cell include the juxtamembrane portion (JM), 




The EGFR ectodomain has been crystallized in both monomer and dimer forms, and a 
review of these structures can be found in (34). The monomer exists in a tethered, closed, or 
autoinhibited state (35), with DII and DIV forming a tether contact (Figure 1-4, left). However, 
in the dimer structures of EGFR bound to EGF (36) or TGF-α (37) ligand, the receptor is in an 
untethered, open, or extended conformation, with ligand binding between DI and DIII (Figure 
1-4, right). Although most cytokine receptors dimerize through ligand bridging the two receptor 
monomers (38), all dimerization contacts in the EGFR dimer are fully receptor-mediated. The 
dimer exists in a 2:2 receptor to ligand ratio, with multiple contacts through the DII dimerization 
arm (residues 242-259). An additional DII loop, residues 271-283, also contributes important 
dimer contacts (32). The dimerization interface may include DIV; however, in the dimer 
structures, DIV is either unresolved (36) or was not present in the crystallized protein (37). 
Peptides mimicking portions of DIV can inhibit EGFR heterodimerization with Her3 (39), and 
DIV mutations can impair the ability of ligand to bind and induce EGFR phosphorylation (40). 
However, these potential DIV contacts contribute <9% of the free energy of dimerization as 
demonstrated by studies on soluble EGFR dimer formation (32). For illustrative purposes, DIV 
has been added to the dimer structure in Figure 1-4 in the same relative orientation to DIII as 
seen in the tethered monomer. A low-resolution molecular envelope structure of the full EGFR 
dimer in solution has been obtained from small-angle X-ray scattering (SAXS), and it is 
consistent with this dimer structure (41). 
12 
 Figure 1-4: Crystal structures of monomeric and dimeric EGFR. Left, autoinhibited EGFR monomer (1NQL), with 
domain I (DI), red; DII, orange; DIII, blue; DIV, green. A 130o rotation of DI and DII allows DI and DIII to come 
together to bind EGF ligand. Right, dimeric EGFR bound to EGF ligand in yellow (1IVO). DIV is not resolved in 
this structure, but has been added in the same relative orientation to DIII as seen in the monomer. This figure was 
adapted from (34). 
 
From the crystal structures of the monomer and dimer, a model for EGFR activation has 
been proposed (34). In this model, the monomer mostly exists in a tethered conformation, in 
which the DII dimerization arm and other residues are obscured, thus preventing receptor 
dimerization. The monomer equilibrates between the tethered conformation and an extended 
conformation similar to that seen in the dimer. The binding of ligand between DI and DIII 
stabilizes the extended conformation, which exposes the DII dimerization arm and other 
residues, thus allowing the formation of the dimer. However, the breaking of the tether is 
necessary but not sufficient for dimer formation, as demonstrated through mutations and 
deletions of DIV (37,42,43). It also appears that certain types of receptor glycosylation can shift 
the equilibrium toward the extended form (44,45). It has subsequently been found that the DII-
DIV tether interaction is not necessarily responsible for maintaining the receptor in the 
autoinhibited conformation; in fact, mutating every tether interaction in soluble EGFR still leads 
13 
to an autoinhibited conformation (41). In addition, it appears that ligand binding is necessary to 
stabilize the conformation of the DII loop 271-283, which is an important dimerization contact 
(32). 
Ectodomain crystal structures are also available for the EGFR family members Her2 (46), 
Her3 (47), and Her4 (48). The Her2 monomer, in contrast to EGFR, adopts an extended 
conformation similar to that of EGFR in the dimer structure. Since Her2 has no activating ligand, 
it is extended and poised to interact with other ErbB receptors. However, since ligand binding is 
necessary to activate Her3 and Her4, these monomers adopt a tethered conformation. 
EGFR has a single transmembrane domain, and the intracellular portion contains a short 
juxtamembrane region, the tyrosine kinase, and a C-terminal tail containing tyrosine residues 
which become phosphorylated upon receptor activation (Figure 1-3). The EGFR kinase domain 
has been independently crystallized, revealing an intrinsically autoinhibited domain resembling 
Src and cyclin-dependent kinases (CDKs) (49). In contrast to most kinases, phosphorylation of 
the EGFR activation loop is not necessary for its activation (50). Instead, the EGFR kinase is 
activated by an asymmetric dimer in which the C-terminal lobe of one kinase domain binds to 
the second kinase domain in a manner analogous to cyclin in activated CDK/cyclin complexes. 
Thus, ligand binding brings two receptor monomers together and allows for the dimerization and 
subsequent activation of the kinase domains. In this model, the extent of EGFR kinase activation 
depends on the effective local concentration of the receptor, since the probability of dimerization 
will increase with increasing kinase domain density. This phenomenon has been demonstrated 
experimentally using increasing concentrations of EGFR kinase domains tethered to the surface 
of vesicles (49). 
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1.3 EGFR in cancer 
 EGFR was the first receptor to be directly linked to human cancer (51), and because 
EGFR activation often leads to cellular growth, its signaling can provide tumor cells with 
substantial survival advantages. In addition, EGFR signaling has been implicated in tumor cell 
production of pro-angiogenic factors and cellular migration and invasion (52). EGFR 
dysregulation has been observed in a wide variety of carcinomas, including head and neck, 
breast, bladder, and non-small-cell lung cancer (5). Excessive EGFR signaling can arise from 
receptor overexpression, autocrine signaling, or mutation. Normal cells usually express 4x104 to 
1x105 EGF receptors per cell, but tumor cells can express as many as 2x106 (53). Receptor 
overexpression commonly develops due to gene amplification, although it was recently reported 
that the hypoxic microenvironment of tumors can also induce overexpression of EGFR by 
increasing EGFR mRNA translation (54). In head and neck cancer, at least 80% of tumors 
overexpress EGFR (55), and the observed percentages of tumors overexpressing EGFR in 
various types of cancer are listed in Table 1-1. Furthermore, elevated levels of EGFR serve as a 
prognostic indicator for poor survival rates (56). 
 
Tumor type Percentage of tumors 
overexpressing EGFR 
Colon 22-75% 
Head and neck 80-100% 
Pancreatic 30-50% 






Table 1-1: EGFR overexpression in different tumor types. Table has been adapted from (53). 
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In addition, EGFR ligands can be overexpressed, resulting in high levels of autocrine 
signaling when the receptor is present (57). Autocrine production of TGF-α or EGF is also 
associated with reduced cancer survival (21). Finally, various activating EGFR mutations have 
been observed in tumor samples. Gene rearrangements in glioblastoma often lead to truncation 
mutants, the most common of which is EGFRvIII (EGFRΔ2-7), where amino acids 6-273 
(encoded by exons 2-7) are deleted from the gene (58-60). This leads to a mutant which is 
missing DI and most of DII, with EGFR amino acids 1-5 fused to the rest of the receptor through 
a novel glycine residue resulting from the gene fusion. Although most frequently seen in 
glioblastoma, EGFRvIII has also been observed in other types of tumors, including non-small-
cell lung, breast, and ovarian cancers (61-63). EGFRvIII is not activated by ligand, but signals 
constitutively at low levels (64) and thus confers enhanced tumorigenicity to cancer cells (65). 
There is also evidence that EGFRvIII is downregulation defective, leading to prolonged 
signaling (66). In addition, point mutants of the EGFR ectodomain have recently been observed 
in glioblastoma, and select mutants showed high basal phosphorylation and conferred 
tumorigenicity to NIH-3T3 cells (67). 
In non-small-cell lung cancer (NSCLC), mutations in the EGFR kinase domain, which 
are clustered around the ATP-binding pocket of the enzyme, have been observed (68). These 
mutations appear to be restricted to a subset of NSCLC patients, particularly non-smokers, 
women, and those of Asian ethnicity (69). Exon 19 in-frame deletions of some or all of residues 
746-750 account for 45% of reported mutations, exon 21 substitutions (especially L858R) 
account for 45%, and the remaining 10% involve exons 18 and 20, such as G719S and V765A 
(68). Most of these mutations have been shown to hyperactivate the kinase and have oncogenic 
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activity. Although predominately seen in NSCLC, very rare kinase domain mutations have also 
been observed in other types of tumors, including ovarian, colorectal, and head and neck (68). 
Other EGFR family members have been shown to be dysregulated in cancer. Her2 
overexpression due to gene amplification has been observed in various tumors, including breast, 
ovarian (70), and bladder cancer (71). In particular, Her2 overexpression is an indicator of poor 




1.4 Current EGFR-targeted therapeutics 
 Because of the importance of the EGFR family in cancer, the receptors are promising 
targets for rational oncology therapies designed to inhibit receptor signaling. The two main 
classes of such therapeutics are tyrosine kinase inhibitors (TKIs) and monoclonal antibodies. 
TKIs are small molecule drugs which are designed to bind the ATP pocket of the kinase domain 
and inhibit EGFR phosphorylation (73). Two EGFR-targeted TKIs have been approved by the 
U.S. Food and Drug Administration (FDA) for the treatment of non-small-cell lung cancer: 
gefitinib (Iressa, ZD1839; AstraZeneca) (74) and erlotinib (Tarceva, OSI-774; 
OSI/Genentech/Roche) (75), which has been co-crystallized with the EGFR kinase domain (76). 
Although these two TKIs are targeted to the EGFR tyrosine kinase, with IC50 values 
(concentration required for 50% inhibition of activity) in the nanomolar range, they also will 
inhibit the Her2 tyrosine kinase with IC50 values in the micromolar range (73). A small subset of 
NSCLC patients dramatically respond to treatment with gefitinib (73) or erlotinib, and the 
characterization of these patient tumors led to the discovery of activating EGFR kinase domain 
mutations (described in Section 1.3). In fact, 77% of NSCLC patients who respond to gefitinib or 
erlotinib harbor certain kinase domain mutations, as opposed to a 7% incidence of mutation in 
non-responders. It has been hypothesized that these activating EGFR kinase domain mutations 
lead to a state of oncogene addiction for tumor cells, thus explaining the extreme sensitivity of 
mutation-bearing tumors to EGFR TKIs (68). Unexpectedly, in cells expressing the ectodomain 
truncation mutant EGFRvIII, gefitinib induces signaling at low concentrations (77). Gefitinib 
and erlotinib are reversible kinase inhibitors; however, irreversible TKIs which bind the kinase 
domain covalently, such as HKI-357 (78), have also been developed. These have been shown to 
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be effective against reversible-TKI resistant cells expressing a secondary kinase mutation 
T790M. Additional TKI drugs in development are reviewed in (79) and (68). 
 An alternative to TKI therapeutics is treatment with anti-EGFR monoclonal antibodies 
(mAbs; for a general discussion on antibody structure, see Section 3.1). While TKIs can be 
conveniently delivered orally and have a reduced chance of inducing allergic reactions, 
monoclonal antibodies have superior stability in vivo and lower gastrointestinal toxicity (79). 
Cetuximab (Erbitux, IMC-C225; ImClone Systems) was the first anti-EGFR monoclonal 
antibody to be approved by the FDA. Originally approved for the treatment of EGFR-expressing 
metastatic colorectal cancer, it has also recently been approved for head and neck cancer. The 
antibody was initially isolated by immunization of mice with EGFR, and the murine monoclonal 
antibody was designated mAb 225 (80). In vitro experiments revealed that this antibody inhibited 
the binding of ligand to EGFR, resulting in decreased tyrosine phosphorylation and reduced cell 
proliferation (80,81). The crystal structure of the cetuximab Fab bound to the EGFR ectodomain 
reveals that the antibody directly competes with EGF ligand by binding to DIII on an epitope 
which overlaps the EGF binding site (82). It was also found that mAb 225 can induce EGFR 
internalization (83), which may reduce the number of receptors available to bind ligand. The 
bivalency of the mAb 225 molecule was shown to be important for its ability to internalize and 
downregulate EGFR and inhibit subsequent growth (84). In addition, cetuximab has been shown 
to exhibit anti-angiogenic properties, leading to even more effective treatment of tumor 
xenografts in vivo (85). Cetuximab may also induce antibody-dependent cellular toxicity 
(ADCC) in vivo (86), and the antibody’s various mechanisms of action are further discussed in 
(87). To decrease its potential immunogenicity, the mouse mAb 225 was chimerized with human 
IgG1 by adding the mouse antibody variable regions to the human constant IgG regions. This 
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chimeric antibody, designated C225, was shown to have a higher affinity for EGFR and was 
effective against human tumor xenografts (88). Additionally, cetuximab is able to inhibit the 
growth of lung cancer xenografts expressing the L858R/T790M EGFR kinase mutants, which 
are resistant to reversible TKI treatment (89). In clinical trials, cetuximab was well-tolerated with 
mild toxicities, which included acneiform rash, fatigue, and hypersensitivity (90). The effects to 
normal tissue appear to minimal, since many healthy cells expressing EGFR are not rapidly 
turned over, with the intestinal epithelium as an exception (53). In a Phase III clinical trial with 
329 irinotecan-refractory metastatic colorectal cancer patients, 10.8% responded to cetuximab 
therapy alone while 22.9% responded to cetuximab plus irinotecan (90), leading to the FDA 
approval of this drug. Interestingly, cetuximab treatment was able to reverse tumor cell 
resistance to the chemotherapeutic irinotecan. 
 Other antibodies have been developed which similarly inhibit ligand binding to EGFR as 
cetuximab does. Panitumumab (Vectibix, ABX-EGF; Amgen/Abgenix) has also been FDA-
approved for the treatment of metastatic colorectal cancer and blocks the binding of ligands to 
EGFR (91). Panitumumab has one potential advantage over cetuximab; it is a fully human 
antibody developed from the XenoMouse technology, in which human antibody genes were 
cloned into mice (91). However, panitumumab is a class IgG2 antibody and thus incapable of 
activating ADCC, although it is unclear how important this is for tumor inhibition (92). Data 
from clinical trials shows that panitumumab produces an 8% overall response rate in metastatic 
colorectal cancer, with progression-free survival extended from 60 days to 96 days (92). Another 
cetuximab-like antibody is matuzumab (EMD72000; EMD Pharmaceuticals/Merck KgaA), 
which is currently in various phase II clinical trials. The antibody was originally isolated from 
mice (mAb 425/EMD55900) and inhibits the binding of ligands to EGFR (93). The murine 
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version of the antibody was humanized by grafting the murine complementarity-determining 
regions (CDRs) onto a human IgG1 framework (94). A phase I study of matuzumab treatment of 
patients with advanced pancreatic adenocarcinoma showed partial responses and stable disease 
in eight of twelve patients (95). However, in a recent phase II trial, matuzumab showed no 
evidence of significant clinical activity in ovarian tumors (96). In addition, a bispecific version of 
the humanized mAb 425, named MDX-447 (Medarex/Merck KgaA), has been developed, with 
the other arm of the antibody binding to the high affinity Fc receptor (FcγRI) (97). MDX-447 is 
currently undergoing further clinical trials in combination with activated monocytes in an effort 
to direct these immune cells to tumor sites. Finally, nimotuzumab (hR-3, TheraCIM; YM 
Biosciences/Center of Molecular Immunology, Cuba) is a humanized antibody which also blocks 
ligand binding to EGFR (98). Phase I/II trials of glioblastoma and anaplastic astrocytoma 
patients showed a 38% objective response rate (99), and the antibody is currently undergoing 
further trials in the U.S.  
Antibodies which target the truncation mutant EGFRvIII have also been developed. Since 
EGFRvIII contains a novel glycine residue at the junction between two EGFR fragments, this 
junctional peptide is a potential target for antibody binding and represents an epitope specific to 
tumor cells. One antibody targeting this peptide is MR1-1, which is an affinity-matured single 
chain variable fragment (scFv) specific for EGFRvIII (100). However, antibodies against the 
junctional peptide have no intrinsic anti-EGFRvIII activity, and thus must be conjugated to 
cytotoxic agents such as immunotoxins in order to kill tumor cells (101). Another antibody, mAb 
806, was isolated from immunization of mice with EGFRvIII, and it was shown to bind and 
inhibit the growth of cells expressing the mutant protein. However, it was discovered that mAb 
806 also bound to a small portion of wild-type EGFR (~5-10%) on cells overexpressing the 
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receptor and inhibited cell growth, but it did not bind to or inhibit cells expressing normal EGFR 
levels (102-104). Therefore, mAb 806 has the unique ability to recognize EGFR expressed by 
tumor cells but not on normal tissues. Characterization of mAb 806 revealed that it binds a 
peptide epitope shared by both EGFRvIII and EGFR (105). However, this epitope is only 
exposed in certain situations: in EGFRvIII due to the deletion of DI and DII, when wild-type 
EGFR transitions from the autoinhibited to open conformation, or by high-mannose forms of the 
receptor in cells overexpressing EGFR (44). The mAb 806 epitope is discussed in further detail 
in Chapter 2. mAb 806 has also been chimerized to reduce murine sequences, generating 
antibody ch806 (106). In mouse models of cancer, 806 was effective in inducing regression of 
lung tumors expressing either EGFR harboring an activating kinase domain mutation or 
EGFRvIII (107). However, 806 is ineffective against kinase-dead EGFRvIII, suggesting that it 
functions by blocking receptor trans-phosphorylation (108). Phase I clinical trial data showed 
that ch806 was well-tolerated by patients, with highly specific targeting to tumors versus normal 
tissues (109), and further trials are currently ongoing. 
The only FDA-approved antibody which targets Her2, trastuzumab (Herceptin, 4D5; 
Genentech), was isolated by mouse immunization (110) and humanized (111). Trastuzumab 
inhibited the proliferation of breast tumor-derived cell lines (110) and also supported ADCC 
killing against the SK-Br-3 tumor line (111). Trastuzumab was shown to be effective against 
human gastric carcinoma xenografts (112), as well as breast cancer BT-474 xenografts (113). In 
phase III trials, the addition of trastuzumab treatment to chemotherapy was associated with a 
longer time to disease progression (7.4 vs. 4.6 months) and a higher objective response rate (50% 
vs. 32%) (114), leading to the FDA approval of this drug for the treatment of Her2-positive 
metastatic breast cancer. The main toxicities were cardiac adverse events, since Her2 signaling 
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appears to be important for adult heart function (115). Recent trials have shown that adjuvant 
trastuzumab therapy reduces the 3-year risk of recurrence by half in early breast cancer patients 
(116). Despite the success of trastuzumab, its mechanism of action is not immediately apparent. 
A crystal structure of trastuzumab bound to Her2 reveals that it binds the C-terminal portion of 
domain IV (117); however, it does not block Her2 heterodimerization with Her3 (118). Although 
initial reports suggested that trastuzumab could inhibit tumors through downregulation of the 
Her2 receptor (119,120), a more recent study demonstrated that the antibody is internalized and 
recycled back to the cell surface without mediating receptor degradation (121). The Her2 
ectodomain undergoes cleavage, and the resulting membrane-bound kinase fragment shows 
increased tyrosine kinase activity (122). Trastuzumab blocks this Her2 shedding (123), 
presumably by restricting access to the protease cleavage site, thus preventing the formation of 
the activated kinase fragment (119). Finally, trastuzumab can induce ADCC killing of tumor 
cells (124), but this cannot be its sole mechanism since ADCC cannot explain the antibody’s 
efficacy in vitro. Additional experiments with trastuzumab are reviewed in (125). Another anti-
Her2 antibody named pertuzumab (Omnitarg, 2C4; Genentech) binds to domain II of Her2 
(demonstrated by co-crystallization (126)), and thus it inhibits Her2/Her3 heterodimerization and 
breast and prostate xenograft tumor growth (118). The murine version, mAb 2C4, was 
humanized (127), and initial results from a phase II trial treating prostate cancer showed no 
objective responses (128). However, a clinical trial evaluating pertuzumab treatment plus 
trastuzumab is currently ongoing, motivated by preclinical studies where the two antibodies 
synergistically inhibited the survival of breast cancer cells (129). 
Although therapeutics directed at the EGFR receptor family have been somewhat 
effective in inhibiting the growth of tumor cells, optimal cancer treatments will likely include 
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some form of combination therapy. Since multiple genetic alterations contributing to a malignant 
phenotype normally arise during the course of tumor development (130), it may be difficult to 
inhibit these tumors by blocking only one receptor. Synergistic inhibition effects of combining 
anti-EGFR antibodies with chemotherapeutic agents in vitro were initially reported by (131). 
Treatments of trastuzumab plus chemotherapy (114) or cetuximab plus irinotecan (90) both 
improved patient outcome in clinical trials. Additional trials examining combinations of anti-
EGFR antibodies with other chemotherapeutics have been and are currently being investigated 
(3,53,132). However, not all combinations are synergistic or even additive, as demonstrated by 
failed clinical trials combining gefitinib or erlotinib with chemotherapy (133). Using two 
different classes of anti-EGFR inhibitors may be effective, since tumor xenograft experiments 
have shown synergy between mAb 806 and the TKI AG1478 (134). In addition, the combination 
of two anti-EGFR antibodies directed against different epitopes has been shown to stimulate 
receptor downregulation and inhibit signaling (135,136). Other successful combinations include 
simultaneously inhibiting EGFRvIII and c-Met (137), and rationales for treatment using ErbB 
plus mTOR inhibitors or ErbB plus estrogen inhibitors are discussed in (132). 
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1.5 Overview of thesis work 
 In this thesis work, we have sought to characterize and engineer antibodies against the 
epidermal growth factor receptor. Multiple anti-EGFR antibodies have been developed, but their 
binding epitopes had not been determined due to a lack of convenient epitope mapping methods. 
To alleviate this, we developed a novel method of epitope mapping using random mutagenesis 
and yeast surface display. In our approach, we disrupted the antibody-antigen interaction through 
point mutations. However, since we did not know the epitopes of the antibodies, we made a 
library of random mutations, and then combinatorially screened this library using yeast surface 
display. EGFR mutants which displayed a loss of binding to the antibody being mapped were 
thus potential epitope residues. It was also necessary to screen for retention of binding to a 
conformation-specific antibody to remove misfolded EGFR mutants. The development of our 
novel method enabled the epitope mapping of a total of 4 antibodies: mAbs 806, 225, 13A9, and 
EMD72000. The determination of the antibody epitopes enabled further understanding of their 
mechanisms of action. Since mAbs 806, 225, and EMD72000 have high therapeutic relevance, 
this information may have clinical impact as well. In addition, the epitope mapping method was 
extended to mapping the binding of three designed ankyrin repeat proteins (DARPins) against 
EGFR. 
 Instead of using the common inhibition strategy of using antibodies to block ligand 
binding, we opted to engineer antibodies to directly inhibit receptor dimerization. Such 
antibodies could have advantages in tumors driven by autocrine signaling or the EGFRvIII 
mutant. We selected epitopes in EGFR domain II and domain IV to target with antibodies, and 
synthesized peptide mimics of these loops to use as antigen. Starting from a nonimmune human 
scFv library in yeast, candidate binders to the peptide epitopes were isolated and characterized. 
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The majority of binders were heavy chain only constructs, many of which were likely mediating 
binding through the VH/VL interface instead of the antibody CDRs. In addition, rabbit 
monoclonal antibodies against a domain IV peptide were developed, but appeared to only bind 
the peptide and not the EGFR ectodomain. 
 Finally, previous experiments had shown that polyclonal antibodies (pAbs) against either 
EGFR domain II or domain IV could eliminate the high affinity facet of EGF binding normally 
observed on the surface of cells. Based on these results, we hypothesized that the pAbs inhibited 
receptor dimerization, and thus inactive preformed EGFR dimers could represent the high 
affinity binding component. We developed a mathematical model incorporating these hypotheses 
to determine whether such a model could be consistent with experimental observations. The 
equilibrium ligand binding and receptor dimerization model was fit to the experimental data 
using three parameters: the high affinity binding constant, the dimerization constant, and the 
maximum binding signal. The model was able to successfully reproduce the experimental data, 
and it could produce characteristic concave-up Scatchard plots for a wide range of values. 
Overall, we have increased understanding of the mechanisms of action of a number of anti-
EGFR antibodies. 
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Chapter 2: Epitope mapping of proteins binding to EGFR 
 
2.1 Background 
 Epitope mapping is the process of determining which antigen residues are responsible for 
mediating antibody-antigen interactions. This information can be important in understanding the 
mechanism of action of the antibody and can aid in the design of novel antibodies against the 
same antigen. One method of determining the epitope of an antibody is through co-crystallization 
of the antibody in complex with its antigen. However, this can be very time-consuming and 
technically difficult, especially for a complex antigen such as EGFR. Only within the past few 
years was the EGFR monomer itself crystallized (1), and the only antibody-EGFR complex 
structure was published recently (2). While co-crystallization is the “gold standard” of 
characterizing the epitope of an antibody, other methods exist to determine which residues of the 
antigen are important for antibody binding. 
 One class of epitope mapping methods utilizes peptide fragments of the antigen. 
Antibody reactivity to each of these fragments is tested, and the epitope can be localized to 
certain stretches of amino acids. SPOT synthesis involves the creation of synthetic peptides, 
which are spotted on cellulose membranes and assayed for antibody binding (3). Alternately, 
peptides can be expressed on the surface of bacteriophage (4), Escherichia coli (5), or yeast (6), 
with subsequent antibody binding analysis. Mass spectrometry has also be used to identify 
digested peptides of the antigen which retain binding to an antibody (7). Phage display and 
SPOT techniques have been utilized to determine the epitopes of various antibodies against ErbB 
receptor family members (8-10). However, peptide-based methods are limited in that they can 
only identify continuous, non-conformational epitopes. If the binding of the antibody depends on 
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the proper tertiary fold of the antigen, other methods must be used to determine its epitope. 
Peptides have been used to mimic epitopes discontinuous in sequence (11,12), although it is not 
guaranteed that for any given epitope, a peptide “mimotope” exists. 
 To identify a discontinuous epitope, H/2H-exchange mass spectrometry has been used to 
localize an epitope to discontinuous proteolytic fragments (13). Antibody epitopes can also be 
resolved to protein fragments or domains displayed on the surface of phage (14) or yeast (15). 
Another useful tool in dissecting protein-protein interactions is site-directed mutagenesis, in 
which residues of interest are mutated and subsequent changes in binding are measured. This 
allows for characterization of antibody binding in the context of the entire protein antigen. 
Initially, only conservative mutations to amino acid homologs (16) or alanine (17) were made to 
minimize disruption to the protein secondary and tertiary structure. This method requires soluble 
protein expression and characterization of each mutant to ensure proper folding, which can be 
time consuming. Also, some knowledge of the general location of the epitope is necessary to 
indicate which site-directed mutants should be constructed. Alternately, shotgun alanine or 
homolog scanning mutagenesis is a high-throughput method using phage display libraries and 
can incorporate saturation mutagenesis so that no knowledge of the epitope is necessary. Shotgun 
scanning has been used to map paratopes and protein-protein interactions (18-20). However, the 
prokaryotic expression system used by this method may not be amenable to epitope mapping of 
complex eukaryotic proteins such as EGFR ectodomain, which contains 25 disulfide bonds and 
10 N-linked glycosylation sites (21). Finally, other methods have utilized random mutations to 
all amino acids in order to disrupt antibody-antigen interactions. Random mutagenesis of the 
antigen followed by secretion by yeast in 96-well plates enabled epitope mapping in a semi-high-
throughput manner (22). Libraries of randomly mutagenized antigen have also been displayed on 
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the surface of filamentous phage (23) and mammalian cells (24), and selection of nonbinding 
mutants was performed in a combinatorial manner in these studies. 
 To overcome some of the shortcomings of existing techniques, we developed a novel 
method of epitope mapping using random mutagenesis and yeast surface display. In this method, 
a library of mutated antigen was displayed on the surface of yeast and screened using 
fluorescence-activated cell sorting (FACS). We applied this method to antibodies and designed 
ankyrin repeat proteins (DARPins) against EGFR, and we successfully determined the epitopes 
of several proteins, many of which bind in a conformation-specific manner. 
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2.2 Materials and methods 
Construction and expression of epitope mapping libraries 
The epitope mapping libraries were constructed using the Stratagene GeneMorph random 
mutagenesis kit to give a low mutagenesis rate. The template used for library construction was a 
pCT302 yeast-display plasmid backbone containing either the EGFR fragment 273-621 with a 
C283A mutation to prevent disulfide mispairing (15) (Appendix 1.2) or the 404SG EGFR 
ectodomain mutant (25) (Appendix 1.3). The PCR products were gel purified and extracted using 
a Qiagen Qiaquick gel extraction kit. The library was transformed into Saccharomyces cerevisiae 
strain EBY100 (26) by electroporation and homologous recombination using a Bio-Rad 
(Richmond, CA) Gene Pulser Transfection Apparatus (27). The final library contained a roughly 
Poisson distribution of amino acid changes to the EGFR fragment as demonstrated by plasmid 
recovery using a Zymoprep kit (Zymo Research) and sequencing of 100 library clones (MIT 
Biopolymers Laboratory). Yeast were grown in SDCAA media overnight at 30 oC and were 
induced to express protein on the cell surface by induction at a starting OD600 of 0.5 at 30 oC in 
SGCAA media (27) with a 1/25 volume of SDCAA. 
 
Labeling and sorting of yeast 
 The anti-human EGFR mouse monoclonal antibodies 806 and 175 were generously 
provided by the Ludwig Institute for Cancer Research, mAb 13A9 was provided by Genentech 
(San Francisco, California), and mAb EMD72000 was provided by EMD-Lexigen 
Pharmaceuticals. mAb 225 was purchased from LabVision (Fremont, CA), anti-c-myc chicken 
IgY fraction was purchased from Invitrogen (Carlsbad, CA), and mAbs 528 (28), 199.12, 
EGFR1 (29), and ICR10 (30) were purchased from Abcam (Cambridge, UK). 
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  Yeast cells were labeled as described (27). Briefly, yeast cells (at least 10X library size) 
were washed with PBSA buffer (phosphate buffered saline containing 1 mg/ml bovine serum 
albumin). The cells were incubated with 1:250 anti-c-myc chicken IgY and the appropriate 
concentration of mAb for 30 min at 25 oC. The cells were then washed with PBSA and incubated 
with 1:50 phycoerythrin (PE)-labeled goat anti-mouse IgG (Sigma) or 1:100 goat anti-human-PE 
IgG (Rockland) and 1:100 goat anti-chicken-Alexa488 IgG (Invitrogen) for 20 min at 4 oC. The 
labeled cells were washed with 1 ml PBSA, and cell libraries were sorted using either a MoFlo 
(DakoCytomation) or Aria (BD Biosciences) FACS machine at the MIT flow cytometry core 
facility. In addition, a positive control of antibody binding to wild-type antigen was labeled to 
assist in drawing the selection window. 
 
Identification and testing of single clones 
  Plasmids from the sorted library populations were recovered using a Zymoprep kit and 
sequenced at the MIT Biopolymers Laboratory. Site-directed mutants were made using 
QuickChange mutagenesis (Stratagene). Single clones were transformed into yeast using EZ 
Yeast Transformation (Zymo Research) and grown and induced as above. For each clone, 106 
cells were labeled as before in a final volume of 50 μL. Fluorescence data was obtained using a 
Coulter Epics XL flow cytometer (Beckman-Coulter) and was analyzed using either 
DakoCytomation Summit or FloJo (Tree Star, Inc.) software. 
 
Titration of EGFR fragments against mAb806 
 Cells were grown, induced, and labeled as above. Mean fluorescence data of c-myc 
positive yeast were obtained using a Coulter Epics XL flow cytometer and were normalized by 
40 
maximal and minimal mean fluorescence intensities. The binding interaction was assumed to be 
a single site binding model with no ligand depletion. Titration data was fit to the equation: 
fmAb = [mAb][mAb]+ Kd
      (1) 
where fmAb is the fractional binding of mAb 806 to yeast-surface displayed EGFR 273-621, 
[mAb] is the concentration of mAb 806, and Kd is the apparent dissociation constant. A global fit 
of three data sets was performed using Microsoft Excel, and 68% confidence intervals were 
calculated according to (31). 
 
Protein images and surface area calculations  
 All EGFR protein images were generated using PyMOL software (DeLano Scientific 
LLC, at http://www.pymol.org). The solvent accessible surface area of each residue of EGFR 
(using structure 1NQL) was calculated using Getarea 1.1 (Sealy Center for Structural Biology, 
University of Texas Medical Branch, at http://www.scsb.utmb.edu/cgi-bin/get_a_form.tcl). A 
water probe size of 1.0 was used to allow for correct identification of EGF contact residues as 
being on the surface. Residues with a value of 20 or above were considered surface residues. 
 
DARPin epitope mapping 
 Designed ankyrin repeat protein (DARPin) clones E1, E67, E68, E69, and E72 containing 
C-terminal His tags were provided by Dr. Andreas Plueckthun (University of Zurich). DARPin 
binding to 404SG on the surface of yeast was detected using 1:100 biotinylated mouse Penta-His 
antibody (Qiagen) followed by 1:50 streptavidin-PE (Invitrogen). All other cell growth, sorting, 
and clone analysis was performed as above. 
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2.3 Results 
2.3.1 Creation of epitope mapping library 
 In order to determine the epitopes of antibodies binding to EGFR, we created a novel 
method of epitope mapping using random mutagenesis and yeast surface display. Previously, 
Cochran et al. reported domain-level epitope mapping through yeast surface-displayed fragments 
of EGFR (15). Large polypeptide fragments of EGFR were expressed on the surface of yeast 
cells and were used to localize antibody binding to particular regions of the receptor for both 
continuous and discontinuous epitopes. Yeast surface display is a tool originally developed for 
protein engineering (32), in which the gene for a protein of interest is fused the yeast native Aga2 
protein. The yeast cells are then induced to display this protein fusion on the cell wall, where it is 
accessible for binding to other soluble proteins (Figure 2-1). 
 
Figure 2-1: Schematic of yeast surface display. The yeast native proteins Aga1 and Aga2 are displayed on the yeast 
cell wall, allowing the fusion protein Aga2p-EGFR to be displayed. Fluorescent antibody against either the HA or 
c-myc epitope tag allows for the detection of EGFR on the yeast surface, while antibody binding to the EGFR can be 
detected through a differently colored fluorescent probe. 
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In creating our novel fine epitope mapping method, we sought to further resolve antibody 
epitopes to individual residues involved in antibody-antigen contacts. To do so, we specifically 
disrupted the interaction between the antibody being mapped and the EGFR antigen through 
point mutations. If a single mutant displayed of a loss of binding to the antibody, then that 
particular residue was potentially a contact residue. However, mutating each individual residue 
of the EGFR ectodomain (621 amino acids) would be prohibitively time-consuming. To make 
the process high-throughput, we employed random mutagenesis of a fragment of the EGFR 
ectodomain (residues 273-621), and transformed this library into yeast. Then, using yeast surface 
display, we could induce each yeast cell to display a different EGFR mutant on its surface. High-
throughput screening of this library for EGFR mutants with a loss of antibody binding was 
accomplished using fluorescence-activated cell sorting (FACS). Once the nonbinding population 
was enriched, the individual clones were sequenced to identify potential epitope residues. The 
process of epitope mapping using yeast display is summarized in Figure 2-2. 
A low mutation-rate library was constructed by error-prone PCR of the EGFR fragment 
273-621. The initial library size was 5x105, and sequencing of 100 clones from the unscreened 
library indicated that 72% were wild-type EGFR, 17% contained single amino acid mutations, 
and 11% contained multiple mutations or a frameshift. This corresponds to an effective library 
size of 8.5x104, which is an order of magnitude higher than the largest theoretical diversity of 
single amino acid mutants of this 349-residue protein fragment (6.6x103), and nearly two orders 
of magnitude higher than the 1.0x103 diversity of amino acids accessible by a single nucleotide 
mutation. Yeast were transformed with the DNA library, and the cells were induced the express 
the EGFR mutants on their surfaces. Using this epitope mapping method, we sought to determine 
the epitopes of several therapeutically relevant antibodies against EGFR. 
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 Figure 2-2: Summary of epitope mapping method. A mutant library of the antigen is transformed into yeast, and the 
yeast cells are induced to express the mutant antigens on their surfaces. The antibody to be mapped is added to the 
yeast mixture, and cells with reduced antibody binding are isolated using FACS. 
 
2.3.2 Epitope mapping of mAb 806 
mAb 806 against EGFR served as a positive control since its epitope had previously been 
shown to reside in the disulfide-bonded loop between EGFR residues 287-302 (33). In order to 
map the mAb 806 epitope, the library of EGFR mutants displayed on the surface of yeast was 
labeled with chicken anti-c-myc IgY to detect full-length EGFR 273-621 expression. The cells 
were also labeled with a high concentration of mAb 806 to allow for differentiation between 
cells possessing wild-type binding and those with a decrease in binding affinity. The library was 
sorted using successive rounds of FACS to isolate those cells displaying mutants with a decrease 
in affinity to mAb 806 (Figure 2-3).  
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 Figure 2-3: Flow cytometry data for mAb 806 binding to epitope mapping library. EGFR expression as detected 
through the c-myc tag is shown on the abscissa, and mAb 806 binding is shown on the ordinate. The yeast EGFR 
mutant library was labeled with 10 nM mAb 806 for sort 1 and 75 nM mAb 806 for sort 2. The yeast were also 
labeled with chicken anti-c-myc IgY, followed by goat anti-chicken-Alexa488 IgG and goat anti-mouse-PE IgG. 
The cell collection gates are indicated by the dotted lines, and the double negative population results from yeast 
plasmid loss. 
 
Three sorts were performed for mAb 806, with round 1 labeled at 10 nM mAb 806, and rounds 2 
and 3 labeled at 75 nM mAb 806. Clone isolation and DNA sequencing were performed after 
sorts 2 and 3. Out of 100 sequenced clones, ~20% contained multiple amino acid mutations and 
were omitted from subsequent analysis to facilitate interpretation of the data and to eliminate 
spurious neutral mutations. The single mutants isolated from the library for loss of binding to 
















Table 2-1: EGFR mutants isolated for loss of binding to mAb 806. Binding scores were determined by testing for 
binding at 75 nM mAb 806 to mutants displayed on the surface of yeast. + indicates a partial loss of binding and − 
indicates a large loss of binding. 
 
After the mutations were sequenced, the plasmids containing the EGFR mutants were re-
transformed into yeast, and each mutant was retested to ensure that all mutations were correctly 
identified as having reduced binding to mAb 806. The mutations were also scored according to 
the degree of binding loss at a concentration of 75 nM mAb 806 (Table 2-1). Example flow 
cytometry data for various EGFR mutants binding to mAb 806 is shown in Figure 2-4.  
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 Figure 2-4: Flow cytometry data for representative EGFR mutants and their binding scores to 75 nM mAb 806. 
Yeast displaying the mutants were also labeled with chicken anti-c-myc IgY, followed by goat anti-chicken-
Alexa488 IgG and goat anti-mouse-PE IgG. ++ indicates wild-type binding, + indicates a partial loss of binding, and 
− indicates a large loss of binding (equal to negative control at this concentration). 
 
To quantitatively correlate mAb 806 labeling scores with particular affinity constants, 
binding titrations on the yeast surface were performed to determine the apparent dissociation 
constant (Kd) of mAb 806 for wild-type EGFR 273-621 (++), mutant C287R (+), and mutant 
E293K (−). The titration curves are shown in Figure 2-5. The data were fit to a single site 
binding model with no depletion. Although the bivalent mAbs could potentially result in avidity 
effects, these apparent dissociation constants could still be used for comparison between EGFR 
mutants. The apparent dissociation constant of mAb 806 for yeast surface-displayed wild-type 
EGFR 273–621 is 2.13 nM (68% confidence interval of 1.83–2.50 nM), which is consistent with 
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the affinity of mAb 806 binding to mammalian cells expressing EGFR vIII (34). The C287R 
substitution increases the Kd to 127 nM (68% confidence interval of 103–160 nM), which gives a 
ΔΔG value of +2.4 kcal/mol when compared to wild-type and, in alanine scanning terms, is a 
significant loss of binding (35). The E293K substitution leads to a Kd value of at least 30 μM, 
corresponding to a ΔΔG of at least +5.7 kcal/mol. This large loss of binding is consistent with the 
charge-reversing nature of the amino acid substitution. The above ΔΔG values demonstrate the 
relative energetic importance of these mutations, and the results from these three representative 
clones were used to roughly estimate the energetic importance of the other untitrated mutants 


















Figure 2-5: Titration of mAb 806 against yeast surface-displayed EGFR 273-621 and mutants. Red, wild-type (++); 
green, C287R (+); blue, E293K (−). A global fit to a single site binding model was performed with three 
independent sets of data. Square, triangles, and diamonds represent separate data sets. 
 
To verify the results from the fine epitope mapping method, we performed alanine 
scanning through site-directed mutagenesis on the residues comprising the EGFR disulfide-
bonded loop 287-302 (Table 2-2). All amino acid sites with a loss of mAb 806 binding by 
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substitution by alanine corresponded to mutants identified using our yeast-displayed library 
method (287, 293, 298, and 302). Conversely, residues 297, 300, and 301 were not identified as 
important for mAb 806 binding by alanine scanning, yet form an energetically important 
component of the epitope as determined by our method. Clearly, using mutations to residues 
other than alanine allows for greater discrimination of the epitope of an antibody. 
 



















Table 2-2: EGFR mutants created by site-directed mutagenesis. Binding was tested at a concentration of 75 nM 
mAb 806 against mutants displayed on the surface of yeast. ++ indicates wild-type binding, + indicates a partial loss 
of binding, and − indicates a large loss of binding. 
 
 All of the mutations leading to a decrease in mAb 806 binding were localized to the 
disulfide loop between cysteine residues 287 and 302, consistent with published results (33). 
However, the residue-level resolution afforded by our method provides additional insight into the 
mAb 806 binding epitope. The residues identified as energetically important for mAb 806 
binding are shown in terms of the EGFR structure are shown in Figure 2-6. These residues are 
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clustered on one face of the disulfide loop between cysteines 287 and 302, indicating that this 
region is the mAb 806 binding epitope. Interestingly, Val299 is located in the middle of these 
residues, but was not identified in the library or alanine scan. Thus, the V299K and V299D site-
directed mutants were created and tested, and although the epitope can accommodate a lysine 
residue without effect, an aspartic acid substitution ablates detectable binding (Table 2-2). This 
further indicates that mAb 806 is likely to contact this face of loop 287–302.  
Although mAb 806 binds to heat and SDS-denatured EGFR (33), implying a linear 
binding epitope, the library analysis performed here suggests that the epitope is not entirely 
continuous in sequence. Examination of the structure of the loop shows that the sidechain of 
Glu293 projects from one side of the loop to the putative contact face. In addition, the mAb 806 
epitope is constrained by a disulfide bond between cysteines 287 and 302, and two salt bridges 
(Glu293-Arg300 and Asp297-Lys301) (Figure 2-6c). All six residues involved in these 
interactions were isolated from the library for loss of binding to mAb 806, highlighting the 
importance of the constrained nature of the epitope for high affinity binding. It is unclear 
whether these residues directly make contact with the antibody, or if they are only important for 
constraining the peptide and reducing its entropy. The cysteine at position 287 tolerated a wide 
variety of substitutions that led to an intermediate loss of binding (Table 2-1), indicating that its 
energetic contribution to the epitope may arise more from constraining the loop rather than 
directly contacting the antibody. In contrast, the cysteine at position 302 may be a contact 
residue since it only tolerated substitutions to larger residues with aromatic character. 
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 Figure 2-6: mAb 806 binding epitope on EGFR. (a) and (b) Front and back views of residues 287-302 in chain a of 
the EGF-bound dimerized EGFR structure (1IVO), which was used because Glu293 is not resolved in the monomer 
structure (1NQL). Residues shown in color are those which were identified as important for mAb 806 binding using 
our yeast library method. Red, residues that also caused loss of binding upon alanine substitution; orange, residues 
that did not; gray, residues that were not identified as important for binding by both library and alanine scanning 
methods. (c) The epitope is constrained by a disulfide bond and two salt bridges. Negatively charged residues, red; 
positively charged residues, blue; cysteine residues, yellow. Image includes residues 287-302 on both EGFR 
molecules in dimer structure (1IVO). (c) mAb 806 epitope in context of full tethered EGFR monomer (1NQL), 




The mAb 806 epitope in context of the tethered EGFR monomer structure (1) is shown in Figure 
2-6d. From viewing the structure, it appears that in this conformation, an antibody would be 
partially blocked from accessing the epitope. This is consistent with the observation that mAb 
806 does not bind soluble EGFR, but does bind to an untethered EGFR mutant perturbed away 
from the autoinhibited conformation (33). 
 
2.3.3 Effects of EGFR mutations on binding of mAbs 806 and 175 
 Because of the convenience of performing titrations on the surface of yeast, the binding 
of mAb 806 to additional EGFR mutants was characterized in further studies. This work was 
conducted in collaboration with Arvind Sivasubramanian and Jeff Gray at Johns Hopkins 
University. We combined computational protein-protein docking with computational and 
experimental mutagenesis to predict the structure of the complex formed by mAb 806 and 
EGFR. Initially, Arvind docked mAb 806 to its peptide epitope of EGFR residues 287-302. 
Potential mAb 806-EGFR structures, or decoys, were generated, and computational mutagenesis 
was used to filter them according to their agreement with the previously generated experimental 
mutagenesis data in Tables 2-1 and 2-2. Further computational mutagenesis suggested additional 
mutations, which we tested to differentiate between three potential docked models. The site-
directed mutants were created and transformed into yeast, and mAb 806 binding to these mutants 
was scored as before in Section 2.3.2. The results are listed in Table 2-3, and they allowed 
Arvind to arrive at a final structure with the highest agreement between computational and 






















Table 2-3: mAb 806 binding to EGFR mutants used to discriminate between computational models. Binding was 
tested at a concentration of 75 nM mAb 806 against mutants displayed on the surface of yeast. ++ indicates wild-
type binding, + indicates a partial loss of binding, and − indicates a large loss of binding. 
  
Another antibody, mAb 175, was also characterized using binding to EGFR mutants 
displayed on the surface of yeast. mAb 175 was isolated at the same time as mAb 806, and 
displays similar reactivity to the peptide of EGFR residues 287-302 (T.G. Johns et al., 
manuscript in preparation). Therefore, the mutants originally tested for binding to mAb 806 were 
tested for mAb 175 reactivity. The binding scores for mAb 175 compared to those for mAb 806 
are shown in Table 2-4. The results show only minor binding differences between mAbs 175 and 
806, with mAb 175 showing slightly reduced binding to mutants D297A, V299A, and V299K. 
This is consistent with the crystal structures of mAbs 175 and 806 each bound to the EGFR 
peptide 287-302, which show identical contact residues for the two antibodies (T.G. Johns et al., 
manuscript in preparation). 
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C287A,G,R,S,W,Y + + 
G288A ++ ++ 
A289K ++ ++ 
D290A ++ ++ 
S291A ++ ++ 
Y292A ++ ++ 
E293A,D,G + + 
E293K − − 
M294A ++ ++ 
E295A ++ ++ 
E296A ++ ++ 
D297A + ++ 
D297Y + + 
G298A + + 
G298D,S − − 
V299A,K + ++ 
V299D − − 
R300A ++ ++ 
R300C + + 
R300P − − 
K301A ++ ++ 
K301E + + 
C302A,G,S − − 
C302F,R,Y + + 
Table 2-4: Binding of mAb 175 to EGFR mutants compared to mAb 806. Binding was tested at a concentration of 
75 nM mAb 175 or mAb 806 against mutants displayed on the surface of yeast. ++ indicates wild-type binding, + 
indicates a partial loss of binding, and − indicates a large loss of binding. 
 
2.3.4 Epitope mapping of mAbs 225 and 13A9 
 The binding of mAbs 806 and 175 to EGFR did not depend on the correct tertiary fold of 
the protein; therefore, their epitopes were not strictly conformational. However, epitope mapping 
of mAbs 225 and 13A9 presented a greater challenge because these two antibodies have 
conformational epitopes (15). mAb 225 is the murine precursor to the FDA-approved antibody 
drug cetuximab (Section 1.4). Both antibodies bind to EGFR domain III, compete with each 
other (data not shown), and compete with TGF-α ligand binding (37,38). However, mAb 225 
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competes with EGF ligand binding, while mAb 13A9 does not (38,39). This is unexpected, 
because it appears from the crystal structures of EGF and TGF-α bound to EGFR that the two 
ligands bind in the same location (40,41). We sought to determine the epitopes of these 
antibodies to better understand their behavior and mechanisms of action. 
 For epitope mapping of mAb 225, the EGFR mutant library described in Section 2.3.1 
was screened for loss of binding to 50 nM mAb 225 for sort 1 and 100 nM for sorts 2-4, with 
clone sequencing after sorts 3 and 4. Out of 185 clones sequenced, ~40% contained multiple 
amino acid mutations and were omitted from subsequent analysis. In total, 84 unique single 
amino acid substitutions were isolated from the library and were re-transformed and retested in 
yeast to confirm loss of mAb 225 binding. These mutations are shown in Figure 2-7a. The 
majority of the mutations are localized or adjacent to domain III, consistent with the observation 
that mAb 225 blocks ligand binding to this domain. Since mAb 225 recognizes a conformational 
epitope (15), a properly folded domain III is required for antibody binding. Clearly, all of the 
residues shown in Figure 2-7a cannot comprise the mAb 225 epitope; therefore, it seems that 
most of these mutations are instead causing a perturbation of the domain III conformation, 
leading to the observed loss of mAb 225 binding. As shown by this analysis, it appears that 
domain III is very sensitive to conformational perturbation through mutation. Although it was 
expected that the yeast secretory quality control apparatus would not allow misfolded mutants to 
be displayed on the cell surface (42,43), it appears that many of these conformationally altered 
EGFR mutants are able to circumvent quality control. In fact, the intertwined disulfides Cys482-
Cys491 and Cys486-Cys499 of EGFR domain IV are required for the proper folding of domain 
III (44), and, accordingly, all of these mutations were isolated from the library for loss of binding 
to mAb 225. 
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 Figure 2-7: (a) All single amino acid mutation sites isolated from the library that exhibited a loss of binding to mAb 
225, yellow. EGFR fragment 273-621 (1NQL) is shown in surface representation in grey. (b) and (c) Front and back 
view of surface only mutation sites that were not mutated to/from proline, glycine, or cysteine or from a 
glycosylation site, yellow. (d) Residues identified after antibody cross-testing; mAb 225 residues, yellow; mAb 
13A9 residues, red. (Note: Lys465 and Glu472 side chains are not resolved in this structure.) 
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In an attempt to extract useful contact residue information from these mutational data, we 
developed two criteria to eliminate those mutations which seemed particularly disruptive to 
protein folding. First, we only considered mutations of surface residues (based on solvent-
accessible surface area), since mutations to the protein core could be expected to disrupt protein 
conformation. The mutations with loss of binding to mAb 225 and disregarded from analysis in 
this step are listed in Table 2-5, top. However, the remaining mutations were still dispersed 
across the surface of EGFR domain III in a fashion that would not allow simultaneous contact 
with a single antibody-binding surface. Mutations to or from a proline, glycine, or cysteine 
residue could potentially perturb the EGFR domain III secondary structure, and such mutations 
were found to be abundantly represented amongst the pool of non-binding mutants. Therefore, 
we applied a second criterion to disregard mutations of a potentially disruptive nature, and 
residues that were mutated to or from a proline, glycine, or cysteine or from a glycosylation site 
were eliminated from the mAb 225 epitope analysis (Table 2-5, middle). Since elimination of all 
of these mutations is overly restrictive, the sites eventually identified by this procedure can 
formally only be a subset of the energetically significant contact residues. While the use of these 
two criteria reduced the number of potential mAb 225 contact residues, the remaining mutations 














































































 mAb 13A9, another antibody that binds to a conformational epitope, was also screened 
against the EGFR mutant library. The library was labeled at 50 nM mAb 13A9 for sort 1 and 100 
nM for sorts 2-5, with individual clone analysis after sort 5. Out of 170 clones sequenced, ~40% 
contained multiple amino acid mutations and were omitted from subsequent analysis. A total of 
73 unique single amino acid mutations were identified as leading to a loss of binding to mAb 
13A9. As seen with mAb 225, the majority of mutations were located in or adjacent to domain 
III but were not localized to an epitope. The same criteria used to eliminate potentially misfolded 
mAb 225 mutants were applied to the mAb 13A9 mutants (Table 2-6). Notably, many of the 
eliminated mutants were isolated for loss of binding to both mAb 13A9 and mAb 225. This 
further supports the hypothesis that these mutants are conformationally altered such that they can 
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no longer bind conformation-specific antibodies and justifies their elimination from the epitope 
mapping analysis. 
 






























































 The recurrence of the same mutations in the mAb 225 and mAb 13A9 sorts led to the 
concept of antibody cross-tests, in which the conformation-specific antibodies were used as 
probes for the proper folding of EGFR domain III. We hypothesized that loss of binding to only 
one but not the other antibody indicated a specific, energetically important contact residue for the 
antibody that showed loss of binding to the mutant. Representative antibody cross-tests are 
shown in Figure 2-8. For example, the EGFR mutant I467M does not bind to mAb 225 but 
shows wild-type binding for mAb 13A9. Therefore, the loss of binding to mAb 225 is most 
likely due to the mutation of a specific contact residue for the antibody, and not due to protein 
misfolding. Although unlikely, the possibility exists that a mutation might cause a 
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conformational change in domain III that permits binding of one antibody but not the other, 
therefore generating a false positive. For the EGFR mutant A329V, loss of some degree of 
binding to both mAb 225 and mAb 13A9 indicates that it is either altered in domain III 
conformation or the residue is in an overlapping portion of the two antibody epitopes. Such 
mutants with loss of binding to both antibodies were eliminated from the analysis, although this 
will also eliminate any residues that form important energetic contacts with both antibodies. 
Using the antibody cross-tests, we were able to identify two epitope residues each as 
energetically important for the binding of mAbs 225 and 13A9. EGFR mutants K465E and 
I467M showed loss of binding to mAb 225, but retained binding to mAb 13A9; therefore, 
Lys465 and Ile467 were implicated as energetically significant contact residues for mAb 225. 
Likewise, S468I and E472K showed loss of binding to mAb 13A9, but retained binding to mAb 
225; therefore, Ser468 and Glu472 were identified as the mAb 13A9 epitope. The epitopes in 
context of EGF and TGF-α ligand binding are shown in Figure 2-9. 
60 
 Figure 2-8: Flow cytometry data for antibody cross-tests of mAbs 225 and 13A9 binding to yeast surface-displayed 
EGFR 273-621 mutants at 50 nM mAb. EGFR display fluorescence is shown on the abscissa, and mAb binding is 




 Figure 2-9: mAb 225 and mAb 13A9 epitopes in context of ligand binding. Blue, mAb 225 epitope; red, mAb 13A9 
epitope; green, ligands. (a) Domain III of EGF-bound EGFR dimer (chain a of 1IVO). (b) Domain III of TGF-α-
bound EGFR dimer (chain a of 1MOX). 
 
The experimental work leading to the identification of the epitopes of mAbs 806, 225, and 13A9 
(described in Sections 2.3.1-2.3.2 and 2.3.4) was published in (45). After the publication of this 
paper, the crystal structure of the Fab fragment of mAb 225 bound to EGFR was solved (2). The 
residues Lys465 and Ile467, which were identified by our library method, were found to be in the 
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center of the mAb 225/EGFR complex interface; thus, the results of the epitope mapping method 
have been independently verified by co-crystallization. 
 
2.3.5 Epitope mapping of mAb EMD72000 
 In a partnership with EMD-Lexigen Pharmaceuticals, the epitope of mAb EMD72000 
was determined. mAb EMD72000 is a humanized antibody, and like mAb 225, inhibits the 
binding of EGF to EGFR (46). However, initial experiments using EGFR fragments on the 
surface of yeast revealed that mAb EMD72000 did not bind EGFR 273-621. Although mAbs 
225 and 13A9 were able to detectably bind EGFR 273-621, at least a portion of the protein 
displayed on the yeast surface was misfolded and thus unreactive to the antibodies, as evidenced 
by the lower fluorescence signal at saturating binding conditions compared to mAb 806 binding 
(Figure 2-8 vs. Figure 2-4). mAb EMD72000 binding may be extremely sensitive to 
conformational perturbation or yeast hyperglycosylation (O-linked or hypermannosylation of N-
linked sites). Although the full EGFR ectodomain is not correctly expressed by yeast, previous 
work has identified an EGFR ectodomain mutant, 404SG, which is properly folded on the 
surface of yeast (25). 404SG contains two point mutations in domain I (A62T and L69H) and 
two mutations in domain III (F380S and S418G). This receptor is able to bind the conformation-
specific antibodies 199.12, ICR10, EGFR1, 225, and 13A9 (25). mAb EMD72000 also bound 
the 404SG mutant displayed on the surface of yeast and did not compete for binding with mAb 
225 or mAb 806 (Figure 2-10). However, the binding of mAb 225 to EGFR appears to slightly 
decrease the affinity of mAb EMD72000 for the receptor. One possibility is that mAb 225 
perturbs the conformation of EGFR domain III upon binding, thus decreasing the binding of 
mAb EMD72000 to the receptor. 
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Figure 2-10: mAb EMD72000 binding to yeast surface-displayed 404SG EGFR ectodomain mutant. (a) Binding 
histograms to yeast labeled with either 40 nM mAb 225 or 0.5 μM mAb EMD72000. (b) Binding histograms to 
yeast labeled with mAb 225 and mAb EMD72000 simultaneously. (c) Binding histograms to yeast labeled with 
either 75 nM mAb 806 or 0.5 μM mAb EMD72000. (d) Binding histograms to yeast labeled with mAb 806 and 
mAb EMD72000 simultaneously. 
 
 The epitope of mAb EMD72000 was determined as before using random mutagenesis 
and yeast surface display (Section 2.3.1). However, a new low mutation rate epitope mapping 
library was created using 404SG as the DNA template. The library had a diversity of 6.5x105, 
and sequencing of 10 random clones from the library yielded 5 wild-type clones, 1 single mutant, 
and 4 multiple mutants and/or frameshifts. The library was sorted to enrich for mutants with loss 
of binding to mAb EMD72000 with four rounds of FACS at 0.5 µM EMD72000 (Figure 2-11a). 
Then, instead of antibody cross-tests as were performed in Section 2.3.4, high-throughput FACS 
selection was then used to remove the misfolded 404SG mutants from the analysis. The library 
was sorted for retention of binding to mAb 225 with 2 rounds of positive FACS (Figure 2-11b). 
Since mAb 225 binding is dependent on the correct conformation of EGFR domain III, this 
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ensured that only properly folded EGFR mutants were subsequently sequenced and analyzed. 
These selections also abrogated the need to apply filtering criteria to remove potentially 
misfolded mutations from the epitope analysis, as was necessary for mAbs 225 and 13A9. 
 
 
Figure 2-11: FACS selections for mAb EMD72000 epitope mapping. 404SG expression as detected through the c-
myc tag is shown on the abscissa, and antibody binding is shown on the ordinate. Selection windows are shown in 
red. (a) 404SG mutant library labeled with 0.5 μM mAb EMD72000, sorted for a loss of binding to the antibody. 
The yeast were also labeled with chicken anti-c-myc IgY, followed by goat anti-chicken-Alexa488 IgG and goat 
anti-human-PE IgG. (b) Enriched mutants from (a) labeled with 40 nM mAb 225, sorted for retention of binding to 
mAb 225. The yeast were also labeled with chicken anti-c-myc IgY, followed by goat anti-chicken-Alexa488 IgG 
and goat anti-mouse-PE IgG. 
 
 After the selections using FACS were completed, the plasmids from the yeast were 
rescued, and a total of 100 clones were sequenced. All unique sequences were then re-
transformed into yeast to ensure their loss of binding to mAb EMD72000 and retention of 
binding to mAb 225, and these mutants are listed in Table 2-7. For this selection, a total of seven 
residues were identified as being energetically important for mAb EMD72000 binding, instead 
of only two residues as before with mAbs 225 and 13A9. One reason was that the elimination of 
misfolded mutants was high-throughput through the use of FACS, thus enabling the sequencing 
and identification of many more properly folded mutations than before. Also, since the probe for 
proper EGFR mutant folding, mAb 225, did not compete with mAb EMD72000, more epitope 
residues could be identified. The mutants showed different degrees of loss of binding to mAb 
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EMD72000 (Figure 2-12), and these residues thus represent the mAb EMD72000 epitope. The 
epitope is compared to other antibody epitopes on EGFR domain III in Figure 2-13 and the 
EGFR dimer in Figure 2-14. 
 
N 452 I 
K 454 E*, Q, N 
F 457 I* 
S 460 A, F, P, T, Y 
G 461 D 
Q 462 K*, L 
K 463 E, I, N, T 
Table 2-7: Mutants with loss of binding to b 7 ention of binding to mAb 225. Mutants marked 
with an asterisk were only found in the lib  a e onal irrelevant mutations, which were mutated 
Figure 2-12: Examples of s e surface of yeast. 404SG 
expression as detected through the c-myc tag is shown on the abscissa, and antibody binding is shown on the 
 mA  EMD 2000 and ret
s with additirary s clon
back to wild-type sequence, and the single mutant was then re-tested to confirm its behavior. 
 
 
ingle-clone analysis of 404SG and mutants displayed on th
ordinate. Yeast were labeled with 0.5 μM mAb EMD72000 or 40 nM mAb 225 and chicken anti-c-myc IgY, 
followed by goat anti-chicken-Alexa488 IgG and goat anti-human-PE or goat anti-mouse-PE IgG. 
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 Figure 2-13: Space-filled representation of EGFR domain III bound to EGF ligand (1IVO). Green, EGF; red, mAb 
EMD72000 epitope; Yellow, mAb 13A9 epitope; Blue, mAb 225 epitope residues identified by this work; cyan, 
additional mAb 225 epitope residues from the mAb 225/EGFR crystal structure (2). 
 
 
Figure 2-14: Space-filled representation of EGFR dimer bound to EGF (1IVO). EGFR residues 1-272 (the residues 
absent from EGFRvIII) are shown in beige and brown, while the remaining EGFR residues are shown in grey and 
olive. EMD72000 epitope,  red; mAb 806 epitope, violet; all other coloring as in Figure 2-13. 
67 
2.3.6 Epitope mapping of DARPins 
Designed ankyrin repeat proteins (DARPins) are a novel class of proteins which, like 
antibodies, can be engineered for binding specificity to other proteins (47). DARPins that bind to 
a number of proteins have been isolated, including binders against Her2 (48), maltose binding 
protein (49), and caspase-2 (50). Originally, the molecules were designed from structure and 
sequence alignments of natural ankyrin repeats to generate a module with fixed framework 
residues and randomized residues for interaction with other proteins. For the full molecule, 
various numbers of this module are assembled (2 to 6) between N- and C-terminal capping 
repeats, and thus the randomized positions on several adjacent repeats comprise the binding 
interface. DARPins are extremely stable, with midpoints of thermal denaturation in the range of 
65 to 85 oC (47) and thus are easily expressed and purified from E. coli. Five DARPin clones 
(E1, E67, E68, E69 and E72) binding to EGFR were isolated by Daniel Steiner of the Andreas 
Plueckthun laboratory at the University of Zurich. Initial characterization of the DARPin clones 
performed by Daniel is detailed in Table 2-8. It was determined that E1, E67, and E68 competed 
with mAb 225 for binding to EGFR, while E69 did not. In addition, E67 and E68 competed for 
binding with E1. 
 












E1 3 28.0 yes yes 43.00 0.21 0.48
E67 3 26.8 yes yes 2.95 0.22 7.30
E68 3 58.8/26.8 yes yes 314.00 1.89 0.60
E69 4 33.4 no no 7.25 1.05 14.52
E72 3 26.8 - - - - >100
Table 2-8: Summary of characterization of DARPin clones performed by Daniel Steiner. MW, molecular weight; 
kon, on-rate; koff, off-rate; Kd, apparent dissociation constant. Because of a low binding signal for clone E72, 
competition data was inconclusive. 
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First, domain-level mapping of the DARPins was accomplished using EGFR fragments 
on the surface of yeast as before (15). E1 was found to bind yeast-surface displayed 404SG but 
did not bind EGFR 273-621 or 294-543, most likely for the same reasons that mAb EMD72000 
binding to these fragments was not observed (Section 2.3.5). The same binding pattern was seen 
for E67 and E68. Based on the previous experimental results, it was inferred that these three 
clones bound to EGFR domain III, and thus binding to the other EGFR fragments not containing 
this domain was not tested. E69 showed binding to 404SG and EGFR 1-294, very slight binding 
to EGFR 1-176, and no binding to EGFR 1-124. Therefore, it appears that E69 is binding either 
domain I or domain II, very possibly to residues spanning from just before amino acid 176 to 
amino acid 294. However, we cannot exclude the possibility of misfolding of the fragments 
which do not show E69 binding; therefore, formally, the epitope is located between amino acids 
1-294. E72 only showed binding to 404SG and not to any of the other EGFR fragments tested. 








1-124 Ν − − 
1-176 Ν ~ − 
1-294 Ν + − 
273-621 − − − 
294-543 − − − 
475-621 Ν − − 
1-621 (404SG) + + + 
Table 2-9: Binding of DARPins to yeast surface-displayed EGFR fragments. +, binding; −, no binding; ~, very 
slight binding; N, not tested. 
 
Binding of the DARPins to yeast surface-displayed 404SG is shown in Figure 2-15. 
Although each DARPin was labeled at a concentration to give >90% receptor occupancy 
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according to its affinity, appreciable differences in binding signal were observed for the different 
DARPins. Since 404SG has two mutations in domain III, these mutations may be affecting the 
binding of the DARPin clones to the yeast-displayed protein, with binding of clone E67 
especially affected. 
 
Figure 2-15: Labeling of yeast surface-displayed 404SG with DARPin clones. 404SG expression as detected 
through the c-myc tag is shown on the abscissa, and DARPin binding is shown on the ordinate. The yeast were 
labeled with each of the DARPins and detected using biotinylated Penta-His antibody followed by streptavidin-PE. 
Yeast were also labeled with chicken anti-c-myc IgY and goat anti-chicken-Alexa488 IgG to detect display level of 
404SG. Cells were labeled with (a) 50 nM E1 (b) 150 nM E67 (c) 50 nM E68 (d) 150 nM E69 (e) 500 nM E72. 
 
 Competition binding experiments were conducted for DARPins and conformation-
specific anti-EGFR antibodies binding to yeast-displayed 404SG. The DARPin and antibody 
were added simultaneously to the yeast mixture, and the change in DARPin binding was 
measured using FACS (Figure 2-16). E1 competed with mAb 225 and mAb EMD72000 for 
binding to 404SG, but not with mAb 528. Likewise, E67, E68, and E72 all displayed similar 
behavior to E1. E69 competed with ICR10 and 199.12 binding, but not with EGFR1. 
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 Figure 2-16: DARPin competition with anti-EGFR mAbs binding to 404SG on the surface of yeast. Cells were 
labeled with DARPins at the same concentrations as Figure 2-15. mAbs were added at a concentration of 50 nM 
simultaneously with the DARPins. DARPin binding fluorescence as detected using biotinylated Penta-His antibody 
followed by streptavidin-PE is shown on the x-axis. 
 
DARPins E1, E68, and E69 were selected for further fine epitope mapping. The 404SG 
mutant library used for mAb EMD72000 epitope mapping (Section 2.3.5) was also utilized for 
the DARPin mapping. First, misfolded EGFR mutants were removed from the library through 
one FACS selection for retention of binding to either 50 nM mAb 528 or mAb EGFR1. Then, the 
mAb 528-positive library was sorted for loss of binding to E1 (sort 1 at 50 nM and sorts 2-3 at 
100 nM) or E68 (sort 1 at 50 nM and sorts 2-3 at 100 nM). The mAb EGFR1-positive library 
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was sorted for loss of binding to E69, with sort 1 at 150 nM and sorts 2-3 at 300 nM. The 
enriched populations from the sorts were sequenced, and individual mutants were transformed 
into yeast and tested for proper folding and loss of binding to the DARPins. From 98 clones 
sequenced for DARPin E69, the epitope was localized to ten residues in EGFR domain I (listed 
in Table 2-10). The E69 epitope on the EGFR ectodomain is shown in Figure 2-17. 
 
Y 101 H 
D 102 E 
A 103 P 
N 104 I 
K 105 E, I, N 
T 106 P 
P 130 H, L, S 
H 159 Y 
L 160 P 
G 161 D 
Table 2-10: Mutants with loss of binding to DARPin E69 and retention of binding to mAb EGFR1. 
 
 
Figure 2-17: Epitope of E69. Epitope residues are shown in red, with the rest of the EGFR ectodomain (from 1IVO, 
chain a) shown in grey. EGF ligand is shown in stick representation in green. 
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For E1 and E68, 48 clones were sequenced from each enriched population, yielding 14 
residues for both epitopes. As seen in Table 2-11, many residues were shared between the two 
DARPins. The mutants Q408H, H409Y, Q411K, K465I, and G471D, which led to loss of E1 
binding, were tested against E68 and retained binding to this DARPin. The mutant Q384H 
showed loss of binding to E68, but retained binding to E1 (data not shown). However, some 
mutants isolated for loss of binding to one DARPin (H409Y, F412V, A415E, I438K, 
K463E/I/N/T, K465E, I467M/T, N469D) were not assayed for loss of binding to the other. Thus, 
these mutants may not be unique to either the E1 or E68 epitopes, but perhaps were not sampled 
in the clones sequenced. Amino acid 418 is an epitope residue for both E1 and E68, and it is 
mutated from serine to glycine in the 404SG EGFR ectodomain mutant, likely causing the lower 
than expected binding of these DARPins to 404SG (as seen in Figure 2-15). 
 
Residue E1 E68 
L 381 V V 
Q 384  H 
Q 408 H  
H 409 D, P, Q, Y D, P, Q 
Q 411 K, R R 
F 412  V 
A 415 T, V E, T, V 
V 417 A A 
G 418 D D 
I 438 K  
G 441 E, R E, R 
K 463  E, I, N, T 
K 465 E, I, N N 
I 467 M T 
S 468 G, R G, R 
N 469 H H, D 
G 471 D  
Table 2-11: Mutants with loss of binding to DARPins E1 and E68 and retention of binding to mAb 528. 404SG 
wild-type residues are shown in the left hand column, and mutations isolated for loss of binding to each DARPin are 
shown in the right columns. 
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The E1 and E68 epitopes are shown in Figure 2-18. Both DARPins bind to EGFR domain 
III and are expected to directly compete with ligand binding to the receptor. In addition, the 
DARPin epitopes share many residues with the mAb 225 epitope, consistent with these two 
DARPins competing with mAb 225 binding (as seen in Table 2-8 and Figure 2-16). 
 
Figure 2-18: (a) E1 and (b) E68 epitope residues (red) shown on EGFR domain III (chain a of 1IVO) bound to EGF 
ligand (green), compared to (c) mAb 225 epitope residues as identified by the crystal structure (2). 
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2.4 Discussion 
This work describes a novel method of fine epitope mapping using screening of randomly 
mutagenized antigen displayed on the yeast cell surface. The method is capable of identifying 
conformational epitopes of antibodies binding to complex eukaryotic proteins without prior 
knowledge of potential contact residues, which are several advantages over peptide epitope 
mapping and alanine scanning. The yeast surface display system enables convenient protein 
expression without the need to solubly express and purify each individual mutant. Clone 
characterization and titration are also efficiently performed on the surface of yeast. Initially, we 
identified the epitope of mAb 806, whose binding is not dependent on antigen tertiary structure. 
Because of this, all single mutations initially isolated from the library for loss of binding to mAb 
806 were localized to a single plausible antibody contact surface. In contrast, in order to identify 
the epitopes of mAb 225 and mAb 13A9, it was necessary to apply filtering criteria and antibody 
cross-tests to remove misfolded mutants from the analysis. Later, while mapping mAb 
EMD72000, we improved our epitope mapping method through the use of high-throughput 
selection of mutants which retained binding to a different conformation-specific antibody, thus 
ensuring that all sequenced clones were properly folded. 
This method can be generalized to map any protein-protein interaction. Yeast must be 
able to surface display one binding partner, and the other binding partner must be made solubly. 
Finally, another conformation-specific binder to the yeast-displayed protein is necessary to 
eliminate misfolded mutants. Preferably, this protein should not compete with the interaction 
being mapped, although useful information can still be gained if they do compete (as in the case 
of mAbs 225 and 13A9). For a multi-domain protein such as EGFR, the probe for proper 
conformation should preferably bind the same domain as the interaction being mapped. 
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Additionally, if yeast are unable to properly surface display a protein of interest, a small number 
of mutations can often be found through directed evolution that enable the correct folding of the 
protein, as in the case of EGFR and the 404SG mutant (25). Our method of random mutagenesis 
and yeast surface display has since been used to map the paratope of a single-chain antibody (51) 
and to determine the epitope of antibodies against botulinum toxin (52) and the West Nile virus 
envelope protein (53). 
A potential shortcoming of the fine epitope mapping method is that it is impossible to 
isolate all possible mutants which lead to a loss of antibody binding. For example, C302A is not 
an amino acid change accessible by a single nucleotide mutation; therefore, with a low mutation 
rate library, it is extremely unlikely that this mutation will be seen. In addition, although the 
epitope mapping library size was theoretically large enough to accommodate all amino acid 
changes accessible by a single nucleotide mutation, the mutant V299D was not isolated from the 
library. However, when this site-directed mutant was constructed, it led to a large loss of binding 
to mAb 806. Since the generation of the library is random, by chance, the initial library may not 
have contained this mutant. Alternately, the mutant may have been lost during growth or sorting 
of the library prior to single clone analysis, or it may have been necessary to sequence more 
clones to identify this mutant. To avoid such events, a larger library could be made to increase 
the number of mutations, or a larger number of cells could be grown, sorted, and sequenced. 
Despite the potential for loss of relevant mutants, the significantly reduced effort required in this 
approach outweighs the alternatives of site-directed mutagenesis or saturation mutagenesis of the 
entire gene. In any case, the fine epitope mapping method can be used to localize antibody 
binding to certain residues, followed by the creation of site-directed mutants to confirm and/or 
expand the epitope. 
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In this method, substitutions other than those to alanine can be sampled. As demonstrated 
here, some energetically important residues are not significantly impacted by mutation to alanine 
(e.g. Asp297, Arg300, and Lys301 for mAb 806), and consequently would lead to false negatives 
in an alanine scan. In some instances, the mutations in the library led to reversals of amino acid 
charge. Such mutations at some distance from the antibody contact interface might conceivably 
contribute to a loss of binding through electrostatic steering effects. However, this formal 
possibility did not appear to pertain in the cases of the mAb 806, mAb 225, and mAb 13A9 
epitopes, given the clustering of mutants in contiguous locations. 
Using this epitope mapping method, the binding site for mAb 806 was localized to one 
face of the constrained disulfide loop of EGFR 287-302, with Asp297-Cys302, Glu293, and 
possibly Cys287 acting as contact residues. The mAb 806 epitope is an example of a cystine 
noose, which is a disulfide-constrained, surface-exposed loop important in binding specificity 
(54). Cystine nooses have also been identified as major antigenic epitopes on various proteins, 
including protein G of bovine respiratory syncytial virus (55) and measles virus hemagglutinin 
protein (56). This suggests that a disulfide-constrained loop is a favorable antigenic structure; 
since it is already constrained, there is a smaller entropic cost upon antibody binding. Thus, a 
number of other disulfide loops on EGFR are potential epitope targets for antibody binding. mAb 
806 has been shown to exhibit increased binding to EGFR on cells lacking the domain II 
dimerization arm (33). Therefore, it has been hypothesized that mAb 806 binds to a transitional 
form of the receptor as it changes from a closed to extended monomer (33). It is thought that 
upon mAb 806 binding, the EGFR monomer can no longer dimerize and activate the receptor, 
accounting for its anti-tumor activity. The mAb 806 epitope presented here and as a result of 
protein docking simulations (36) is consistent with this hypothesis. The epitope is only partially 
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accessible in the tethered monomer structure, with residues Glu293 and Cys302 obscured (Figure 
2-6d). These residues could become exposed upon a conformational transition and allow binding 
of mAb 806. The mAb 806 epitope of one EGFR monomer is adjacent to the other monomer in 
the EGFR dimer structures, and antibody binding to this epitope could sterically prevent EGFR 
dimerization. Likewise, the mAb 175 epitope was found to be highly similar to that of mAb 806, 
and the two antibodies are expected to possess the same characteristics. 
 Two energetically important residues for each of the mAb 225 and mAb 13A9 epitopes 
were also identified. Because of a lower fluorescence binding signal to noise ratio for these 
conformation-specific antibodies, only mutants with a complete loss of binding could be 
differentiated from wild-type. The location of these energetically important contact residues 
might provide insight into the mechanisms of these antibodies (Figure 2-9). The mAb 225 
epitope is positioned adjacent to the binding sites of both EGF and TGF-α, and thus mAb 225 
most likely blocks binding of both ligands sterically. The epitope of mAb 13A9 appears to be 
located further away from the ligand binding site; although Ser468 is adjacent to the EGF 
binding site, Glu472 is farther towards EGFR domain IV. Therefore, it is possible to envision 
both mAb 13A9 and EGF simultaneously binding to EGFR, consistent with the experimental 
observation that mAb 13A9 does not compete with EGF binding (38). As viewed in the crystal 
structures of EGF- and TGF-α-bound EGFR, it does not appear possible to sterically block 
TGF-α binding without also sterically preventing EGF binding. However, mAb 13A9 prevents 
TGF-α binding while allowing EGF binding (38). Based on the location of these residues and the 
ligand binding site on EGFR, mAb 13A9 may prevent TGF-α binding through mediating 
conformational changes to domain III that are sufficient to prevent TGF-α, but not EGF binding. 
We have already shown that domain III is highly sensitive to conformational perturbation 
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through mutation. Conceivably, therapeutic antibodies could bind to a number of epitopes on 
EGFR domain III to mediate such a conformational change without the need to sterically occlude 
ligand binding. However, it also possible that these crystal structures do not give a complete 
picture of ligand binding sterics, and mAb 13A9 may have a different mechanism of action. 
 Seven residues in EGFR domain III were identified as the epitope of mAb EMD72000. 
Based on its location on the crystal structure, it does not appear that mAb EMD72000 directly 
inhibits EGF binding (Figure 2-13). However, mAb EMD72000 may inhibit EGF binding by 
preventing EGFR from adopting the fully extended conformation necessary to sandwich the 
ligand between domains I and III (Figure 2-14). This has also been suggested as an additional 
mechanism of mAb 225 (2). Alternately, mAb EMD72000 may perturb the conformation of 
domain III and prevent ligand binding in the same manner as we hypothesize mAb 13A9 does. 
Finally, the yeast surface display epitope mapping method was extended to the mapping of 
DARPin molecules binding to EGFR. Clone E69 bound to EGFR domain I and is not expected 
to inhibit ligand binding. However, clones E1 and E68 bound to domain III and are expected to 
inhibit ligand binding in a manner similar to mAb 225. The E1 and E68 DARPin epitopes highly 
overlap with the mAb 225 epitope, and all of these molecules also share contact residues with 
ligands which bind to EGFR. This portion of domain III represents a hot spot for protein 
recognition, with three very different types of proteins binding to the same location on EGFR.  
 In conclusion, we have developed a novel method of fine epitope mapping using random 
mutagenesis and yeast surface display. The technique was used to identify the binding epitopes 
of a total of four anti-EGFR antibodies and three DARPin molecules. The locations of these 
epitopes may aid in the understanding of EGFR antibody mechanisms of action and suggests 
new targets for EGFR inhibition. 
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Chapter 3: Engineering antibodies against EGFR 
 
3.1 Background 
Directed evolution is a common procedure for engineering antibodies against an antigen 
of interest. In directed evolution, mutations of the antibody are made at the DNA level, and these 
mutants are then expressed as proteins. The mutants with improved binding to an antigen of 
interest are isolated, and these improved clones can be further mutated for increased antigen 
binding. The entire process is repeated multiple times until the desired antibody properties are 
attained (Figure 3-1). 
 
Figure 3-1: Process of directed evolution. 
 
In order to engineer antibodies through directed evolution, a display system must be used 
to link the genotype of an antibody to its phenotype. Tools to accomplish this include phage 
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display, mRNA display, and yeast surface display. Since it is difficult for these systems to 
display or express full antibody immunoglobulin (IgG) molecules, smaller fragments of the IgG 
are often used instead (Figure 3-2). The IgG molecule contains two identical antigen-binding 
sites at the end of each variable arm, and a Fab consists of one set of variable domains and CH1 
and CL domains. A single chain variable fragment (scFv) molecule contains the minimal 
sequences necessary for antigen binding, with the variable heavy and light chains connected by a 
flexible polypeptide linker, usually (Gly4Ser)3. The complementarity-determining regions 
(CDRs) are the antibody residues responsible for mediating antigen binding and consist of six 
loops in the variable domain (Figure 3-2c). 
 
Figure 3-2: Immunoglobulin (IgG) protein and its fragments. (a) Schematic of an IgG. Ag, antigen; scFv, single 
chain variable fragment; VH, variable heavy region; VL, variable light region; CH, constant heavy region; CL, 
constant light region. (b) Crystal structure of an immunoglobulin molecule (1HZH). Heavy chain, blue; light chain, 
yellow. (c) scFv of the antibody in (b), with CDRs shown in yellow and blue for the light and heavy chains, 
respectively. 
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Phage display is the most widely used method of antibody isolation and affinity 
maturation. scFvs or Fabs are displayed on the surface of either fd or M13 bacteriophage and 
selected for binding to an antigen of interest (1). Alternately, mRNA or ribosome display is an in 
vitro method where the DNA encoding an scFv is stably linked to the protein through a 
puromycin linker or ribosome, respectively (2). In yeast surface display (3), the scFv is displayed 
on the yeast cell wall as a fusion to the native yeast Aga2 protein (Figure 3-3a). Expression of 
the protein on the yeast surface can be detected through the use of the C-terminal c-myc epitope 
tag, and binding to a biotinylated antigen of interest is detected through a different colored 
secondary reagent. Expression of the Aga2p-scFv is under the control of a galactose-inducible 
promoter on the yeast display plasmid, which is maintained in yeast episomally with a nutritional 
marker. Each yeast cell typically displays 104 to 105 copies of the scFv.  
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 Figure 3-3: (a) Schematic of yeast surface display. The scFv (cyan) is displayed as an Aga2p (pink) fusion on the 
yeast surface. Expression can be detected through fluorescent antibodies binding to the epitope tags (tan), and 
binding of the scFv to a biotinylated antigen (orange) can be detected using fluorescent avidin (violet). HA, 
hemagglutinin; VL, variable light chain; VH, variable heavy chain. (b) Yeast cells labeled as in (a) for surface 
expression (abscissa) and antigen binding (ordinate). The double negative population of yeast cells is due to plasmid 
loss. As yeast surface display increases, so does the antigen binding signal, giving rise to a diagonal binding curve. 
The fluorescence data for two different clones are overlaid, with a mutant with two-fold higher affinity in red and 
wild-type in blue. Because of the expression normalization in yeast surface display, a diagonal sort window can be 
drawn to capture even slightly improved mutants efficiently. (c) The populations in (b) are difficult to differentiate 
based on the antigen-binding histogram alone. PE, phycoerythrin. Figures were reproduced from (4). 
 
In addition, Fab fragments have been displayed on the surface of yeast (5,6). In the 
system described in (6), the heavy chain is expressed as an Aga2p fusion, with the light chain 
expressed from a separate plasmid (Figure 3-4). The two antibody chains associate in the yeast 
endoplasmic reticulum (ER) and are displayed as a full Fab construct on the yeast surface. 
Separate epitope tags on each chain can be used to ensure the presence of both heavy and light 
regions. 
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 Figure 3-4: Schematic of Fab display on the surface of yeast (6). The heavy chain variable and constant regions 
(cyan) are expressed as an Aga2p fusion and can be detected using an Alexa488-labeled antibody binding to the c-
myc epitope tag (violet). The light chain (yellow) is captured by the heavy chain in the yeast ER and can be detected 
through a PE-labeled antibody binding the V5 epitope tag. Binding to an antigen such as biotinylated peptide 
(orange) can be detected using avidin (magenta) labeled with a third fluorophore such as allophycocyanin (APC). 
 
Yeast surface display offers several advantages for the directed evolution of proteins. It 
enables quantitative screens through the use of fluorescence-activated cell sorting (FACS), 
allowing the equilibrium activity and statistics of the sample to be observed directly during the 
screening process. Furthermore, the antigen-binding signal is normalized for expression, 
eliminating artifacts due to host expression bias and allowing for fine discrimination between 
mutants (Figure 3-3b,c). Antibodies can be engineered for improved stability, as expression is 
measured directly and has been shown to correlate with the stability of the displayed protein (7). 
Using a two-color labeling scheme as in Figure 3-3a, stability and affinity engineering can be 
accomplished simultaneously. Once maturation is complete, antibody affinity can be 
conveniently titrated while displayed on the surface of the yeast, obviating the need for 
expression and purification of each clone. In almost every case for dozens of different antibodies, 
the binding properties on the yeast cell surface are in quantitative agreement with those measured 
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in solution or by biosensor methods (8). Finally, the displayed proteins are folded in the ER of 
the eukaryotic yeast cells, taking advantage of ER chaperones and quality-control machinery. 
A theoretical limitation of yeast surface display is the potentially smaller functional 
library size (~107-109) than that of other selection methods (phage display, ~106-1011; 
mRNA/ribosome display, ~1011-1013). However, it is difficult to determine the true functional 
diversity of any display library, and bias-free propagation of yeast libraries has been confirmed 
over an amplification of 1010-fold (9). Furthermore, all of these methods greatly undersample the 
theoretical sequence space of scFv CDR variation (~1080). To realize the advantages of kinetic 
screening and expression normalization, yeast surface display also requires more complex 
equipment than other display methods. Various technologies for screening recombinant antibody 
libraries and their relative strengths and weaknesses have been reviewed in (10). However, in 
parallel selections from the same DNA library, it has been shown that yeast display can yield 
three times as many unique scFv clones as phage display does (11). 
Yeast surface display has been used to engineer antibodies against various antigen 
targets, including T cell receptors (12), huntingtin protein (13), carcinoembryonic antigen (14), 
and botulinum neurotoxin (15). In addition, an antibody to fluorescein has been engineered to 
femtomolar affinity, the highest affinity yet reported (16). A nonimmune human library of 109 
scFv clones displayed on the surface of yeast has been created (9) and can serve as an initial 
library for the isolation of antibodies against an antigen of interest. 
Although there are currently two anti-EGFR antibody drugs (cetuximab and 
panitumumab) approved by the FDA for the treatment of cancer and many more in clinical trials 
(see Section 1.4), these antibodies are only marginally effective. Cetuximab treatment leads to 
objective responses in only 10.8% of patients as monotherapy and 22.9% in combination with 
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irinotecan (17). Panitumumab produces an 8% overall response rate in metastatic colorectal 
cancer, with progression-free survival extended from 60 days to 96 days (18). In a recent phase II 
trial, another anti-EGFR antibody, matuzumab, showed no evidence of significant clinical 
activity in patients with ovarian cancer (19). The low response rates are particularly noteworthy 
since the clinical trials only involved patients who tested positive for EGFR expression in tumor 
biopsies. Clearly, there is room for improved novel antibodies against EGFR. 
In this antibody engineering work, we have opted to use an alternate inhibition strategy 
from existing EGFR therapeutics. Traditional anti-EGFR antibodies such as cetuximab, 
panitumumab, and matuzumab bind to EGFR domain III and inhibit ligand binding, thus 
preventing receptor activation and downstream signaling (Figure 3-5a). However, we sought to 
engineer antibodies against EGFR domains II and IV to directly inhibit receptor dimerization 
(Figure 3-5b). Such antibodies could have advantages over ligand-competitive antibodies in 
certain types of tumors. In particular, cancer cells driven by EGFR autocrine signaling (20) have 
high local effective concentrations of ligand, and it may be difficult for an antibody diffusing 
into a tumor from the plasma to compete with ligand binding. In addition, ligand-competitive 
antibodies such as cetuximab are ineffective against EGFRvIII (21), a truncation mutant which 
signals constitutively in the absence of ligand (22). Finally, novel engineered antibodies could be 
used synergistically with existing EGFR antibody therapeutics. 
 
Figure 3-5: EGFR inhibition strategies for antibodies. (a) Ligand-competitive antibodies such as cetuximab. (b) 
Signaling inhibition by blocking receptor dimerization. Blue, receptor; green, ligand; yellow, antibody. 
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Based on the EGFR dimer crystal structures, antibodies binding to either the domain II 
dimerization arm or portions of domain IV should inhibit receptor dimerization (see Figure 1-4). 
Although domain IV is not resolved in the EGFR dimer crystal structures, it may contain 
receptor dimerization contacts for reasons discussed in Section 1.2. Even if domain IV does not 
mediate receptor dimerization, it is predicted that the two domains are sufficiently close in the 
dimerized form such that antibody binding to domain IV should sterically inhibit dimerization. 
In order to target specific regions of EGFR domains II and IV with antibodies, a former 
postdoctoral associate in the laboratory, Mark Olsen, designed peptide mimics of loops in the 
receptor to use as antigen. Five peptides, one in domain II comprising the dimerization arm and 
four in domain IV, were selected and designed (Figure 3-6). In this thesis, the peptides will be 
referred to according to the first three amino acids in the corresponding EGFR sequence (i.e. 
LYN, CRN, CAH, MGE, and LVW). All five peptides were synthesized with an N-terminal 
biotin molecule for detection, and a glycine amino acid to separate the peptide epitope from the 
biotin molecule. Because of the small size of the MGE peptide, a larger spacer molecule, 
6-aminohexanoic acid, was used instead of glycine. The peptides were cyclized through a 
disulfide bond to mimic the structures of the loops in EGFR. 
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 Figure 3-6: EGFR peptide epitopes targeted for antibody engineering. Peptides are shown in space-filled 
representation on the tethered EGFR monomer structure (1NQL). Peptides synthesized for use as antigen are shown 
on the right, with the corresponding EGFR residues shown below the peptide sequence. Aha, 6-aminohexanoic acid. 
 
The peptide epitopes were chosen for their potential to inhibit EGFR dimerization. The 
LYN peptide consists of the tip of the domain II dimerization arm (23,24), and proteins binding 
to this epitope would be analogous to pertuzumab, an antibody which binds to domain II of Her2 
(25). The CRN peptide was chosen as a control peptide in domain IV. The other three domain IV 
peptides (CAH, MGE, and LVW) are analogous to the binding epitope of Herceptin on Her2 
(26). The CAH peptide corresponds to part of the Herceptin epitope on Her2 residues 570-573, 
the LVW peptide corresponds to another part of the epitope on Her2 residues 593-603, and MGE 
corresponds to residues immediately N-terminal of the LVW peptide. In addition, the LVW 
peptide has previously been synthesized, and its binding to EGFR has been shown to inhibit 
receptor heterodimerization with Her3 (27). However, antibodies against this peptide have not 
been published. A monoclonal antibody (2D2) against the peptide 556IQCAHYIDGPHC567, 
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which includes the CAH peptide, has been generated for diagnostic purposes (28), but the effect 
on EGFR dimerization of binding to this epitope has not been tested. 
To isolate antibodies binding to these peptides, Mark Olsen performed the first round of 
screening against the nonimmune human scFv library expressed on the surface of yeast (9). For 
each of the peptides, he first performed one magnetic bead isolation (MACS) at 1 μM peptide, 
followed by three selections using fluorescence-activated cell sorting (FACS). These screens 
yielded candidate clones binding to all of the peptides except the CAH peptide. 
In this thesis work, antibody engineering against the above EGFR peptides was 
continued. It was discovered that all the clones isolated previous to this thesis work were heavy 
chain only binders. Full scFv molecules were engineered by adding random light chains to the 
selected heavy chains. In addition, rounds of affinity maturation through random mutagenesis 
using both peptide and soluble EGFR ectodomain as antigen were performed. Fab display on the 
surface of yeast and rabbit monoclonal antibody technology were utilized to further engineer 
binding to peptides LYN and MGE. However, affinity maturation of Fabs to the MGE peptide 
led again to binders consisting of only the heavy chain, and the rabbit monoclonal antibodies 
binding to the MGE peptide did not bind the full EGFR ectodomain. 
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3.2 Materials and methods 
Peptide and 404SG antigen 
The peptides listed in Figure 3-6 were synthesized by Cell Essentials, Inc. (Boston, MA). 
The molecular weights of the peptides were confirmed by mass spectrometry to 95% purity: 
LYN, 1973; CRN, 1516; CAH, 1452; MGE, 1208; and LVW, 1565. 
 For the secretion of soluble 404SG, the S. cerevisiae strain YVH10 was used, which is 
modified from BJα5464 to overexpress protein disulfide isomerase (29). The DNA for 404SG, a 
mutant of the EGFR ectodomain (30), was cloned using NheI and BamHI into the secretion 
plasmid pBala, which contains an N-terminal flag epitope tag (DYKDDDDK) and C-terminal 
His tag (HHHHHH). YVH10 was transformed with this DNA in addition to an empty pRS314 
vector (which enables tryptophan synthesis) using the EZ yeast transformation kit 
(ZymoResearch). Transformed cells were plated on SDCAA plates (yeast media preparation is 
described in (4)), and individual colonies were grown in 5 ml SDCAA media at 30 oC overnight. 
The seed culture was transferred to 1 L SDCAA media in a 2 L Tunair flask (Shelton Scientific) 
and grown at 30 oC for 20-22 h. The cells were harvested and pelleted in 500 ml centrifuge tubes 
for 15 min at 5000 rpm and 4 oC. The yeast were resuspended in 1 L SGCAA containing 0.5 g 
lysozyme as a carrier protein and were induced in a 2 L glass shake flask with no baffles at 20 oC 
for 3 d. The supernatant was separated from the yeast as above, and the pH was adjusted to 7.4. 
404SG protein was initially purified according to the manufacturer’s instructions using a batch 
protocol with TALON Superflow resin (BD Biosciences), which binds to the His6 tag. 
Alternately, the yeast supernatant was concentrated to ~50 mL volume using an Amicon stirred 
cell concentrator (Millipore). The protein was then digested with EndoH (New England 
Biosciences) to remove excess glycosylation and was purified using mAb 528 agarose resin 
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(Santa Cruz Biotechnology). The protein was eluted with 0.1 M glycine HCl, pH 3.5 and was 
neutralized with 1 M Tris, pH 8. The protein concentration was determined using an extinction 
coefficient of 55,900 M-1cm-1 at 280 nm absorbance. 
 
Yeast labeling for FACS and clone characterization 
Yeast were labeled as in (4). Additional yeast surface display protocols are available in 
(31) and (32). Briefly, EBY100 yeast transformed with the pCT2 yeast display plasmid were 
grown in SDCAA media at 30 oC and induced in SGCAA at 20 oC. For FACS analysis and 
sorting, 1x106 yeast (for individual clones) or 10X the library diversity were labeled for display 
using either mouse anti-HA 12CA5 IgG (Abcam; 1:100) or chicken anti-c-myc IgY (Invitrogen; 
1:250), followed by goat anti-mouse Alexa488 or goat anti-chicken Alexa488 (Invitrogen; 
1:100). Yeast were labeled with biotinylated peptides, followed by either streptavidin-PE (1:50), 
streptavidin-APC (1:100), or neutravidin-PE (1:50; all from Invitrogen). For 404SG labeling, 
404SG was pre-incubated with up to 0.5 μM biotinylated M2 anti-flag antibody (Sigma) for at 
least 1 h on ice, followed by streptavidin-PE. All incubations were performed in PBS buffer with 
0.1% BSA, with primary incubations for 30 min at room temperature and secondary incubations 
for 20 min on ice. 
For characterization of individual clones, DNA was harvested from yeast cells using a 
Zymoprep kit (ZymoResearch), transformed into XL-I Blue E. coli (Stratagene), and sequenced 
by the MIT Biopolymers Laboratory. BLAST searching against germline genes was performed 
using IgBlast at http://www.ncbi.nlm.nih.gov/projects/igblast. Fluorescence data was collected 
using a Coulter Epics XL flow cytometer (Beckman-Coulter) and was analyzed using FloJo 
software (Tree Star, Inc.).  
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Construction of scFv libraries 
 For the first round of affinity maturation pairing selected heavy chains with light chains, 
plasmid DNA from the original scFv library construction (9) was amplified by transformation 
and growth in E. coli strain XL-I Blue (Stratagene). Plating of transformed cells showed that the 
maximum diversity of this amplified DNA was 8.5x105, which is slightly lower than the original 
library’s reported VL diversity (1.2x106). However, in order to conserve the original library 
DNA, it was determined that this was sufficient to proceed. The library DNA was digested with 
NheI and BamHI to remove the original VH sequence. Then, the DNA containing the originally 
selected VH clones (LYN-1, etc.) were digested with KpnI and NotI to generate the insert 
fragment. These two DNA fragments were transformed into EBY100 yeast as described to 
generate libraries of full scFvs (4). It was determined that this method yielded more full-length 
scFvs and thus was preferable to using the digested VH clone as backbone and a PCR product 
from the library insert. Libraries were labeled as above and sorted using either a MoFlo or Aria 
FACS machine at the MIT flow cytometry core facility. For the generation of subsequent 
random mutagenesis libraries, the nucleotide analog mutagenesis protocol in (32) was used. 
Yeast were transformed and libraries were sorted as above. 
 
Fab display 
Fab display vectors pPNL200 and pPNL300 (adapted from (6)) were generously 
provided by Mike Feldhaus. For individual clone analysis, both plasmids were transformed into 
the yeast strain JAR200 (Ura-, Trp-) and grown and induced as strain EBY100 above. To clone 
scFv genes into the Fab display vectors, 5’ NheI and 3’ MluI restriction sites were added to the 
variable heavy region using PCR, and for the light chain, 5’ DraIII and 3’ BsiWI sites were 
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added. Populations of yeast were cloned into the Fab display vectors by designing primers based 
on sequenced clones and PCR using the zymoprep DNA as template. The primers used for 
nucleotide analog mutagenesis of antibodies in the Fab vectors are listed in Table 3-1. For library 
backbone generation, pPNL200 was digested with NheI and MluI and pPNL300 with DraIII and 
BsiWI. Heavy and light chain libraries were constructed separately, with the heavy library 
transformed into JAR200 and grown in SDCAA+20 mg/L uracil (added from 0.2% stock) and 
the light library transformed into YVH10 and grown in SDCAA+20 mg/L tryptophan (added 
from 1% stock). The Fab library was created using yeast mating by resuspending 109 freshly 
grown cells from each of the libraries in 10 mL YPD. The yeast were pipetted onto 4 YPD plates 
(15 cm diameter) in a pool (not spread) and incubated at 30 oC overnight. The mated cells were 
scraped off and resuspended in SDCAA, and dilutions were plated to determine mating 
efficiency. This protocol was adapted from (6). 
 
Table 3-1: Sequences of primers used in Fab display 
VH: 200for 5’-CTAAAGAAGAAGGGGTATCTCTCGAAAAAAGAGAGGCTGAAGCAACGCGT-3’ 
VH: 200rev 5’-CTCTTGGAGGAGGGTGCCAGGGGGAAGACCGATGGGCCCTTGGTGCTAGC-3’ 
VL: 300for 5’-TAAAGAAGAAGGGGTATCTCTCGAAAAAAGAGAGGCTGAAGCACGATGTG-3’ 
VL: 300rev 5’-TGCTCATCAGATGGCGGGAAGATGAAGACAGATGGTGCAGCCACCGTACG-3’ 
VH, VL sequencing: 5’-CTATTGCCAGCATTGCTGC-3’ 
 
Growth and labeling of mammalian cells 
A431NS cells (A431 cells passaged to become less adherent) were obtained from 
American Type Culture Collection (ATCC) and grown in DMEM (ATCC) supplemented with 
10% fetal bovine serum (FBS). NR6 cells (33) were obtained from Doug Lauffenburger (MIT) 
and grown in MEM-α supplemented with L-glutamine, sodium pyruvate, non-essential amino 
acids, and 350 mg/L G418. Mammalian cell monolayer panning was conducted as described in 
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Appendix 2. For FACS labeling, A431 cells were lifted from the plate using versene (Invitrogen) 
at 37 oC for 30 min. 2.5x105 cells were labeled in 200 μL/tube in PBS + 1% BSA on ice. Goat 
anti-rabbit-PE (Invitrogen) was used to visualize rabbit antibody binding. 7-amino-
actinomycin D (7-AAD) for labeling dead cells was purchased from Calbiochem. 
 
Production and growth of rabbit hybridomas 
 Rabbit hybridoma production was performed by Epitomics, Inc. (Burlingame, CA). LYN 
and MGE peptides (lacking biotin) were conjugated to KLH and injected into rabbits. Rabbit 
hybridoma clones were grown in RPMI 1640 supplemented with 0.05 mM 2-mercaptoethanol, 
Epitomics RabMab supplement A, 10% FBS, and 1X HAT (Hypoxanthine, Aminopterin, and 
Thymidine). Hybridoma cells were grown in 10 cm culture dishes and expanded to T-175 flasks 
(60 mL media). For rabbit monoclonal antibody production, cells were adapted to serum-free 
conditions by diluting growth media 1:4 in serum-free media (BD cell mAB medium (BD 
Biosciences) supplemented with 1% glutamax (Gibco)). After 1-3 days of adapting, full serum-
free media was used and changed every 3 days until antibody harvesting was complete (usually 3 
media changes). 
 
Purification and sequencing of rabbit monoclonal antibodies 
 Rabbit hybridoma supernatants were concentrated in an Amicon stirred cell concentrator 
(Millipore) and diluted 1:1 in Ig binding buffer (Pierce). Antibodies were purified using Protein 
A resin (Pierce) and eluted using Ig elution buffer (Pierce). Elutions were buffer-exchanged with 
PBS using an Amicon ultra-15 centrifugal filter unit (Millipore). Typical yields were ~2 mg from 
1 L of culture media. For rabbit monoclonal antibody sequencing, total hybridoma mRNA was 
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harvested using an RNeasy kit (Qiagen). The mRNA was reverse-transcribed using an 
Omniscript RT kit (Qiagen) and primers IgGHrev (primes to heavy constant region) and 
IgGKrev (primes to kappa constant region). The reverse transcription product was amplified 
using PCR with primers IgGHfor (primes to heavy leader sequence)/IgGHrev and 
IgGKfor/IgGKrev for kappa light chains. Primers are listed in Table 3-2, with additional unused 
primers for rabbit IgGL (lambda light chain) sequences. For PCR of clone 31, the reverse primer 
IgVHJrev was used to prime to the variable J region since this clone was not an IgG. PCR 
products were sequenced using the reverse primers, and cloned into an scFv format using overlap 
extension PCR. 
 
Table 3-2: Primers used for sequencing rabbit monoclonal antibodies 
IgGHfor   5’-ATGGAGACTGGGCTGCGCTGGCTT-3’ 
IgGHrev   5’-GGTCACCGTGGAGCTGGGTG-3’ 
IgGKfor   5’-GGGCCCCCACTCAGCTGCTGGG-3’ 
IgGKrev   5’-CATCCACCTBCCAGGTGACGGTG-3’ 
IgGLfor1  5’-GGAGACTGGGCTGCGCTGGC-3’ 
IgGLfor2  5’-GGCCTGCACCCCGCTCCTCC-3’ 
IgGLrev   5’-GGGTAGAAGTCATTGATCAGAC-3’ 
IgVHJrev  5’-GGTGACCAGGGTGCCYKGGCCCCA-3’ 
 




3.3.1 Characterization of antibody clones against EGFR peptides 
 The antibody clones enriched for binding to peptides CRN, CAH, MGE, and LVW after 
one round of selection by Mark Olsen were sequenced. Unexpectedly, all of the enriched clones 
were not full-length scFvs, but only consisted of the heavy chain (VH) and not the light chain 
(VL). Such clones may have arisen from errors in the PCR construction of the library or in yeast 
homologous recombination, leading to a frameshift and eventual premature termination of 
translation. The closest germline genes to the selected clones as determined by a BLAST search 
engine IgBlast are listed in Table 3-3, and the amino acid sequences of the selected clones are 
shown in Figure 3-7. Overall, each of the two clones isolated for binding to a particular peptide 
were highly similar in sequence, with the exception of CRN-1 and CRN-2. The VH clones 
contain most of the (Gly4Ser)3 linker region and additional amino acids after the linker, 
terminating in a stop codon. These additional amino acids are not light chain residues, as they are 
frame-shifted from the original sequence. Each clone listed in Figure 3-7 was tested for binding 
to its cognate peptide (Figure 3-8). Given the intermediate labeling of the clones at 1 μM 
peptide, it appeared that the affinity of these VH domains for the peptides was on the order of 10 
μM or greater. It was confirmed that the VH clones did not bind any secondary reagents. In 
addition, each VH was tested for binding to all of the other peptides. No appreciable cross-
binding was observed at 1 μM peptide except for clones LYN-1 and LYN-2 binding to CAH 






LYN-1, LYN-2 V3-30 
CRN-1 V6-1 
CRN-2 V4-34 
MGE-1, MGE-2 V4-39 
LVW-1, LVW-2 V2-5 
Table 3-3: Heavy chain germline genes of VH clones selected for binding to peptides. 
 
 
 FR1       CDR1    FR2  CDR2
LYN-1 QVQLVQSEGGVVQPGRSLRLSCAAP GFTFSSYAMH   WVRQAPGKGLEWVA VISYDGSNKY 
LYN-2 ------------------------S ----------   -------------- ---------- 
 
CRN-1 QVQLQQSGPGLVKPSQTLSLTCDIS GDSVSSDSAAWN WIRLSPSRGLEWLG RTYYWSKWYTD 
CRN-2 ------W----L---E------GV- -G-L-GYYWS   ---Q--GKE---I- EINQGGSTN 
 
MGE-1 QVQLQESGPGLVKPSETLSLTCTFS GGSIRSSSDYWG WVRQPPGKGLEWIG SISSSGSTY 
MGE-2 -----------------------V- ----SN-DY--- -I--------R--- --NYY-T--  
 
LVW-1 QITLKESGPTVVKPTQTLTLTCTFS GFSLSTSGVGVG WIRQPPGKALEWLA LISWDDDKR  
LVW-2 ------------------------- ------------ -------------- ---------  
 
 
 FR3          CDR3 
LYN-1 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DEGYYGSGCIDY 
LYN-2 --------------------------------------- ------------ 
 
CRN-1 YAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYFCAR ERYCSSTSCYLDAFDI 
CRN-2 –NP-LR--V--SV----K-L--KV----AS-----Y--- -TFRG-NCFDS 
 
MGE-1 YNPSLKSRVTISVDTSRNQFSLRLSSVTAADTAIYYCAR YNHYWYFDL 
MGE-2 ---------AM-----K-----K----------V----- RGANSWFFDL 
 
LVW-1 YSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYFCAH LNNFVDAIELRTGWCFDV 
LVW-2 --------------------------------------- -I---------------- 
 
 













Figure 3-7: Amino acid sequences of VH clones selected for binding to peptides. FR, framework region; CDR, 
complementarity determining region; -, conserved residue; *, stop codon. 
101 
 Figure 3-8: Characterization of individual VH clones isolated for binding to peptides. Yeast cells displaying the VH 
clones were labeled with anti-HA antibody 12CA5 (abscissa) and 1 μM peptide (ordinate), followed by goat anti-
mouse-Alexa488 IgG and streptavidin-PE. (a-b) Clones LYN-1 and LYN-2 binding to LYN peptide. (c-d) LYN-1 
and LYN-2 binding to CAH peptide. (e-f) CRN-1 and CRN-2 binding to CRN peptide. (g-h) MGE-1 and MGE-2 
binding to MGE peptide. (i-j) LVW-1 and LVW-2 binding to LVW peptide. 
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3.3.2 Initial round of selection for scFvs against peptides 
Single-domain antibodies have proven useful for some applications, such as intracellular 
expression (13) or increased stability (34). However, for our purposes, single-domain antibodies 
would provide little advantage over full scFvs; therefore, we sought to pair our selected VH 
clones with VL domains. This was accomplished by creating libraries joining the VH DNA with 
light chain DNA from the original library (9). The resulting scFv DNA was transformed into 
yeast using electroporation, yielding libraries designated LYN-A (~107 diversity), CRN-A 
(9x105), MGE-A (~107), and LVW-A (~107). In addition, the original nonimmune human scFv 
library on the surface of yeast (9) was screened for binders against the CAH peptide using one 
round of MACS, since no clones were previously isolated against this peptide.  
Selections of the above five populations of yeast were performed using FACS to screen 
for binding to the peptides. For the LYN peptide, 4 FACS selections were performed at 1 μM 
peptide, and clones from the enriched population were sequenced. However, only one clone 
(LYN-A4-8, sequence in Appendix 1.4) was a full scFv, while 9/10 clones only had heavy chains 
with no C-terminal c-myc tag. Since the anti-c-myc antibody used was a chicken IgY polyclonal, 
it appeared that some molecules in this population were able to weakly bind a motif in the VH 
clones. The enriched cells after 3 FACS selections (LYN-A3) were re-sorted with an improved 
sorting window drawn to avoid these VH clones. Nine clones from the enriched population 
(LYN-A5) were sequenced, revealing 7 unique clones (Appendix 1.4). However, tests of these 
clones for binding to 1 μM LYN peptide did not show appreciable binding. For the CRN peptide, 
3 FACS selections were performed at 1 μM peptide, and the enriched cell population (CRN-A3) 
was sequenced. Out of 10 clones sequenced, all were unique (listed in Appendix 1.5) and showed 
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binding to 1 μM CRN peptide (Figure 3-9). It was further confirmed that these clones indeed 
bound the peptide and did not bind the secondary streptavidin reagent. 
 
Figure 3-9: Binding of CRN-A3 clones selected for the CRN peptide. Yeast were labeled with chicken anti-c-myc 
IgY (abscissa) and 1 μM CRN peptide (ordinate), followed by goat anti-chicken-Alexa488 IgG and streptavidin-PE. 
Clones CRN-A3-1 through CRN-A3-10 are shown in (a)-(j), respectively. 
 
For the CAH peptide, the MACS-enriched population was subjected to 3 FACS 
selections at 1 μM CAH peptide. At this point, it appeared that the sorted population contained 
some binders to streptavidin instead of the CAH peptide. However, two more FACS selections 
using alternating secondary reagents allowed the elimination of the streptavidin binders, resulting 
in the CAH-A6 population. Out of 10 clones sequenced, 8 were unique and tested for binding, 
and 4 of these clones bound to CAH peptide (Figure 3-10). It was confirmed that these clones did 
not bind the streptavidin secondary reagent, and sequences for these clones are listed in 
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Appendix 1.6. For the MGE peptide, 4 FACS selections were performed at 1 μM peptide, and 
the enriched population (MGE-A4) was sequenced. Out of 10 clones sequenced, 1 clone was a 
VH only, with 8 unique scFv sequences. However, only 4 of these clones (sequences in Appendix 
1.7) showed appreciable binding to 1 μM MGE peptide (Figure 3-11), and it was confirmed that 
these clones did not bind streptavidin-PE. Finally, for the LVW peptide, 3 FACS selections were 
performed at 1 μM peptide. 10 clones from the enriched population (LVW-A3) were sequenced, 
revealing 1 VH only clone and 8 unique scFv sequences (Appendix 1.8). Of the 7 scFv clones 
tested, all appeared to bind peptide to different degrees (Figure 3-12) and did not bind 
streptavidin.  
 
Figure 3-10: Binding of selected CAH-A6 clones. Yeast cells were labeled with 1 μM CAH peptide, followed by 
streptavidin-PE. Binding histograms for clones CAH-A6-2 (labeling similar to CAH-A6-1) and CAH-A6-5 (labeling 
similar to CAH-A6-4) were omitted for clarity. 
 
 
Figure 3-11: Binding of MGE-A4 clones selected for the MGE peptide. Yeast were labeled with chicken anti-c-myc 
IgY (abscissa) and 1 μM MGE peptide (ordinate), followed by goat anti-chicken-Alexa488 IgG and streptavidin-PE. 
(a) MGE-A4-2 (b) MGE-A4-3 (c) MGE-A4-4 (d) MGE-A4-7. 
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 Figure 3-12: Binding of LVW-A3 clones selected for LVW peptide. Yeast were labeled with chicken anti-c-myc 
IgY (abscissa) and 1 μM LVW peptide (ordinate), followed by goat anti-chicken-Alexa488 IgG and streptavidin-PE. 
(a) LVW-A3-2 (b) LVW-A3-3 (c) LVW-A3-4 (d) LVW-A3-5 (e) LVW-A3-7 (f) LVW-A3-8 (g) LVW-A3-9. 
 
 As shown above, full scFv clones binding to the various peptides were successfully 
isolated in the first round of selections. However, based on binding data at 1 μM peptide, it 
appeared that these clones were of similar or worse affinity than the VH only clones. Since the 
antigen consisted of only a small peptide, there may not have been enough surface area for the 
light chain to also make contacts to the antigen. The closest germline genes for the light chains of 
the selected clones listed in Appendix 1.4-1.8 are shown in Table 3-4. Selections for binding to 
the five different peptides yielded only 7 unique germline genes out of 34 unique sequences. 
These genes are from the most abundantly represented germline families in the original 
unselected nonimmune library (9). The observation that many VL germline genes are shared 
between the scFv clones binding to different peptides lends further support to the hypothesis that 
the light chain is not significantly contributing to antigen peptide binding. In this round, it 
appears highly possible that we have selected for light chains that are merely compatible with the 
original VH only clones. 
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κ (Kappa) germline λ (Lambda) germline  
V1-39 V3-20 V5-2 V1-44 V2-14 V2-23 V6-57 
LYN   X X   X 
CRN X X X    X 
CAH  X     X 
MGE X    X X X 
LVW X  X    X 
Table 3-4: Light chain germline genes represented by selected clones against peptides are indicated with an X.  
 
3.3.3 Second round of affinity maturation 
 To improve the affinities of the clones from the first round of scFv selection, new 
antibody libraries were constructed. Random mutagenesis of the entire scFv gene was 
accomplished through PCR with nucleotide analogs, using DNA from the entire enriched 
population of yeast as a template. Therefore, this DNA population most likely contained 
additional clones which had been enriched, but had not been sequenced or characterized. The 
DNA was transformed into yeast to create libraries with the following diversities: LYN-B, 
6.4x105; CRN-B, 4.4x106; CAH-B, 1.7x107; MGE-B, 1.6x106; and LVW-B, 1.3x106. 
Sequencing of random clones from the libraries showed a wide range of mutations (discernible 
by comparison of the heavy chains to the original VH clones), from 0-20 amino acid changes. At 
this point, the antigen was changed from the peptides to the full EGFR ectodomain for library 
screening. Since the light chain did not appear to be contacting the peptide antigen based on the 
previous round’s analysis, it was hypothesized that moving to a large protein antigen would 
provide more potential surface area for the light chain to bind, thus improving the affinity of the 
scFv. The specific antigen used was 404SG, an EGFR ectodomain mutant which has been 
engineered to be expressed solubly by yeast. 404SG contains four point mutations, none of 
which are in domains II or IV (30). Excess glycosylation was removed from the 404SG antigen 
using EndoH digestion prior to use. 
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 The LYN-B library was enriched for binding to 404SG using 4 FACS selections. The 
CRN-B library was similarly selected using 4 FACS sorts. Clones from the enriched population 
(CRN-B4) were sequenced (listed in Appendix 1.9-1.11). The selection appeared to enrich for 
some binding artifacts, including light chain only clones and peptides. The CAH-B library was 
enriched for binding to 404SG through 4 FACS selections, yielding only one scFv clone due to 
library contamination with yeast-displayed EGF (CAH-B4-1 sequence in Appendix 1.12). The 
MGE-B library was sorted using 6 FACS screens against soluble 404SG antigen, and the 
enriched MGE-B6 clones were sequenced (Appendix 1.13). Finally, the LVW-B library was 
selected using 4 FACS sorts, and the enriched yeast population (LVW-B4) was sequenced. In 
addition to scFvs, this library also yielded 2 clones consisting of a light chain only (Appendix 
1.14). 
Clones CAH-B4-1 and MGE-B6-2 from the second round of selections were tested for 
their 404SG antigen-binding properties and compared to negative (D1.3, a lysozyme-binding 
scFv) and positive (EGF) controls displayed on the surface of yeast (Figure 3-13). Initially, 
binding could only be seen at very high 404SG concentrations, with cells labeled at 20 and 140 
μM. The selected scFv clones also showed an unusual pattern of binding; instead of the normally 
observed diagonal, the binding curves were more vertical. Such binding is normally indicative of 
avidity effects, which may occur at high levels of yeast scFv expression and multimeric antigen. 
This is a possibility since a bivalent molecule, biotinylated anti-flag IgG, was pre-incubated with 
the 404SG to allow binding to the N-terminal flag tag. However, it is still unusual that there is a 
population of cells which show no antigen labeling even though they express a high number of 
scFv molecules. 
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 Figure 3-13: Clone binding to soluble 404SG. Yeast were labeled with chicken anti-c-myc IgY (abscissa) and 
404SG antigen which had been pre-incubated with biotinylated M2 anti-flag IgG (ordinate), followed by Alexa488 
goat anti-chicken IgG and streptavidin-PE. (a-d) D1.3 negative control, EGF positive control, CAH-B4-1, and 
MGE-B6-2, respectively, displayed on the surface of yeast and labeled with 20 μM 404SG. (e-h) Yeast displaying 
proteins as in (a-d), labeled with 140 μM 404SG. (i) MGE-B6-2 labeled with 200 nM 404SG (mAb 528 affinity-
purified). (j) MGE-B6-2 labeled as in (i) plus 3.6 μM soluble EGF. 
 
For the labeling data in Figure 3-13 a-h, the 404SG antigen was affinity purified using the 
C-terminal His6 tag and digested with EndoH to remove excess glycosylation. However, the high 
concentration necessary to label even the positive control suggested that a portion of the 404SG 
may have been misfolded. Therefore, the EndoH-digested protein was affinity purified using a 
conformation-specific EGFR antibody, mAb 528. 404SG purified in this manner could label 
cells at a much lower concentration of 200 nM 404SG (Figure 3-13i). Pre-incubation of the 
404SG with soluble EGF ligand only slightly increased antigen binding (Figure 3-13j). In 
addition, clones CAH-B4-1 and MGE-B6-2 were tested for binding to EGFR on the surface of 
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A431 cancer cells (expressing ~2x106 receptors/cell) using monolayer cell panning (35). In this 
technique, yeast displaying antibodies are captured by adherent mammalian cells expressing an 
antigen of interest (protocol in Appendix 2). No appreciable binding of these clones was seen in 
this assay (data not shown), but their affinities may have been below the sensitivity of the 
method. scFvs selected against 404SG were tested for binding to their cognate peptides, showing 
that some clones still retained affinity for the peptides while other no longer did (Figure 3-14). 
 
Figure 3-14: Binding of clones to peptides. Yeast were labeled with chicken anti-c-myc IgY (abscissa) and 1 μM 
peptide (ordinate), followed by goat anti-chicken-Alexa488 IgG and streptavidin-PE. (a) Clone CAH-B4-1 labeled 
with CAH peptide. (b-k) Clones MGE-B6-1 to MGE-B6-10 labeled with MGE peptide. 
 
3.3.4 Third round of affinity maturation 
In this round, the affinity maturation against 404SG antigen was narrowed down to 
libraries based on two peptides, LYN and MGE. Random mutagenesis libraries were again 
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constructed using nucleotide analog mutagenesis of the DNA from the population enriched in the 
previous round. The libraries were transformed into yeast with diversities of 5.4x106 for LYN-C 
and 1.8x106 for MGE-C. For the LYN-C library, 2 FACS selections were performed, with the 
first selection against 0.5 μM 404SG and the second at 200 nM 404SG. The enriched population 
(LYN-C2) was sequenced, and representative clones are listed in Appendix 1.15. Individual 
clones were also tested for their binding to the 404SG antigen (Figure 3-15). The vertical pattern 
of binding seen in the previous round was again observed. The addition of soluble EGF did not 
improve 404SG binding, and clones MGE-C2-1, 3, 5, 6, and 7 did not show appreciable binding 
to 1 μM LYN peptide (data not shown). 
 
Figure 3-15: Binding of 404SG to LYN-C2 clones. Yeast displaying the scFvs were labeled with chicken anti-c-
myc IgY (abscissa) and 200 nM 404SG antigen which had been pre-incubated with biotinylated M2 anti-flag IgG 
(ordinate), followed by goat anti-chicken-Alexa488 IgG and streptavidin-PE. (a) LYN-C2-1 (b) LYN-C2-3 (c) 
LYN-C2-5 (d) LYN-C2-6 (e) LYN-C2-7 (f) LYN-C2-8 (g) LYN-C2-10 (h) LYN-C2-11. 
 
Library MGE-C was sorted against 500 nM 404SG using 4 FACS selections with no 
enrichment for antigen binders. In addition, it was noted that the quality of the 404SG protein 
varied between different preparations. Thus, we returned to using peptide as an antigen source, 
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and the CRN peptide was used for new selections. A library based on CRN-A from the first 
round was made, and this library (CRN-2B) had a diversity of 1.2x107. 6 FACS selections were 
performed, starting at 500 nM CRN peptide decreasing to 10 nM. Clones from this enriched 
population (CRN-2B6) were sequenced and are listed in Appendix 1.16. Based on the labeling of 
these clones, they appeared to have affinities on the order of 100 nM. To increase this affinity, 
the CRN-C library (6x107 diversity) was made based on random mutagenesis of the selected 
clones from the previous round. After 5 FACS selections at 10 nM peptide, the enriched CRN-
C5 population was sequenced. The two best clones, CRN-C5-1 and CRN-C-11 (sequences in 
Appendix 1.16) were titrated on the surface of yeast and found to have ~50 nM affinity for the 
CRN peptide (data not shown). However, clone CRN-C5-1 showed no appreciable binding to 
400 nM 404SG or 1 μM Alexa488-labeled EGFR ectodomain produced by insect cells 
(generously supplied by Jennifer R. Cochran). Likewise, clone CRN-C5-11 did not bind 200 nM 
404SG or 400 nM insect cell EGFR. 
 
3.3.5 Fab display libraries 
 At this point, all antibody selections were moved from scFv display to Fab display on the 
surface of yeast. Eventually, we envisioned reformatting our selected scFv clones into full IgG 
molecules for cancer therapy. However, it has been observed that antibody affinity may change 
during reformatting (36). Therefore, Fab display enabled testing of the effects of adding the 
antibody constant regions to the variable regions, while still being able to work conveniently 
with yeast. The scFv clones LYN-C2-6, LYN-C2-13, CRN-C5-1, and CRN-C5-4 were 
reformatted to Fabs displayed on the surface of yeast. The yeast displaying these clones were 
tested for the presence of both heavy and light chains (Figure 3-16a to d). The LYN-C2 clones 
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appeared to reformat well, with good association of the heavy and light chains, and the Fab 
clones retained binding to the antigen (Figure 3-16e,f). However, the CRN-C5 clones did not 
reformat well, with little light chain captured by the heavy chain and displayed on the surface. 
Consequently, these clones also showed poor antigen binding, demonstrating that both heavy and 
light chains were necessary for peptide binding. 
 
Figure 3-16: Properties of Fab-reformatted clones. For (a-d), yeast displaying Fabs were labeled with chicken anti-
c-myc and mouse anti-V5 to detect the VL (ordinate), followed by goat anti-chicken-Alexa488 and goat anti-mouse-
PE IgG. (a) Clone LYN-C2-6 (b) LYN-C2-13 (c) CRN-C5-1 (d) CRN-C5-4. For (e-h), the clones in (a-d) were 
labeled with chicken anti-c-myc to detect the VH (abscissa) and antigen (ordinate). For (e-f), yeast were labeled with 
200 nM 404SG antigen which had been pre-incubated with biotinylated M2 anti-flag IgG, followed by streptavidin-
PE. For (g-h), yeast were labeled with 1 μM CRN peptide followed by streptavidin-PE. Cells in the c-myc positive, 
V5 negative quadrant may represent yeast which contain the heavy chain plasmid but have lost the light chain 
plasmid. 
 
 scFv clones from the MGE-A4 and MGE-B6 populations were also reformatted into Fab 
display vectors and showed good association between the heavy and light chains on the surface 
of yeast. Therefore, a new library was made using nucleotide analog mutagenesis of the variable 
regions. The heavy and light libraries were transformed separately into two different strains of 
yeast, and the Fab library was created using yeast mating of the heavy and light libraries. 
Because of the uncertainty of the quality of the 404SG antigen, the Fab library was sorted against 
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MGE peptide using 6 FACS selections starting at 1 μM peptide decreasing to 250 nM. 3-color 
sorts (as shown in Figure 3-4) were performed to select clones that showed both heavy and light 
chain expression, as well as antigen binding. The enriched population (MGE-Fab-M6) was 
sequenced (listed in Appendix 1.17). Of the 5 sequenced light chains, 4 contained only a 
fragment of the variable light chain consisting of the first 12 amino acids of a variable region 
fused directly to the constant region (Figure 3-17). Sequencing of the original unselected library 
demonstrated that this was a rare event in the starting library, and thus these clones had been 
selected for better antigen binding. It appeared these clones preferred to be heavy chain only 
binders since they were originally selected as such. Most likely, the MGE peptide was not 
binding to the antibody CDRs, but instead to somewhere near the VH/VL interface. Another 
single-domain antibody, a light chain clone, was previously selected using yeast surface display 
(13) and has been shown to bind antigen at the VH/VL interface (Arne Skerra, personal 
communication). During selections of light chains compatible with the original heavy chains, we 
may have simply selected for light chains which did not associate well with the heavy chains (but 
were still connected through the linker), thus allowing the peptide access to the binding site. 
Clones MGE-Fab-M6-1, 2, and 3 were tested by mammalian cell panning for binding to EGFR 




Figure 3-17: Light chain sequence of clone MGE-Fab-M6-1. The variable light region (VL) is truncated to 12 
amino acids, and the beginning portion of the constant region (CL) is shown. 
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3.3.6 Rabbit monoclonal antibodies 
 Since the leads isolated from the nonimmune human library in yeast did not appear 
promising, we sought to obtain antibodies from rabbits against the LYN and MGE peptides. 
Rabbits typically produce higher affinity antibodies than mice due to the use of both gene 
conversion and somatic hypermutation for antibody diversification (37). In addition, previous 
work had demonstrated that rabbits injected with these peptides were capable of generating 
antibodies against EGFR (38). Thus, rabbits were immunized with the peptides, and the binding 
of the rabbit antisera to A431 cancer cells was tested. The rabbits did not appear to produce a 
response against the LYN peptide (data not shown), but one rabbit showed a response against the 
MGE peptide (Figure 3-18). The binding of the rabbit antiserum to the A431 cells could also be 
competed off by excess MGE peptide. In addition, the MGE antiserum appeared to inhibit EGFR 
phosphorylation, although the pre-bleed showed inhibition of the receptor to some extent as well 
(data not shown). 
 
Figure 3-18: FACS data for rabbit polyclonal antiserum against MGE peptide bound to A431 cells. Cells were 
labeled overnight at 4 oC with rabbit pre-bleed or post-peptide immunization bleed, followed by goat anti-rabbit-PE. 
Antiserum binding was competed down to pre-bleed levels using 200 μM MGE peptide, but not LYN peptide. 
 
The rabbit which produced a response against the MGE peptide was sacrificed, and its spleen 
cells were fused with a plasmacytoma cell line to generate immortalized hybridoma cells (39). 
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The hybridoma supernatants were screened for their binding to A431 cells, and three hybridomas 
were selected for further subcloning (Figure 3-19). 
 
Figure 3-19: Binding of hybridoma supernatants to A431 cells. Cells were labeled with supernatant at 4 oC for (a) 
2 h or (b) overnight, followed by goat anti-rabbit-PE. 
 
The sequences of the rabbit monoclonal antibodies secreted by each of the subcloned 
hybridomas was determined (Figure 3-20). All three clones contained kappa light chains, with 
high sequence similarity between antibodies 13 and 32. During the course of sequencing, it was 
determined that antibody 31 was not an IgG molecule, but some other class of immunoglobulin. 
Thus, the purification of antibody 31 was unsuccessful, with the antibody precipitating out of 
solution. However, antibodies 13 and 32 were purified for testing on A431 cells. Both antibodies 
showed unusual labeling, with a large negative peak of cells even after overnight incubation with 
the antibody (Figure 3-21a), although this binding could be competed by excess MGE peptide. It 
was determined that antibody 13 only labeled dead cells, as shown by co-staining with 7-AAD 
(Figure 3-21b). The antibody may be recognizing a different protein which is only accessible for 
binding once the cell membrane has been compromised, or it may only be able to bind to slightly 
degraded EGFR in dead cells. 
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   VH-FR1                   VH-CDR1    VH-FR2         VH-CDR2 
13 QSVEESGGRLVTPGTPLTLTCTVS GFSLSTHGMI WVRQAPGEGLEWIG IINSNHYTA  
31 ------------------------ -----SV--S -------K------ ---NYGRAY 
32 ------------------------ ----N-Y--- -----------Y-- VV-TD-T-Y 
 
   VH-FR3              VH-CDR3 
13 YANWAKGRVTISKTSTTVDLKMTSLTTEDTAIYFCGR RGNFAFNL   WGQGTLVTVSS 
31 --S-----F---R--------I--P------T---A- IYPDDSIGNL ----------- 
32 --S-V---F-----------------AA---T----- -S------ ----------- 
 
   VL-FR1                  VL-CDR1      VL-FR2          VL-CDR2
13 AQVLTQTASSVSAAVGGTVTISC QSSQSVYNNNWLA WYQQKAGQPPNLLIY QASKLAS 
31 DI-M---PA--E---------K- -A-ERIG-ALA   -----P----K---- G--T-T- 
32 -R-----P-P------------- ---E---R----- -----P----K---- ------- 
 
   VL-FR3                           VL-CDR3
13 GVPSRFSGSGSGTHFTLTISGVQCDDAATYYC QGEFSCSIADCVA  FGGGTEVVVK 
31 ------K------Q------DLE-A------- -SYYASGSRIYGYD ---------- 
32 -------------Q------------------ ------RSG--I-  ---------- 
Figure 3-20: Sequences of rabbit monoclonal antibodies. 
 
 
Figure 3-21: Flow cytometry data for rabbit monoclonal antibody 13 binding to A431 cells. (a) Cells were labeled 
with 133 nM antibody 13 overnight at 4 oC, and binding was competed with 200 μM MGE peptide. (b) Cells were 
labeled with 133 nM antibody 13 overnight and then labeled with 7-AAD, which stains dead cells. 
 
The antibodies were cloned into an scFv format and displayed on the surface of yeast. 
Titrations with MGE peptide indicated that the clones bound the peptide with affinities of ~25 
nM. However, the clones did not bind 404SG or EGFR domain IV secreted by yeast (provided 
by Ben Hackel). In addition, the clones were negative for binding to EGFR on the surface of 
A431 cells as assayed by cell monolayer panning. Therefore, it appeared that the rabbit had 
produced antibodies which bound to the MGE peptide, but not to EGFR. 
117 
3.4 Discussion 
 In this work, we have continued efforts to engineer antibodies against epitopes in 
GFR. To do so, we used previously designed peptide mimics of EGFR 
finity purified against a 
conform
domains II and IV of E
loops as antigens. However, many of the antibodies we selected were specific for the peptide 
mimcs, but not the full EGFR protein (such as the clones against peptides CRN and MGE). This 
suggests that the peptides may not accurately represent the conformations of the EGFR loops. 
However, it has been shown that rabbits are capable of producing antibodies against the MGE 
peptide that also bind EGFR on the surface of cells (38). Another possibility is that the some of 
the peptides are accurate mimics, but the antibody clones which we happened to select bound the 
peptides in such a manner that would not allow EGFR protein binding. 
Another issue that arose during antibody engineering was inconsistency in antigen 
quality. The yeast 404SG EGFR ectodomain mutant, even when af
ation-specific antibody, showed variation between batches. In addition, it was later 
discovered that the EGFR ectodomain mostly adopts a closed or tethered conformation when in 
solution (40), thus masking many of the targeted domain II and IV epitopes. The addition of EGF 
to 404SG did not appear to improve binding, presumably because these epitopes were also 
masked in the dimerized EGFR. In an attempt to untether the EGFR ectodomain, mutants 
directed at disrupting the domain II/domain IV tether were secreted (Y246D, H566F, 
Y251A/R285S, and K585A). However, these mutants did not show increased binding to the 
antibodies, and it was later published that the domain II/domain IV tether does not contribute 
significantly to maintaining the receptor in the autoinhibited state (40). Finally, since domain IV 
is unresolved in the EGFR dimer crystal structure (24), it may be inherently disordered and thus 
difficult to bind. 
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In order to overcome these problems for selections against EGFR domain IV in the 
future, one possibility is to use the EGFR ectodomain mutant Y251A/R285S plus EGF as an 
antigen. This mutant has been shown to adopt the extended conformation, but not dimerize, upon 
addition of EGF ligand (40). An isolated EGFR domain IV could also be used, but it would need 
to be extensively characterized for proper folding. Finally, if the receptor could be constrained in 
such a way as to prevent dimerization, such as C-terminal immobilization on a surface, EGF 
could be added to untether the receptor. 
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Chapter 4: Mathematical modeling of high affinity EGF binding 
 
4.1 Background 
Equilibrium titrations of EGFR on the surface of cells reveal two populations of EGFR 
which appear to bind EGF with high and low affinity (1). The two populations become apparent 
at low EGF concentrations, where the binding signal is higher than one would expect based on 
simple receptor-ligand equilibrium. An alternate representation of equilibrium titration data is a 
Scatchard plot, where bound ligand divided by free ligand is plotted versus bound ligand (2). 
High affinity EGF binding thus manifests itself as a concave-up Scatchard plot. The high affinity 
receptors comprise ~5-10% of the total population with an apparent EGF affinity in the range of 
100-300 pM, while the remaining receptors bind EGF with an affinity of 2-15 nM (3). 
Although ligand binding is the main driving force for receptor dimerization, a small 
number of preformed dimers have been observed on the surface of cells in the absence of ligand. 
These preformed dimers have been studied using imaging (4-6) and biochemical (7,8) 
techniques, but they are only basally phosphorylated (7). This suggests that there may be inactive 
and active conformations of the dimer, with ligand binding inducing a conformational change or 
rotation leading to activation (4,9). In addition, early experiments suggested that purified EGFR 
dimers bound EGF with a higher affinity than isolated monomers (10,11). Introduction of a 
cysteine residue in the extracellular juxtamembrane region of EGFR led to the formation of 
covalent dimers and an increase in the proportion of high affinity receptors (12). Imaging 
techniques have also found that EGF bound EGFR dimers faster than monomers (13). 
Taken together, this experimental evidence suggested that EGFR dimers may be 
responsible for the high affinity population of receptors seen on the cell surface. Subsequent 
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mathematical modeling of ligand binding and dimerization events using this experimental 
information was able to produce concave-up Scatchard plots; however, the model was unable to 
adequately fit experimental data (14). Expansions to this model which incorporate heterogeneity 
in receptor density on the cell surface can sufficiently fit experimental data (14,15). Additional 
models have been developed where receptor binding to a hypothetical third site leads to the 
experimentally observed high affinity EGF binding. These models can either adequately fit 
experimental data without modeling dimerization events (16) or produce concave-up Scatchard 
curvature while modeling dimerization and monomer untethering events (17). Overall, there is 
still a lack of consensus on the origin of the apparent high affinity population of EGFR. 
In previous work by Alejandro Wolf-Yadlin, rabbit polyclonal antisera against the LYN 
and MGE peptides (see Figure 3-6 and Section 3.1) were characterized. The LYN peptide 
mimics the EGFR domain II (DII) dimerization arm, and the MGE peptide represents an EGFR 
domain IV (DIV) epitope. Based on the epitopes of the rabbit polyclonal antibodies (pAbs), they 
were expected to inhibit receptor homo- and heterodimerization. Accordingly, it was found that 
both pAbs inhibited EGFR phosphorylation at tyrosine 1173 and trans-phosphorylation of Her2 
(18). This inhibition was not caused by the blockade of ligand binding, as the pAbs and EGF 
could simultaneously bind mammalian cells expressing EGFR at saturating ligand 
concentrations. However, pretreatment of cells with the pAbs led to a blockade of EGF binding 
to only the high affinity receptor population, as revealed by equilibrium titrations (18). 
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In the present thesis work, we have used this experimental result to develop a 
mathematical model describing high affinity EGF binding. The equilibrium model for receptor 
dimerization and ligand binding assumes that the high affinity EGF binding component is due to 
inactive preformed dimers and that the antibodies inhibit receptor homo- and heterodimerization. 
The model can successfully reproduce the previous experimental data with only three fit 




4.2.1 Model formulation and output 
 Previous experiments revealed that pAbs against either EGFR DII or DIV eliminated 
high affinity EGF binding (18). Based on the epitopes of the pAbs and their ability to inhibit 
receptor phosphorylation, we hypothesized that the pAbs were blocking receptor dimerization. 
Therefore, it appeared that receptor dimerization was involved in high affinity EGF binding; 
specifically, it was hypothesized that preformed receptor dimers were the high affinity binding 
component. We developed an equilibrium ligand binding and dimerization model incorporating 
these hypotheses to test whether such a model could be consistent with the experimental data. 
The molecular events described by the model are indicated in Figure 4-1. Reactions 1-6 detail 
EGF binding to and dimerization of the extended EGFR monomer, the scheme proposed in (14). 
Reactions 7-8 indicate the tethered monomer converting to the untethered state and binding to 
ligand as modeled in (17). Finally, reactions 9-11 are necessary to describe the analogous 
heterodimerization events, since the cells used in the experiments, human mammary epithelial 
cells (HMECs) (18), also express HER2. 
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 Figure 4-1: Model schematic. The equilibrium binding of EGF ligand to monomeric extended EGFR is represented 
by reaction 1. Reactions 2 and 3 represent the binding of EGF to unoccupied and singly occupied preformed EGF 
dimers, respectively. Reactions 4-6 represent dimerization of occupied and unoccupied EGFR extended monomers. 
Reaction 7 represents the tethered EGFR monomer becoming untethered, and reaction 8 represents EGF binding to 
tethered EGFR. Reactions 9-10 represent heterodimerization with HER2, and reaction 11 represents EGF binding to 
a preformed heterodimer. Each reaction is shown with its relevant equilibrium dissociation constant value. 
 
 When the HMECs are pretreated with either the DII or DIV pAb, both dimerization and 
tether formation could potentially be inhibited. In this case, the reactions outlined in Figure 4-1 
would simplify to only the first reaction, which corresponds to a single-site binding model 
characteristic of simple receptor-ligand binding equilibrium. Then, the fractional EGF binding 
yEGF is described by the equation 
1KL
LyyEGF +=
max ,         (1) 
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where L is the free ligand concentration. The data for cells pretreated with pAb were first fit to 
this simple equation varying two parameters: the single-site equilibrium binding constant K1 and 
the maximum binding signal ymax. As seen in Figure 4-2a, the data fit the single-site binding 
model well for both pAbs, giving K1 = 6.04 nM (68% confidence interval [4.95, 7.37] by support 
plane analysis (19)) for the DII pAb and K1 = 7.34 nM (68% confidence interval [6.05, 8.90]) for 
the DIV pAb. This value for the dissociation constant is consistent with previous estimates for 
the low affinity EGFR population (3,16), and is also consistent with surface plasmon resonance 
measurements for soluble untethered EGFR ectodomain (C-terminal truncation starting at 
residue 502) binding to immobilized EGF (20). The pAb pretreatment titration data is also 
plotted in Figure 4-2c,d as Scatchard plots. Although the data points below 100 pM bound EGF 
may appear to give a slightly concave-down Scatchard plot, this is likely due to experimental 
error at these low concentration points. While Scatchard representations are useful for 
visualization of data, the transformation distorts errors, especially at low ligand concentrations 
(21). It appears from the data that the signals from these low concentration points may be below 
the sensitivity of the experimental binding measurement using flow cytometry. Therefore, we 


































































Figure 4-2: Fit of model results to experimental data from (18). (a) Data from HMECs titrated at 4 oC using the 
indicated concentrations of Alexa488-EGF without (filled diamonds) or with pretreatment of 2 μM DII (open 
squares) or DIV (open triangles) pAb. Best fits of the model to the experimental data are shown in solid lines for no 
pAb and DII pAb pretreatment and in dotted lines for DIV pAb pretreatment. (b) Scatchard representation of 
titration data for no pAb pretreatment (diamonds). Best fit of the model is indicated by the solid line. The data point 
indicated in grey in (a) and (b) was not used for fitting the model. (b, inset) Residual errors between the model and 
experimental data are plotted for no pAb pretreatment. Titration data for DII pAb pretreatment (c) and DIV pAb 
pretreatment (d) are shown in Scatchard representation. Best fit of the model is indicated by the solid line. All error 
bars indicate standard deviation of at least 3 replicates. 
 
Next, the full model shown in Figure 4-1 was used to fit the EGF titration data without 
pAb pretreatment. All reactions were described by mass action relations through equilibrium 
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From these reactions, the following relations were derived: 
C
RLK =1   
1K



















































































CD ==        (8) 
R
TK =7           (9) RKT 7=
130 
TC














































KKK =   (13) 
 
Using a mass balance on total Her2 receptors (HT = 0.075 nM in the experiments) yields an 
expression for the concentration of Her2: 











22 ++=         (16) 
 
Likewise, a total EGFR balance yields an equation relating the concentration of EGFR (RT = 0.5 
nM in the experiments) to free ligand, L: 
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To solve for R, Equation 18 was transformed to the form: 
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1091 KKKRD T−=           (23) 
 
From Equation 19, R can be calculated and then used to compute the total amount of bound 
ligand by summing the different ligand-bound species as a function of L: 
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 Nonlinear least squares fit of the model parameters to experimental data was performed 
using MATLAB (Mathworks) function lsqnonlin. Despite what appears to be many free 
parameters, thermodynamic and physical constraints reduce the number of fit parameters to 
three. Representative values for model parameter K1 were determined earlier from fitting the 
pAb pretreatment data to a single-site binding model, and therefore K1 was set equal to 7 nM. K2 
represents the binding constant for the high affinity preformed dimers and was left as a free 
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parameter for data fitting. K3 represents the affinity of binding a second EGF to a singly 
occupied EGFR dimer. Previously, it has been shown that for an equilibrium 
dimerization/ligand-binding model such as this one, K3 must be greater than K2 to produce a 
concave-up Scatchard plot (14). Also, if K3 were equal to K2, the dimerization of bound and 
unbound monomers (reaction 5) would lead to the creation of many more high affinity sites than 
are experimentally observed. To reduce the number of fit parameters, as a simplifying 
assumption K3 was therefore set equal to K1, the binding constant for the low affinity binding 
site. K4 represents the dimerization or cross-linking coefficient, and was left as a free parameter. 
Three of the equilibrium constants are not independent; K5, K6, and K10 can be derived as a 
function of the other parameters (see Equations 4, 5, and 13). K7 was set to 30 according to the 
estimated energy of untethering (17,20,22), and K8 was set to 400 nM as the affinity of EGF for 
EGFR domain III (17,23). K9, the EGFR/HER2 heterodimerization constant, was set equal to the 
EGFR homodimerization constant K4. Modeling and experiments have shown that homo- and 
heterodimerization occur with comparable affinities, with the prevalence of heterodimers 
observed in many cell types arising from a combination of relative expression levels and 
differential endocytic trafficking properties (24). Finally, K11 was set equal to K2, the high 
affinity interaction, since increasing expression of HER2 has been shown to increase the fraction 
of receptors in the high affinity state (25). The EGFR and HER2 receptor concentrations, RT and 
HT, respectively, were calculated as the total average concentration in the sample based on the 
average number of receptors per cell and number of cells per labeling volume. Therefore, for 
modeling of the EGF titration without pAb pretreatment, a total of three parameters were varied 
to fit the data: K2, K4, and the maximum binding signal. 
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4.2.2 Model characterization 
 As seen in Figure 4-2, the model fits the EGF titration data well. The residual errors 
between the model and the data are randomly distributed around zero, indicating an adequate fit 
(Figure 4-2b, inset). The model and experimental data are also shown in Scatchard format in 
Figure 4-2b. One data point, indicated in gray, was determined to be an outlier and not used for 
the model fitting. One possible explanation is that the reaction was under depleting ligand 
conditions, leading to a lower signal than expected. Nevertheless, if this data point was used in 
the analysis, the fit parameters were not affected by more than twofold, and the model fit was 
only slightly worse (data not shown). The best-fit parameters from the model were K2 = 110 pM 
for high affinity EGF binding to preformed dimers and K4 = 13 pM for the dimerization constant. 
This K2 value is consistent with previous estimates for the high affinity EGFR population (3,16). 
For EGFR on the surface of cells, the value of K4 depends on the total receptor concentration 
used in the model and is normally within an order of magnitude of RT (17), as it is in this case. 
Also, K4 and RT being within an order of magnitude is required if both receptor monomers and 
dimers are present in the absence of ligand, which has been experimentally observed (4-7). 
Although K3 was fixed and set equal to the binding constant for the low affinity site K1 (7 nM), 
allowing K3 to vary as a free parameter yielded similar results, with K3 = 18 nM, indicating a low 
affinity binding site. 
For the HMECs, the model predicts that in the absence of ligand, the EGF receptors are 
distributed as 81% tethered monomers, 6% preformed homodimers, 10% preformed 
heterodimers with HER2, and 3% untethered monomers. Half of the homodimers plus the 
heterodimers, ~13% of the receptors in this case, are thus predicted to be in a high affinity state. 
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While the percentage of receptors in the high affinity state will vary according to cell line and 
EGFR and HER2 expression levels, this percentage is within the generally reported range (3,6). 
In order to assess the parameter space of the model, a support plane analysis (19) was 
performed (Figure 4-3a). The analysis yielded a defined confidence interval when the product of 
the high affinity binding constant and the receptor dimerization constant, K2K4, was used as a 
lumped parameter. K2K4 was varied, and the remaining parameters, K4 and maximum signal, 
were re-fit at each of the values of K2K4. This was repeated until the resulting error exceeded an 
acceptable value as judged by the appropriate F-statistic for the system, yielding a 68% 
confidence interval of [4.6x10-4, 2.4x10-3] for K2K4. Next, we sought to determine how well the 
model can capture the experimentally observed concave-up Scatchard behavior of EGF binding. 
K2 and K4 were varied over 9 orders of magnitude, and the concavity of the resulting Scatchard 
plot was determined. For the model, a concave-up Scatchard plot is obtained for a wide range of 




























Figure 4-3: Model characterization. (a) Support plane analysis of parameter space of the model. The product K2K4 
was varied, and the remaining parameters K4 and maximum signal were re-fit at each value of K2K4. The y-axis 
shows the error at the corresponding value of K2K4 divided by the minimum error (when all 3 parameters are 
allowed to vary). The dotted line indicates the 68% confidence interval. (b) Parameter space giving a concave-up 
Scatchard plot. Parameters K2 and K4 were varied, and the shaded area indicates parameter values for which the 
resulting Scatchard plot was concave-up. Scatchard plots were considered concave-up if all calculated points were 




 Since pretreatment of cells with the DII and DIV pAbs eliminated the high affinity EGF-
binding component typically seen with cell-surface EGFR, we speculated that pAb binding 
inhibited receptor homo- and heterodimerization and that dimers may represent that high affinity 
binding mode. To probe this idea, we formulated an equilibrium model where preformed dimers 
were the high affinity component, and the model (Figure 4-1) was successfully fit to the 
experimental data (Figure 4-2). Further analysis of the model demonstrated its appropriateness to 
the system, as a wide variety of parameter values could yield a concave-up Scatchard plot 
(Figure 4-3b). The features of the model that produce concave-up Scatchard plots are: [a] high 
affinity preformed dimers and [b] negative cooperativity of EGF binding to the dimer. Therefore, 
in this model, the first EGF binds an unoccupied preformed dimer with high affinity, and the 
second EGF binds with low affinity to the singly occupied dimer. There exists experimental 
evidence that preformed dimers possess a higher affinity for EGF; dimers stabilized by a 
juxtamembrane disulfide bond on the surface of living cells show an increased percentage of 
high affinity receptors (12), and dimers observed by FRET also appear to be high affinity (4). 
While there is mathematical support for negative cooperativity in EGF binding (14), there is also 
experimental support in that disulfide-stabilized EGFR dimers still display both high and low 
affinity binding to EGF (9,12). One possible structural interpretation of these model features is 
that the preformed dimer holds EGFR domains I and III in an ideal orientation for ligand 
binding, with correct positioning of the domains while allowing enough flexibility for the ligand 
to enter the binding site, thus leading to high affinity binding. However, once the first EGF binds 
to the preformed dimer, this could potentially change the positions of the two EGFR molecules 
with respect to each other, restricting the motion of the unoccupied EGFR site and making it 
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more difficult for the second EGF to bind. It has been shown that ligand binding stabilizes an 
additional EGFR dimerization interface C-terminal to the DII dimerization arm that is not 
present in the absence of ligand (20), and this interface could mediate such a change. 
 Although wild-type EGFR molecules form dimers on the surface of cells in the absence 
of ligand, receptors lacking the cytoplasmic domain through partial truncation or substitution 
with the EpoR cytoplasmic domain do not form these predimers (7). Mutants lacking part of the 
cytoplasmic domain also give rise to linear Scatchard plots of a single low affinity binding site 
(26), but can still dimerize in the presence of ligand (27). Taken together, these data are 
consistent with our model of preformed receptor dimers as the high affinity component and 
suggest that the cytoplasmic domain contributes to stabilizing the EGFR dimer, especially in the 
absence of ligand. Recent modeling and experiments on EGFR with a cytoplasmic domain 
truncation suggest that the low affinity receptors represent interconverting tethered and extended 
receptor conformations (28), which is also the case in our model. Likewise, deletion of the 
domain II dimerization arm (29) or mutations in this region (30) result in a loss of high affinity 
binding. A V583D mutation designed to promote receptor untethering increases the percentage 
of high affinity sites (30), which is consistent with our model. However, the same study found 
that the mutation did not increase the amount of dimers in the absence of ligand, although the 
sensitivity of the immunoblotting assay may have been limited. Further interpretation of 
mutation results is difficult because many mutations designed to inhibit receptor tethering may 
also inhibit dimerization with opposing effects. In addition, fibroblasts in which α1,6-
fucosyltransferase has been deleted (leading to a loss of protein core fucosylation) show no high 
affinity EGF binding. These cells also have substantially lower EGF-induced EGFR 
phosphorylation (31), suggesting a possible defect in receptor dimerization, and this data is 
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consistent with the hypothesis that receptor dimers are the high affinity component. Finally, an 
N579Q mutant designed to eliminate glycosylation at this site leads to both an elevated level of 
preformed dimers in the absence of ligand and a larger fraction of receptors in the high affinity 
state (32). 
 Our model is similar to that of Wofsy et al., which also incorporates high affinity 
preformed dimers with negative cooperativity (14). However, in that model both binding events 
to the dimer were still higher affinity than binding to the monomer, and the best fit parameters 
led to less than 1% of EGFR in preformed dimers in the absence of ligand. Although able to 
produce concave-up Scatchard plots, the authors were unable to successfully fit this model to 
their data, even though this model incorporated two essential elements of our model. The 
experiments in Wofsy et al. used membrane vesicles with a C-terminal truncation of EGFR 
starting at residue 1023 in their experiments, which may have affected the results. A separate 
study showed that membrane vesicles only contained low affinity EGFR (33), demonstrating 
variability in membrane vesicle composition. The parameters in the Wofsy et al. model could not 
be uniquely determined, so certain parameters were fixed while others were fit. It is possible that 
some relatively recent experimentally determined constants not available to the authors at the 
time could have aided in the convergence of their model in a more restricted parameter space. 
Wofsy et al. thus concluded that other factors such as heterogeneity in receptor density could be 
responsible for the concavity of the Scatchard plot, and successfully modeled this hypothesis 
(14). Likewise, Mayawala et al. also recently modeled heterogeneous EGFR density with success 
(15). While receptor heterogeneity likely exists on the cell surface (34), it is unclear how the 
binding of an antibody to either EGFR domain II or IV could lead to a loss in this heterogeneity 
to produce a linear Scatchard plot as observed in previous experiments (18). Thus, heterogeneity 
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may not be the cause, or at least not the sole cause, of observed Scatchard concavity. Finally, our 
model is not inconsistent with models which include a hypothetical third binding partner that 
leads to high affinity EGFR sites (16,17). Klein et al. modeled that only receptor dimers could 
bind to the hypothetical partner, and thus our observation that putatively dimerization-blocking 
antibodies result in loss of high affinity binding could be consistent with this model (17). 
However, we believe that the utility of our model is in its ability to reproduce experimental data 
by incorporating known EGFR molecular events and parameters based on experiments, without 
the need to introduce any additional mechanisms not yet independently verified. 
 A ligand-binding and dimerization model for soluble EGFR ectodomain has also been 
developed in the past (23). It is difficult to compare receptor dimerization constants measured in 
solution with those on the surface of cells, since receptors restricted to the membrane lose 
rotational and translational degrees of freedom (35) and the cytoplasmic domain may also 
contribute to dimerization (see above). Since we have modeled equilibrium binding only, kinetic 
parameters and predictions are beyond the scope of the model. However, a spatially distributed 
Monte Carlo-based simulation that utilized kinetic parameters determined that at low EGF 
concentrations, the predominant ligand-binding mode is binding to preformed dimers (36), which 
is consistent with the model presented here. An additional kinetic model based on experimental 
imaging data found that preformed EGFR dimers bound EGF faster than monomeric sites, but 
their mathematical model suggested positive cooperitivity in EGF binding (37). Also beyond the 
scope of the model are higher-order EGFR and HER2 oligomers, which experiments on the 
surface of cells suggest may exist (38). 
 EGFR antibodies that lead to altered Scatchard plots have previously been described. 
Monoclonal antibody 108 was shown to reduce the number of high affinity EGFR receptors, as 
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the pAbs did; however, unlike the pAbs, 108 both partially inhibited EGF binding and was 
unable to block signaling at saturating EGF concentrations (39). Conversely, another monoclonal 
antibody, 2E9, appeared to block binding to only low affinity EGFR; however, 2E9 competed 
with EGF binding almost completely at saturating concentrations of EGF, and EGFR was still 
able to signal when cells were treated with a 90% saturating amount of 2E9 (40). This is not 
surprising, considering that a calcium signaling response has been demonstrated for a few as 300 
molecules of bound EGF (13). While these antibodies have been reported to alter Scatchard 
plots, they still appear to at least partially compete with EGF binding at saturating 
concentrations; thus, their mechanisms of action are unclear. 
 Physiologically, the formation of high affinity preformed dimers in the absence of ligand 
could aid the cell in responding quickly to a ligand stimulus. These dimers on the cell surface 
would be poised to signal once ligand is present, without needing to wait for two ligand-bound 
monomers to diffuse together. We hypothesize that the function of the autoinhibited EGFR 
conformation is to limit the number of extended monomers that can form dimers in the absence 
of ligand, thus preventing a high level of basal signaling. 
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Appendix 1: Sequences 
 
 

























Note: WT cysteine 283 mutated to alanine (truncation at 273 causes unpaired cysteine) 
      N-terminal c-myc tag included in above sequence 
 
 



























1.4  VL sequences of selected clones from LYN-A4 and LYN-A5 
 
     VL-FR1                  VL-CDR1       VL-FR2
A4-8 NFMLTQPHSVSESPGKTATISC  TRSSGSIASNYVQ WYQQRPGGAPTTVIY 
A5-2 ETTLTQSPAFLSATPGDKVDISC KASQDIDDDLN   WYQQKPGEAAVFIIQ 
A5-3 ETTFTQSPAFMSATPGDKVNIFC KASQDIDDDVS   WYQQRPGEAPIFIIQ 
A5-4 ETTLTQSPAFMSATPGDKVNISC KASQDIDDDMN   WYQQKPGEAAIFIIQ 
A5-5 QPVLTQSPSASGTPGQSVTISC  SGSGSNIGNNKVN WYQQLPGTAPKLLIY 
A5-6 NFMLTQPHSVSESPGETVTISC  TGSSGSIASNSVQ WYQQRPGSAPRTVIY 
A5-8 NFMLTQPHSVSESPGKTVTISC  TGSSGSIATNYVQ WYQQRPGSAPTTVIY 
A5-9 ETTFTQSPAFMSATPGDKVNISC KASQDIDEDVN   WYQQKPGEAPIFIIQ 
 
     VL-CDR2 VL-FR3       VL-CDR3
A4-8 EDNQRPS GVPDRFSGSIDSSSNSASLTISGLRTEDEADYYC QSYDRSNKAV  FGGGTQLTILSGIL 
A5-2 EATTLVP GIPPRFSGSGYGTDFTLTINNIESEDAAYYFC   LHHDDLPLT   FGQGTKLEIKSGIL 
A5-3 EATTLVP GTPPRFSGSGYGTDFTLTIDNIESEDAAYYFC   LQDDSFPLT   FGQGTKLEIKSGIL 
A5-4 EATTLVP GIPPRFSGSGYGTDFTLTINNIESEDAAYYFC   LQHDNFPWT   FGQGTRVEIKSGIL 
A5-5 SNNQRPS GVPDRFSGSKSGTSASLAISGLQSEDEADYYC   AAWDDSLNGYV FGTGTKLTVLSGIL 
A5-6 EDHQRPS GVPDRFSGSIDTSSNSASLTISGLRTEDEGDYYC RSYDSSHTV   FGGGTQLTVLSGIL 
A5-8 ENNQRPS GVPDQFSGSIDSSSNSASLTISGLKTEDKADYYC QSYDSSXLXV  XXXGTKXXVLXXIX 
A5-9 DATTLVP GIPPRFSGSGHGTDFTLTIDNIESEDAAYYFC   LQHDNFPPYT  FGQGTKLEIKSGIL 
 
Note: A4-8, A5-2, A5-3, A5-4, A5-6, A5-8, A5-9: LYN-1 VH 




1.5  VL sequences of selected clones from CRN-A3 
 
   VL-FR1                  VL-CDR1       VL-FR2
1  NFMLTQPHSVSESPGKTVTISC  TGSSGSIATNYVQ WYQQRPGSAPTTVIY 
2  EIVLTQSPGTLSLSPGERVTLSC RASQTVSSSYLA  WYQQKTGQAPRLLMY 
3  DIQVTQSPSSLSASVGDRVTITC RASQSISSYLN   WYQQKPGTAPKLLIY 
4  ETTLTQSPGTLSLSPGERATLSC RASQSVGGSYLA  WYQKKTGQAPRLLIY 
5  ETTLTQSPGTLSLSPGERATLSC RASQGVAGSDLA  WYQQKPGQAPRLLIY 
6  NFMLTQPRSVSESPGKTVTISC  TGSSGSIASNYVQ WYQQRPGSAPTIVIH 
7  ETTLTQSPAFMSATPGDKVNISC KASQDIDDDMN   WYQQKPGEAPILILQ 
8  EIVLTQSPATLSLSPGERATLSC RASQSFTGNYLA  WYQQKPGQAPRLLIY 
9  DIRVTQSPSSLSASVGDRVTITC RASQSINTYLN   WYQQKPGKAPKLLIY 
10 ETTLTQSPGTLSLSPGDRVTISC KASHDVDDDLN   WYQQKPGKAPVLIIR 
 
   VL-CDR2 VL-FR3     VL-CDR3
1  ENNQRPS GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYDSSNHAV FGGGTQLTVLSGIL 
2  GASTRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC   QQYGSSRWT  FGQGTKVEIKSGIL 
3  DATRVES GVPSRFSGSGSGTDFTLTISGLQVEDVATYYC   QRGYNTPRT  FGQGTKVDIKSGIL 
4  DASSRAT GIPDRFSGSGSGTDFTLTINRVEPEDFAMYYC   QQYGSSPVT  FGQGTRLKIKSGIL 
5  GASSRAT GIPDRFSGSGSGTDFSLTISRLEPEDFAVYYC   QQFDTVTWT  FGQGTKVEIKSGIL 
6  EDNQRPS GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYDSSSRWV FGGGTKLTVLSGIL 
7  ESTVLLP GIPPRFSGSGYGSDFTLTINNMQSEDAAYYFC   LQHDSFPFT  FGQGTKLEIKSGIL 
8  GASSRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYHC   QQYGTSPT   FGQ 
9  AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC   QQSYSSPSL  FTFGPGNKVDIKSG 




1.6  Selected clones from CAH-A6 
 
  VH-FR1                    VH-CDR1      VH-FR2           VH-CDR2
1 EVQLVESGGGLVQPGRSLRLSCAAS GFSFADYAMH   WVRQVPGKGLEWVS   SISWNSGIKG 
2 QVQLKQSGPGLVNPSQTLSLTCAIS GDSVSSDSAA   WNWIRQSPSRGLEWLG RTYYRSKWYNE 
4 QVQLVESEGGVVQPGRSLRLSCAAS GFSFSRFAMH   WVRQAPGKGLEWVA   VISYDGSNKF 
5 QVQLQQSGPGLVKPSQTLSLTCAIS GDSVSSNSAAWN WIRQSPSRGLEWLG   RTAYRSKWNSD 
 
  VH-FR3                                  VH-CDR3  
1 YADSVKGRFTISRDNAKNTVYLEVNNIRPEDTALYYCAK VRDPNIEAFDV WGQGTMVTVSS 
2 YTESVKSRIIINPDTSKNQFSLQLNSVTPEDTALYYCAR FLRGTFDI    WGQGSMVTVSS 
4 YADSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCAR HYDSSGRDH   WGQGTLVTVSS 
5 YAASVRSRITINPDTSKNQFSLQLNSVTPDDTAMYYCAR SRSSSPIDY   WGQGTLVTVSS 
 
              Linker          VL-FR1                  VL-CDR1       VL-FR2
1        GILGSGGGGSGGGGSGGGGS EIVLTQSPGTLSLSPGERATLSC RASQSVSSSYLG  WYQQKPGQAPRLLIY 
2 ASTKGPSGILGSGGGGSGGGGSGGGGS NFMLTQPHSVSESPGKTVTISC  TGSSGSIATNYVQ WYQQRPGSAPTTVIY 
4        GILGSGGGGSGGGGSGGGGS EIVMTQSPGTLSSSPGERATLSC RASKDVSSQFLA  WYQQKPGQAPRLLIY 
5        GILGSGGGGSGGGGSGGGGS EIVLTQSPGTLSLSPGERVTLSC RASQRVSSSYVA  WYQQKPGQAPRLLIY 
 
  VL-CDR2 VL-FR3                             VL-CDR3
1 GASSRAT GIPDRFSGSGSGTDFALTISRLEPEDFAVYYC   QQHDRSSWT  FGQGTKVEIKSGIL 
2 ENNHRPS GVPDRFSGSIDSSSNSASLTISGLKTEDEAGYYC QSSDNDFHAV FGGGTQLTVLSGIL 
4 ETSTRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC   QQYGRSPRT  FGQGTKVEIKSGIL 
5 GASSRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC   QQYDSSPRT  FGQGTKLEIKSGIL 
 
 
1.7  VL sequences of selected clones from MGE-A4 
 
  VL-FR1                  VL-CDR1        VL-FR2
2 DIRVTQSPSSLSASVGDRVTITC RASQSISNYLN    WYQQKPGKAPKLLIH 
3 QSVLTQPASVSGSPGQSITISC  TGTSSDVGGYDYVS WYQQHPGKTPKRMIY 
4 QSVLTQPPSVSGSPGQSITISC  TGTSSDVGNYNLVS WYQRHPGKAPKLMIY 
7 NFMLTQPHSVSESPGKTVAISC  TRSSGSIASNYVQ  WYQQRPGSSPTTVIY 
 
  VL-CDR2 VL-FR3                             VL-CDR3
2 AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC   QQSYSMPFN  FGPGTK 
3 EVNKRPS GVSNRFSGSKSGNTASLTISGLQAEDEADYYC   TSYRSGSSYV FGTGTKLTVLSGIL 
4 EVNKRPS GISHRFSGSKSGNTASLTISGLQAED 
7 EDKERPS GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYDGTNTV  FGGGTQLTVLSGIL 
 
Note: All clones MGE-2 VH 
 
 
1.8  VL sequences of selected clones from LVW-A3 
 
  VL-FR1                  VL-CDR1       VL-FR2
1 DIRVTQSPSSLSASIGDRVTITC RASQTIGSYLN   WYQHRPGKAPKLLIY 
2 NFMLTQPHSVSESPGKTVTISC  TGSSGSIASNYVQ WYQQRPGSAPTTVIY 
3 NFMLTQLHSVSGSPGKTITISC  TRSSGSIATNYVQ WYQQRPGRAPSTVIY 
4 ETTLTQSPAFLSATPGDKVTISC KASLDIDDDVN   WYQQKPGQAPIFIIQ 
5 NFMLTQPHSVSESPGKTVTISC  TRSSGSIASNYVQ WYQQRPGRAPTTIIF 
7 NFMLTQPHSVSESPGKTVTISC  TGSSGSIADKYVQ WYQQRPGSAPRNVIF 
8 NFMLTQPHSVSESPGKTVTISC  TGSSGSITINYVQ WYQQRPGSAPTTVIY 
9 NFMLTQPHSVSESPGKTVTISC  TGSSGSIASNYVQ WYQQRPGSAPTTVIY 
 
  VL-CDR2 VL-FR3                             VL-CDR3
1 AASSLQD GVPSRFSGGGSGTDFTLTISNLQPEDFTTYYC   QQSYGXXRDV RXRDQGGXSNPGIL 
2 EDNQRPS GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYDNSNPAV FGGGTQLTVLSGIL 
3 EDKQRPS GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYDSSNYV  FGTGTKLTVLSGIL 
4 EATTLVP GIPPRFSGSGYGTDFTLTINNIQPEDAAYYFC   LQHDNFPYT  FGQGTKLEVKSGIL 
5 EDNQRPS GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYDSSNAV  FGGGTQLTVLSGIL 
7 DDDQRPS GVPDRFSGSIDTSSNSASLIISGLKTEDEADYYC QSFDSSNKTV FGRSTQLTVLSGIL 
8 EDNQRPS GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYDSSNQGV FGRRTKLTVLSGIL 
9 ENNQRPS GVPDRFSGSIDSSSNSASLTISGLKTEDEAEYYC QSYDSSNHAV FGGGTQLTVLSGIL 
 
Note: All clones LWV-2 VH 
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1.9  Selected clones from CRN-B4 
 
   VH-FR1                    VH-CDR1    VH-FR2         VH-CDR2
1   
3  QVQLQQWVPGLLKPSETLSLTCGVS GGSLSGYYWS WIRQSPGKELEWIG EINQGGSTN 
5  QVQLQQWGPGLLEPSETLSLTCGVS GGSLSGYYWS WIRQSPGKELEWIG EINQGGSTN 
6  QVQLQQWGPGLLKPSETLSLTCGVS GGSLSGYYWS WIRQSPGKELEWIG EINQGGSTN 
7  QVQRQQWGPGPLKPSETLFLTCGVS GGSLSGYYWS WVRQSPGKELEWIG DINQGGSTN 
10   QLQQWGPGLLKPSETLSLTCGVS GGSLSGYYWS WIRQSPGKELEWIG EINQGGSTN 
 
   VH-FR3                                  VH-CDR3  
1 
3  YNPSLRSRVTISVDTSKKQLSLKVNSVTASDTAVYYCAR ETFRGSNCFDS WGQGTLVTVSS 
5  YNPSLRSRATISVDTSKKQLSLKVNSVTASDTAVYYCAR ETFRGSNCFDS WGQGTLVTVSS 
6  YNPSLRSRVTISVDTSKKQLSLKVNSVTASDTAVYYCAR ETFRGSNCFDS WGQGTLVTVSS 
7  YDPSLRSRVATSAGTSKKQLSLKVDPATASDTAAYYCAR EIFRGSNRFDS WGQGILVAASS 
10 YNPSLRSRVTISVDTSKKQLSLKVNSVTASDTAVYYCAG ETFKGSNCFDS WGQGTLVTVSS 
 
        Linker          VL-FR1     VL-CDR1  VL-FR2
1                       EIVLTQSPGTLSLSPGERVTLSC RASQTVSSSYLA WYQQKTGQAPRLLMY 
3  GILGSGGGGSGGGGSGGGGS EIVLTQSPGTLSLSPGERVTLSC RASQTVSSSYLA WYQQKTGQAPRLLMY 
5  GILGSGGGGSGGGGSGGGGS EIVLTQSPGTLSLSPGERVTLSC RASQTVSSSYLA WYQQKTGQAPRLLMY 
6  GILGSGGGGSGGGGSGGGGS EIVLTQSPGTLSLSPGERVTLSC RASQTVSSSYLA WYQQKTGQAPRLLMY 
7  GILGPGGGGGGGGGSGGGGP EIVLTQSPGALSLSPGERVTLSC RASQIVGSSYLA WCQRETGQAPRLLTY 
10 GILGSGGGGSGGGGSGGGGS EIVLTQSPGTLSLSPGERVTLSC RASQTVSSSYLA WYQQKTGQAPRLLMY 
 
   VL-CDR2 VL-FR3                           VL-CDR3
1  GASTRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSRWT FGQGTKVEVKSGIL 
3  GASTRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSWWT FGQGTKVEIKSGIL 
5  GASTRAT GIPDRFSGSGSGTDFTLTISRLEPEDLAVYYC QQYGSSRWT FGQGTKVEIKSGIL 
6  GASTRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSRWT FGQGTKVEIKSGIL 
7  GASTRAT GIPDRFSGSGSGTDFTLTISRLEPENLAVYHC QQYGSSRWT LGQGTKVETKPGIL 
















VH-FR1                    VH-CDR1    VH-FR2         VH-CDR2
EVQLVESGGGLVQPGRSLRLSCAAS GFSFADYAMH WVRQVPGKGLEWVS SISWNSGIKG  
 
VH-FR3                                  VH-CDR3
YADSVKGRFTISRDNAKNTVYLEVTNIRPEDTALYYCAK VRDPNIEAFDV WGQGTMVTVSS 
 
     Linker          VL-FR1                  VL-CDR1      VL-FR2
GILGPGGGGSGGGGSGGGGS EIVLTQSPGTLSLSPGERATLSC RASQSVSSSYLG WYQQKPGQAPRLLIY 
 
VL-CDR2 VL-FR3                           VL-CDR3




1.13 Selected clones from MGE-B6 
 
   VH-FR1                    VH-CDR1      VH-FR2         VH-CDR2
1  QVQLQEPGPGLARPSETLSLTCTVS GGPIGDSDYCWG WIRQPPGKGLRWVG GINCYGTTC 
2  QVQLQESGPGLVKPSETLSLTCTVS GGSISNSDYYWG WIRQPPGKGLRWIG SINYYGTTY 
3  QVQLQESGPGLVKPSETLSLTCTVS GGSISNSGYYWG WIRQPPGKGLRWIG SINYYGTTY 
4  QVQLQESGPGLVKPSETLSLTCTVS GGSISNSDYYWG WIRQPPGKGLRWIG SINYYGTTY 
5  QVQLQESGPGLVKPSETLSLTCTVS GGSISNSDYYWG WIRQPPGKGLRWIG SINYYGTTY 
6  QVQLQESGPGLVKPSETLSLTCTVS GGSISNSDYYWG WIRQPPGKGLRWIG SINYYGTTY 
7  QVQLQESGPGLVKPSETLSLTCTVS GGSISNSDYYWG WIRQPPGKGLRWIG SINYYGTTY 
8  QVQLQESGPGLVKPSEALSLTCAVS GGSISNSDYYWG WVRQPPGKGLRWIG SINYYGTTY 
9  QVQLQESGPGLVKPSETLSLTCTVS GGSISNSDYYWG WIRQPPGKGLRWIG SINYYGTTY 
10 QVQLQESGPGLVKPSETLSLTCTVS GGSISNSDYYWG WIRQPPGKGLRWIG SINYYGTTY 
 
   VH-FR3                                  VH-CDR3  
1  YNPSLKNRVAMSVGTSKDQFSLRLGPVAATDTAVYYCAR RGANSWFFDL WGRGTLVTVSS 
2  YNPSLKSRVAMSVDTSKNQFSLKLSSVTAADTAVYYCAR RGANSWFFDL WGRGTLVTVSS 
3  YNPSLKSRVAMSVDTSKNQFSLKLSSVTAADTAVYYCAR RGANSWFFDL WGRGTLVTVSS 
4  YNPSLKSRVAMSVDTSKNQFSLKLSSVTAADTAVYYCAR RGANSWSFDL WGRGTLVTVSS 
5  YNPSLKSRAAMSVDTSKNQFSLKLSSVTAADTAVYYCAR RGANSWFFDL WGRGTLVTVSS 
6  YNPSLKSRVAMSVDTSKNQFSLKLSSVTAADTAVYYCAR RGANSWFFDL WGRGTLVTVSS 
7  YNPSLKSRVAMSVDTSKNQFSLKLSSVTAADTAVYYCAR RGANSWFFDL WGRGTLVTVSS 
8  YNPSLKSRVAMSVDTSKNQFSLKLSSVTAADTAVYYCAR RGANSWFFDL WGRGTLVTVSS 
9  YNPSLKSRVAMSVDTSKNQFSLKLSSVTAADTAVYYCAR RGANSWFFDL WGRGTLVTVSS 
10 YNPSLKSRVAMSVDTSKNQFSLKLSSVTAADTAVYYCAR RGANSWFFDL WGRGTLVTVSS 
 
        Linker          VL-FR1     VL-CDR1    VL-FR2
1  GILGSGGGGSGGGGSGGGGS NFMLTQPHSVSESPGKMAAISC  TRSSGSIASNYVQ  WYQQRPGSSPTTVIY 
2  GILGSGGGGGGGGGSGGGGS QSVLTQPPSVSGSPGQSITISC  TGTSSDVGGYDYVS WYQQHPGKTPKRMIY 
3  GILGSGGGGSGGGGSGGGGS QSVLTQPASVSGSPGQSITISC  TGTSSDVGNYNLVS WYQRHPGKAPKLMIY 
4  GILGSGGGGSGGGGSGGGGS QSVLTQPASVSGSPGQSITISC  TGTGSDVGGYDYVS WYQQHPGKTPKRMIY 
5  GILGSGGGGSGGGGSGGGGS DIRVTQSPSSLSASVGDRVTITC RASQSISSSLN    WYQQKPGKAPNLLIY 
6  GILGSGGGGSGGGGSGGGGS QSVLTQPASVSGSPGQSITISC  TGTSSDVGGYDYVS WYQQHPGKTPKRMIY 
7  GILGSGGGGSGGGGPGGGGS QSVLTQPASVSGSPGQSITISC  TGTSSDVGGYDYVS WYQQHPGKTPKRMIY 
8  GILGSGGGGSGGGGSGGGGP QSVLTQPPSVSGSPGQSITISC  TGTSSDVGNYNLVS WYQRHPGKAPKLMIY 
9  GILGSGGGGSGGGGSGGGGS DIQVTRSPSSPSASVGGRVTITC RASPSTSSSLS    WYQQEPGKASDLLTY 
10 GILGSGGGGSGGGGSGGGGS QSVLTQPASVSGSPGQSITISC  TGTSSDVGGYDYVS WYQQHPGKTPKRMIY 
 
   VL-CDR2 VL-FR3                             VL-CDR3
1  EDKERPS GVPDRLSGSTDSSSNSASLTISGLKPEDGADYYC QPYDRNNRAV FGGGTQLTVLSGIL 
2  EVNKRPS GVSNRFSGSKSGNTASLTISGLQAEDEADYYC   TSYRSGSSYV FGTGTKLTVLSGIL 
3  EVNKRPS GISHRFSGSKSGNTASLTISGLQAKDEGDYYC   CSYTSTGGTV LGGGTQLTVLSGIL 
4  EVNKRPS GASNRFSGSKSGNTASLTISGLQAEDEADYYC   TSYRSGSSYV FGTGTKLTVLPGIL 
5  ATSSLQR GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC   QQSYNTPRT  FGQGTKVEIKSGIL 
6  EVNKRPS GVSNRFSGSKSGNTASLTISGLQAEDEGDYYC   CSYTSTGGTV LGGGTQLTVLSGTL 
7  EVNKRPS GVSNRFSGSKSGNTASLTISGLQAEDEADYYC   TSYRSGSSYV FGTGTKLTVLSGIL 
8  EVNKRPS GISHRFSGSKSGNTASLTISGLQAEDEGDYYC   CSYTSTGGTV LGGGTQLTVLSGIL 
9  ATPSLQR GVPSGSSGSGSGADSTLTASSLQPEDFATCHC   QQSYSTPRT  SGQGARMETKSGIL 




1.14 Selected clones from LVW-B4 
 
  VH-FR1                    VH-CDR1      VH-FR2         VH-CDR2
1 QTTLEEPGPTVVKPAQTLTPTCTFP GSSLSTSGVGVG WIRQSPGKALEWLA PISWDGDKR 
2 QTVLKEPSPTAARPTQALTLTCASS GLSLSTSGVGTD RAHQPPGRALEWPA LISRDDGKR 
3  
5 
8 QIILKESGPTVVRPTQTLTLTCTSF GLSPSTSGVGVG WARQPPGRALEWLA LISWGDGKR 
9 QTTLKESGSTTAKPIQTPTLACTFS GFSLSTSGVGAG WIRRLPGKAPEWPA LISWGDDKR 
 
  VH-FR3                                  VH-CDR3  
1 YSPSLRSRPTITEDTSKNQVVLTMTNMDPVDTATYFCAH LTSFVDVIELRTGWCFDA WGRGTLVTVSS 
2 HSPSPKGRLTITKGTSKNQAVLAVASMDPVGTAACPWAH PVSSVGAVELRTGWCSDT WGRGTLVTVPS 
3 
5 
8 YSPSLKSRLPITKDTSKDQVALTATNMDPVDTATYFCAY PINFADAVELRTGWRFDV WGRGTLVTASS 
9 YSPSLKSRPTITKDTSKSQVILTMTNMDPVGTATYFCTH LINFVDATERRTGWRSDV WGRGTLVTASS 
 
       Linker          VL-FR1                  VL-CDR1  VL-FR2
1 GILGSGGGGSGGDGSGGGGS NSTPTQPHSVSESPGKTVTISR  TRSSGSIASDYVQ WPQQRPGSVPTTVTH 
2 GTLGSGGGGSGGGSSGGGGP DFMLTQPHPVSESPRRTVTVSC  TRNSDGIAGGRAQ RHQQRPGSSPTTTTR 
3                      DIRVTQSPSSLSASVGDRVTITC RPSRSISNYLN   WYQQKPGKAPKLLIY 
5                      ETAFTQSPAFMSATPGDKVNIFC KASQDIDDDVS   WYQQRPGEAPIFIIQ 
8 GTLGSGGGGSGGGGPGGGGP NFMLTQPRAVSESPGKMATASC  TGSSGSIASDPVQ WYQQRPGSAPTTVTH 
9 GILGSGGGGSGGGGSGGGGS NFVLTQPHSVSESPGKAVTISY  ARSGGSVATNYVR WCQQRPGGSPTTVVY 
 
  VL-CDR2 VL-FR3                             VL-CDR3
1 ENNQRPS GVPDRFFGPIDSSSNSASPTISGLKTEDEADHYC QSYDSSNHVV FGGGTQPTVLSGTL 
2 EGERRPP GVPGRLSGSADHPPNSASLTVFGLKAGDGAGHYC QSYDGNSRAV FGEGTQLTVLPGAP 
3 AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDSATYYC   LQHNSLPLT  FGPGTKVDIKSGIL 
5 EATTLVP GTPPRFSGSGYGTDFTLTIDNIESEDAAYYFC   LQDDSFPLT  FGQGTKLEIKSGIL 
8 ETNHRPS GAPDRFSGSIDSSSNSASLTISGLKTEDEADYHR QSYDRSNHVV FGGGTRLAVLSGIP 




1.15 Selected clones from LYN-C2 
 
   VH-FR1                    VH-CDR1    VH-FR2         VH-CDR2
1  QVQLVQSEGGVVQPGRSLGLSCAAS GFTFSSYAMH WVRQAPDKGLEWVA VISYDGSNKY 
3  QVQLVQSEGGVVQPGRSLRLSCAAS GFTFSSYAMH WVRQAPGKGLEWVA VISCDGSNKY 
5  QVQLVQSEGGVVQPGRSLRLSCAAS GFTFSSYAMH WVRQAPGKGLEWVA VISYDGSNKY 
6  QVQLVQSEGGVVQPGRSLRLSCAAS GFTFSSYAMH WVRQAPGKGLEWAA AVSYDGSNKY 
7  QVQLVQSEGGVVQPGRSLRLSCAAS GFTFSSYAMH WVRQAPGKGLEWVA VISYDGSNKY 
8  QVQLVQSEGGVVQPGRSLRLSCAAS GFTFSSYAMH WVRQAPGKGLEWVA VISYDGSNKY 
10 QVQLVQSEGGVVQPGRSLRLSCAAS GFTFSSYAMH WVRQAPGKGLEWVA VISYDGSNKY 
11 QVQLVQSEGGVVQPGRSLRLSCAAS GFTFSSYAMH WVRQAPGKGLEWVA VISYDGSNKY 
12 QVQLVQSEGGVVQPGRSLRLSCAAS GFTFSSYAMH WVRQAPGKGLEWVA VISYDGSNKY 
13 QVQLVQSEGGVVQPGRSLRLSCAAS GFTFSSYAMH WVRQAPGKGLEWVA VISYDGSNKY 
 
   VH-FR3                                  VH-CDR3  
1  YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DEGYYGSGCIDY WGQGTLVTVSS 
3  YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DEGYYGSGCIDY WGQGTLVTVSS 
5  YADSVKGRFTISRDTSKNTLYLQMNSLRAEDTAVYYCAR DEGYYGSGCIDY WGQGTLVTVSS 
6  YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DEGYYGSGCIDY WGQGTLVTASS 
7  YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DEGYYGSGCIDY WGQGTLVTVSS 
8  YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DEGYYGSGCIDY WGQGTLVTVSS 
10 YADSVKGRFTIARDNSKNTLYLQMNSLRAEDTAVYYCAR DEGYYGSGCIDY WGQGTLVTVSS 
11 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DEGYYGSGCIDY WGQGTLVTVSS 
12 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DEGYYGSGCIDY WGQGTLVTVSS 
13 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR DEGYYGSGCIDY WGQGTLVTVSS 
 
        Linker          VL-FR1     VL-CDR1   VL-FR2
1  GILGSGGGGSGGGGSGGGGS NFMLTQPHSVSESPGETVTISC  TGSSGSTASNSVQ WYQQRPGSAPRTVIY 
3  GILGSGGGGSGGGGSGGGGS NFMLTQPHSVSESPGKTVTISC  TRSSGSIATNYVQ WYQQRPGSSPTTVIY 
5  GILGSGGGGSGGGGPGGGGS NFMLAQLHSVSESPGKTVTTSC  TRSSGSIATNYVQ WYQQRPGSSPTTVIY 
6  GILGSGGGGSGGGGSGGGGS SFMLTQPHSAPESPGKTVTISC  TRSSGSTATNYVQ WYQQRPGSSPTTVIY 
7  GILGSGGGGSGGGGSGGGGS NFMLTQPHSVSESPGKTVTISC  TGSSGSIATNYVQ WYQQRPGSSPTTVIY 
8  GILGSGGGGSGGGGSGGGGS NFMLTQPHSVSESPGKTVTISC  TRSSGSIATNYVQ WYQQRPGSSPTTVIY 
10 GILGSGGGGSGGGGSGGGGS NFMLTQPHSVSESPGKTVTISC  TRSSGSIATNYVQ WYQQRPGSSPTTVIY 
11 GILGSGGGGSGGGGSGGGGS NFMLTQPHSVSESPGKAATISC  TRSSGSIASNYVQ WYQQRPGGAPTTVIY 
12 GILGSGGGGSGGGGSGGGGS NFMLTQPHSVSESPGKTATISC  TRSSGSIASNYVQ WYQQRPGGAPTTVIY 
13 GILGSGGGGSGGGGSGGGGS ETTFTQSPAFLSATPGDKVDISC KASQDIDEDVN   WYQQKPGEAPIFIIQ 
 
   VL-CDR2 VL-FR3                             VL-CDR3
1  EDHQRPS GVPDRFSGSIDTSSNSASLTISGLRTEDEGDYYC RSYDSSHTV  FGGGTQLTVLSGIL 
3  EDNQRPS AVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYHSSIVV  FGGGTKLTVLSGIL 
5  EDNQRPS AVPDRFSGSIDSSSNSASLTISGLKTEDEAGYYC QSYHSSIVV  FGGGTKLTVLPGIP 
6  EDNQRPS AVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QPYDSSNPWV FGGGTKLTVLSGIL 
7  EDNQRPS AVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYHSSIVV  FGGGTKLTVLSGIL 
8  EDNQRPS AVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYHSSIVV  FGGGTKLTVLSGIL 
10 EDNQRPS AVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYHSSIVV  FGGGTKLTVLSGIL 
11 EDNQRPS GVPDRFSGSIDSSSNPASLTISGLRTEDEADYYC QFYHSSIVV  FGGGTKLTVLSGIL 
12 EDNQRPS GVPDRLSGSIDSSSNSASLTISGLRTEDEADYYC QSYDRSNKAV FGGGTQLTILSGIL 




1.16 Selected clones from CRN-2B6 and CRN-C5 
 
      VH-FR1                    VH-CDR1    VH-FR2         VH-CDR2
2B6-1 QVQLQQWGPGLLKPSETLSLTCGVS GGSLSGYYWS WIRQSPGEELEWIG EINRDGSTN 
2B6-4 QVQLQQWGPGLLKPSETLSLTCGVS GGSLSGYYWS WIRQSPGEELEWIG EINQGGSTN 
2B6-6 QVQLQQWGPGLLKPSETLSLTCGVS GGSLSGYYWS WIRQSPGEELEWIG EINQGGSTN 
2B6-8 QVQLQQWGPGLLKPSETLSLTCGVP GGSLSGYYWS WIRQSPGEELEWIG EINQGGSTN 
C5-1  QVQLQQWGPGLLKPSETLSLTCGVS GGSLSGYYWS WIRQSPGEELEWIG EINRDGSTN 
C5-11 QVQLQQWGPGLLKPSETLSLTCGVS GGSLSGYYWS WIRQSPGEELEWIG EINQGGSTN 
 
      VH-FR3                                  VH-CDR3  
2B6-1 YNPSLRSRVTISVDTSKKQLSLKVNSVTASDTAVYYCAR ETFRGSNCFDS WGQGTPVTVSS 
2B6-4 YNPSLRSRVTISVDTSKKQLSLKVNSVTASDTAVYYCAR ETFRGSNCFDS WGQGTPVTVSS 
2B6-6 YNPSLRSRVTISVDTSKRQLSLKVNSVTASDTAVYYCAR ETFRGSNCFDS WGQGTPVTVSS 
2B6-8 YNPSLRSRVTISVDTSKKQLSLKVNSVTASDTAVYYCAR ETFRGSNCFDS WGQGTPVTVSS 
C5-1  YNPSLRSRVTISVDTSKKQLSLKVNSVTASDTAVYYCAR ETFRGSDCFDS WSQGTPVTVSS 
C5-11 YNPSLRSRVTISVDTSKKQLFLKVNSVTASDTAVYYCAR ETFRGSNCFDS WDQGTLVTVSS 
 
           Linker          VL-FR1        VL-CDR1      VL-FR2
2B6-1 GILGSGGSGSGGGGSGGGGS EIVLTQSPGTLSLSPGERVTLSC RASRTVSSSYLA  WYQQKTGQAPRLLMY 
2B6-4 GILGSGGGGSGGGGSGGGGS EIVLTQSPGTLSLSPGGRVTLSC RASQTVSSSYLA  WYQQKTGQAPRLLMY 
2B6-6 GILGSGGGGSGGGGSGGGGS EIVLTQSPGTLSLSPGERVTLSC RASQTVSSSYLA  WYQQKTGQAPRLLMY 
2B6-8 GILGSGGGGSGGGGSGGGGS EIVLTQSPGTLSLSPGERVTLSC RASQTVSSSYLA  WYQQKTGQAPRLLMY 
C5-1  GILGSGGGGSGGGGSGGGGS EIVLTQSPGTLSLSPGERVTLSC RASRTVSSSYLA  WYQQKTGQAPRLLMY 
C5-11 GILGSGGGGSGGGGSGGGGP NFMLTQPHSVSESPGKTVTISC  TRSSGSIASNYVQ WYQQRPGSFPTTVIY 
 
 
      VL-CDR2 VL-FR3                             VL-CDR3
2B6-1 GASTRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC   QQYGSSRWT  FGQGTKVGIKSGVL 
2B6-4 GASTRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC   QQYGSSRWT  FGQGTKVEIKSGIL 
2B6-6 GASTRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC   QQYGSSRWT  FGQGTKVEIKSGIL 
2B6-8 GASTRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAMYYC   QQYGSSRWT  FGQGTKVEIRSGIL 
C5-1  GASTRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC   QQYGSSRWT  FGQGTKVGIKSGVL 
C5-11 EDDQRPS GVPERFSGSIDSSSNSASLTISGLKTEDEADYYC QSYDSSDGWV FGGGTKLAVLSGIL 
 
 
1.17 Selected clones from MGE-Fab-M6 
 
  VH-FR1                    VH-CDR1      VH-FR2         VH-CDR2
1 QVQLQESGPGLVKPLETLSLTCTVS GGSISNSGYYWG WIRQPPGKGLEWIG SINHYGTTY 
2 QVQLQESGPGLVKPSETLSLTCTVS GGSISNSDYYWG WVRQPPGKGLEWIG SINYYGTTY 
3 QVQLQESGPGLVKPSETLPLTCTVS GGSISNSDYYWG WVRQPPGKGLEWIG SINYYGTTY 
 
  VH-FR3                                  VH-CDR3  
1 YNPSLKSRVAMSVDTSKSQFSLKLSSVTAADTAVYYCAR RRANSWSFDL WGRGTLVTVSS 
2 YNPSLKSRVAMSADTSKNQFSLKLSSVTAADTAVYYCAR RGANSWFFDL WGRGTLVTVSS 
3 YNPSLKSRVAMSVDTSKNQFSLKLSSATAADTAVYYCAR RGANSWLFDL WGRGTLVTVSS 
 
  VL-FR1                    VL-CDR1    VL-FR2
1 DIQVTRARMETK 
2 DIQVTRARMETK 
3 DFMLTQPHSVSESPGKTVTISCTGS SGSIASNYVQ WYQQRPGSAPTTVIF 
 
  VL-CDR2 VL-FR3                               VL-CDR3
1 
2 





Appendix 2: Protocol 
 
Yeast panning of mammalian cell monolayers  




PBSCM (PBS w/ 1 mM CaCl2, 0.5 mM MgSO4, 0.5% BSA), sterile filtered 
SDCAA, pH 3.5 (20 g/L glucose, 6.7 g/L yeast nitrogen base, 5 g/L casamino acids, 14.7 g/L 
sodium citrate, 4.29 g/L citric acid monohydrate), pH to 3.5, sterile filtered 
 
Note: keep PBSCM and 6-well plate on ice during Steps 3-7. 
 
1. Grow mammalian cell monolayer to confluency. 
2. Serum starve cell monolayers overnight before panning. 
3. Wash monolayers 3x with 1 mL PBSCM. 
4. Wash yeast cells 2x with 1mL PBSCM: 
a. Use 2x106 yeast/cm2 of monolayer cells. 
b. For 6-well plates, use 2x107 cells/well. 
c. Use 1 well for yeast displaying an irrelevant antibody, and 1 well for a yeast-
displayed positive control. 
5. Resuspend cells in 1 mL PBSCM (per well) and pipette yeast slurry onto monolayer 
dropwise to cover all surface area. 
6. Gently swirl plate and incubate at 4 oC with gentle rocking for 2 h. 
7. Wash wells 2x with PBSCM: 
a. Tilt plate and aspirate yeast slurry. 
b. Gently pipette 1 mL buffer onto side of well. 
c. Rock gently at 4 oC for 1 min. 
8. Add 1 mL SDCAA, pH 3.5 to each well and rock vigorously at room temperature for 20 
min to elute the bound yeast from the monolayer. 
9. Measure OD600 to determine number of cells captured. After OD measurement, yeast can 
be removed from cuvette, and dilutions can be plated on SDCAA plates as an alternate 
measure of cells captured. 
 
153 
Office:         Home:    
77 Massachusetts Ave. E19-563      345 Franklin St. #105   
Cambridge, MA  02139       Cambridge, MA  02139 





Education Massachusetts Institute of Technology, Cambridge, MA 
Doctoral candidate in Chemical Engineering, Ph.D. anticipated October 2007 
Minor in Biology, GPA: 4.9/5.0 
 
Rice University, Houston, TX 
Bachelor of Science in Chemical Engineering with Bioengineering Focus 

























Massachusetts Institute of Technology January 2003 – present  
Graduate Research Assistant     
 
Thesis Advisor: K. Dane Wittrup 
Thesis Title: “Characterizing and engineering antibodies against the epidermal 
growth factor receptor (EGFR)” 
 
• Developed a novel method for epitope mapping antibodies using random 
mutagenesis and yeast surface display 
• Utilized above method to determine the epitopes of three therapeutically 
relevant antibodies against EGFR 
• Continued work on engineering single-chain antibodies against dimerization 
epitopes of EGFR using yeast surface display and directed evolution 
• Created a mathematical model for equilibrium receptor-ligand binding and 
dimerization to describe the elimination of high affinity EGF binding to 
EGFR through antibodies against dimerization epitopes 
 
Pharmacia Summer 2001 
Summer Engineering Intern      
Conducted laboratory experiments on catalyst immobilization and reaction 
optimization to yield high enantiomeric selectivity 
 
Rice University Summer 1999 
Undergraduate Research Assistant     
Conducted research sponsored by the BP Amoco Summer Research Program, 
with results included in publication: 
 
Lee, J.T., Chou C.Y., Chao G., Pilaski D.R. & Robert M. (2005). Two-
dimensional diffusion of colloids in polymer solutions. Mol. Physics 103, 
2897-2902. 
154 
Publications Chao G., Cochran J.R. & Wittrup K.D. (2004). Fine epitope mapping of anti-
epidermal growth factor receptor antibodies through random mutagenesis and yeast 
surface display. J. Mol. Biol. 342, 539-550. 
 
Colby D.W., Garg P., Holden T., Chao G., Webster J.M., Messer A., Ingram V.M. 
& Wittrup K.D. (2004). Development of a human light chain variable domain (VL) 
intracellular antibody specific for the amino terminus of huntingtin via yeast 
surface display. J. Mol. Biol. 342, 901-912. 
 
Sivasubramanian A., Chao G., Pressler H.M., Wittrup K.D. & Gray J.J. 
(2006). Prediction of the mAb 806-EGFR complex structure by computational 
docking followed by computational and experimental mutagenesis. Structure 
14, 401-414. 
 
Chao G., Lau W.L., Hackel B.J., Sazinsky S.L., Lippow S.M. & Wittrup K.D. 
(2006). Isolating and engineering human antibodies using yeast surface 





Supervision of MIT Undergraduate Research Opportunity Program 
(UROP) students: 
Heather Pressler, “Mutation analysis of the antibody 806 epitope” (2004-2005) 
Nick Nguyen, “Measuring anti-EGFR antibody endocytosis rates” (2007) 
 
Teaching Assistant Experience: 
Introduction to Experimental Biology, MIT (Spring 2006)  
Conducted daily recitation lectures, provided instruction and management 
during laboratory hours, and graded exams 
 
Thermodynamics I, Rice University (2001-2002) 





Recombinant DNA techniques 
Protein biochemistry 
Protein engineering/directed evolution using yeast surface display 
Fluorescence activated cell sorting (FACS) 


















National Defense Science and Engineering Graduate Fellowship 
National Science Foundation Graduate Fellowship (declined) 
David Koch Graduate Fellowship (MIT Center for Cancer Research) 
Robert T. Haslam Presidential Graduate Fellow, MIT 
Outstanding Chemical Engineering Seminar Award (Fall 2005) 
Rice University President’s Honor Roll 
Tau Beta Pi National Engineering Honor Society 







Chao G., Olsen M.J., Wolf-Yadlin A. & Wittrup K.D. (2005). Engineering 
antibodies against the epidermal growth factor receptor to block dimerization. 
American Institute of Chemical Engineers (AIChE) Annual Meeting. 
 
Chao G., Cochran J.R. & Wittrup K.D. (Sept. 2006). Epitope mapping of 
antibodies against the epidermal growth factor receptor (EGFR). American 
Chemical Society (ACS) National Meeting. 
 
Posters: 
Chao G., Olsen M.J., Wolf-Yadlin A. & Wittrup K.D. (2005). Engineering anti-
epidermal growth factor receptor (EGFR) antibodies to block receptor 
dimerization. Keystone Symposium: Antibody-Based Therapeutics for Cancer. 
 
Chao G., Wolf-Yadlin A., Olsen M.J., Lauffenburger D.A. & Wittrup K.D. (2007). 
Antibodies against domains II or IV of the epidermal growth factor receptor 
(EGFR) inhibit high affinity EGF binding. Keystone Symposium: Antibodies as 
Drugs. 
 
Chao G., Wolf-Yadlin A., Olsen M.J., Lauffenburger D.A. & Wittrup K.D. (2007). 
Antibodies against domains II or IV of the epidermal growth factor receptor 
(EGFR) inhibit high affinity EGF binding. Protein Society Annual Symposium. 
 
Patent Applications: 
Johns T.G., Scott A.M., Burgess A.W., Old L.J., Adams T.E., Wittrup K.D. & 
Chao G. (2005). EGF receptor epitope peptides and uses thereof. 
 
Wittrup K.D., Lauffenburger D.A, Wolf-Yadlin A., Olsen M.J. & Chao G. (2005). 
Antibodies and peptides targeted to specific epidermal growth factor receptor 
epitopes for diagnostic and therapeutic applications in human disease. 
(Provisional). 
 
Way J.C., Chao G., Cresson C., Lauffenburger D.A., Wittrup K.D. (2007). 
Treatment of tumors expressing mutant EGF receptors. 
 
156 
